1 0 3 4 5 2 0 2 3 2 0 1 0 0 1 0 0

HEALTH ANNUAL STATEMENT

FOR THE YEAR ENDED DECEMBER 31, 2023
OF THE CONDITION AND AFFAIRS OF THE

Community Insurance Company

NAIC Group Code 0671 (Current) 0671 (Prior) NAIC Company Code 10345 Employer's ID Number 31-1440175

Organized under the Laws of Ohio, State of Domicile or Port of Entry OH

Country of Domicile United States of America

Licensed as business type: Property/Casualty

Is HMO Federally Qualified? Yes [ ] No [X]

Incorporated/Organized 07/08/1995 Commenced Business 10/01/1995

Statutory Home Office 4361 Irwin Simpson Road (Street and Number), Mason, OH, US 45040-9498 (City or Town, State, Country and Zip Code)

Main Administrative Office 4361 Irwin Simpson Road (Street and Number)
Mason, OH, US 45040-9498 (City or Town, State, Country and Zip Code), 513-872-8100 (Area Code) (Telephone Number)

Mail Address N17 W24222 Riverwood Drive, Suite 300 (Street and Number or P.O. Box), Waukesha, WI, US 53188 (City or Town, State, Country and Zip Code)

Primary Location of Books and Records N17 W24222 Riverwood Drive, Suite 300 (Street and Number)
Waukesha, WI, US 53188 (City or Town, State, Country and Zip Code), 800-331-1476 (Area Code) (Telephone Number)

Internet Website Address www.elevancehealth.com

Statutory Statement Contact Jill M. Waddell (Name), 262-202-1569 (Area Code) (Telephone Number)
jill.waddell@elevancehealth.com (E-mail Address), 262-523-4945 (FAX Number)

OFFICERS

President/Chairperson	Jane Marie Peterson	Vice President/Treasurer	Vincent Edward Scher
Secretary	Kathleen Susan Kiefer	Assistant Secretary	Kristin Kim Cherie Howard

OTHER

Eric (Rick) Kenneth Noble, Assistant Treasurer	Kristen Louise Metzger, Vice President	Bradley Scott Jackson, Medical Director
Gregory Alfonso LaManna, Vice President and Medicaid Plan President		

DIRECTORS OR TRUSTEES

Laurie Helm Benintendi	Ronald William Penczek	Bradley Scott Jackson
Jane Marie Peterson	Vincent Edward Scher #	

State of Indiana
County of Marion
SS

The officers of this reporting entity being duly sworn, each depose and say that they are the described officers of said reporting entity, and that on the reporting period stated above, all of the herein described assets were the absolute property of the said reporting entity, free and clear from any liens or claims thereon, except as herein stated, and that this statement, together with related exhibits, schedules and explanations therein contained, annexed or referred to, is a full and true statement of all the assets and liabilities and of the condition and affairs of the said reporting entity as of the reporting period stated above, and of its income and deductions therefrom for the period ended, and have been completed in accordance with the NAIC Annual Statement Instructions and Accounting Practices and Procedures manual except to the extent that: (1) state law may differ; or, (2) that state rules or regulations require differences in reporting not related to accounting practices and procedures, according to the best of their information, knowledge and belief, respectively. Furthermore, the scope of this attestation by the described officers also includes the related corresponding electronic filing with the NAIC, when required, that is an exact copy (except for formatting differences due to electronic filing) of the enclosed statement. The electronic filing may be requested by various regulators in lieu of or in addition to the enclosed statement.

DocuSigned by: Jane Peterson 283A17CE53F54BC...	DocuSigned by: kathy kiefer D85175EE05784B1...	DocuSigned by: Vincent E. Scher A85A33722D4143E...
Jane Marie Peterson	Kathleen Susan Kiefer	Vincent Edward Scher
President/Chairperson	Secretary	Vice President/Treasurer

Subscribed and sworn to before me this 25th day of January 2024

Louanna Stiner
Executive Admin Assistant
06/29/31

LOUANNA STINER
Notary Public - Seal
Marion County - State of Indiana
Commission Number NP0749866
My Commission Expires Jun 29, 2031

a. Is this an original filing? .... Yes [X] No [ ]
b. If no,
1. State the amendment number........
2. Date filed ....
3. Number of pages attached...........

ASSETS

		Current Year			Prior Year
		1 Assets	2 Nonadmitted Assets	3 Net Admitted Assets (Cols. 1 - 2)	4 Net Admitted Assets
1.	Bonds (Schedule D)	1,906,490,617		1,906,490,617	1,653,183,481
2.	Stocks (Schedule D):				
	2.1 Preferred stocks			0	0
	2.2 Common stocks	4,041,439		4,041,439	5,099,935
3.	Mortgage loans on real estate (Schedule B):				
	3.1 First liens	212,575,000	712,122	211,862,878	75,980,000
	3.2 Other than first liens			0	0
4.	Real estate (Schedule A):				
	4.1 Properties occupied by the company (less $ .... encumbrances)			0	0
	4.2 Properties held for the production of income (less $ .... encumbrances)			0	0
	4.3 Properties held for sale (less $ .... encumbrances)			0	0
5.	Cash ($ (272,983,532), Schedule E - Part 1), cash equivalents ($ 2,900,000, Schedule E - Part 2) and short-term investments ($ 259,752, Schedule DA)	(269,823,780)		(269,823,780)	(171,672,743)
6.	Contract loans, (including $ .... premium notes)			0	0
7.	Derivatives (Schedule DB)			0	0
8.	Other invested assets (Schedule BA)	58,807,318		58,807,318	63,765,236
9.	Receivables for securities	829,917	818,369	11,548	2,646,152
10.	Securities lending reinvested collateral assets (Schedule DL)	162,618,335		162,618,335	72,724,060
11.	Aggregate write-ins for invested assets	0	0	0	0
12.	Subtotals, cash and invested assets (Lines 1 to 11)	2,075,538,846	1,530,491	2,074,008,355	1,701,726,120
13.	Title plants less $ .... charged off (for Title insurers only)			0	0
14.	Investment income due and accrued	16,520,888	11,633	16,509,255	13,521,183
15.	Premiums and considerations:				
	15.1 Uncollected premiums and agents' balances in the course of collection	237,949,519	2,653,217	235,296,302	127,701,979
	15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due (including $ 139,431,791 earned but unbilled premiums)	139,431,791		139,431,791	130,272,270
	15.3 Accrued retrospective premiums ($ 4,950,391) and contracts subject to redetermination ($ 178,048,834)	182,999,225		182,999,225	139,683,503
16.	Reinsurance:				
	16.1 Amounts recoverable from reinsurers	37,035,704		37,035,704	31,625,464
	16.2 Funds held by or deposited with reinsured companies			0	0
	16.3 Other amounts receivable under reinsurance contracts			0	2,025,253
17.	Amounts receivable relating to uninsured plans	397,591,046	37,537,768	360,053,278	346,114,925
18.1	Current federal and foreign income tax recoverable and interest thereon	10,847,167		10,847,167	22,067,441
18.2	Net deferred tax asset	99,857,831	20,958,645	78,899,186	57,159,342
19.	Guaranty funds receivable or on deposit	1,675,629		1,675,629	1,675,629
20.	Electronic data processing equipment and software			0	0
21.	Furniture and equipment, including health care delivery assets ($ ....)	22,402,820	22,402,820	0	0
22.	Net adjustment in assets and liabilities due to foreign exchange rates			0	0
23.	Receivables from parent, subsidiaries and affiliates	123,679,454		123,679,454	203,926,445
24.	Health care ($ 48,893,516) and other amounts receivable	120,144,934	71,251,418	48,893,516	94,796,131
25.	Aggregate write-ins for other than invested assets	323,046,613	71,020,435	252,026,178	228,687,418
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	3,788,721,467	227,366,427	3,561,355,040	3,100,983,104
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts			0	0
28.	Total (Lines 26 and 27)	3,788,721,467	227,366,427	3,561,355,040	3,100,983,104
	DETAILS OF WRITE-INS				
1101.					
1102.					
1103.					
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0	0
2501.	Investments in corporate-owned life insurance	246,971,660		246,971,660	227,692,495
2502.	Premium tax credits	4,110,000		4,110,000	0
2503.	Other miscellaneous accounts receivable	3,688,990	2,777,576	911,414	628,467
2598.	Summary of remaining write-ins for Line 25 from overflow page	68,275,964	68,242,859	33,104	366,457
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	323,046,613	71,020,435	252,026,178	228,687,418

LIABILITIES, CAPITAL AND SURPLUS

	Current Year 1 Covered	2 Uncovered	3 Total	Prior Year 4 Total
1. Claims unpaid (less $ 60,494,754 reinsurance ceded)	890,029,555	32,012,779	922,042,333	994,750,933
2. Accrued medical incentive pool and bonus amounts	144,239,822		144,239,822	79,263,935
3. Unpaid claims adjustment expenses	24,663,216		24,663,216	26,057,642
4. Aggregate health policy reserves, including the liability of $ 7,519,702 for medical loss ratio rebate per the Public Health Service Act	118,061,114		118,061,114	55,435,655
5. Aggregate life policy reserves			0	0
6. Property/casualty unearned premium reserves			0	0
7. Aggregate health claim reserves			0	0
8. Premiums received in advance	63,766,597		63,766,597	53,182,373
9. General expenses due or accrued	133,598,892		133,598,892	121,503,016
10.1 Current federal and foreign income tax payable and interest thereon (including $ on realized capital gains (losses))	0		0	0
10.2 Net deferred tax liability			0	0
11. Ceded reinsurance premiums payable	34,282,712		34,282,712	38,069,448
12. Amounts withheld or retained for the account of others	60,261,479		60,261,479	45,835,259
13. Remittances and items not allocated	57,447,891		57,447,891	41,253,592
14. Borrowed money (including $ current) and interest thereon $ (including $ current)	0		0	0
15. Amounts due to parent, subsidiaries and affiliates	0		0	0
16. Derivatives			0	0
17. Payable for securities	1,858,751		1,858,751	8,466,542
18. Payable for securities lending	162,618,335		162,618,335	72,724,060
19. Funds held under reinsurance treaties (with $ authorized reinsurers, $ 0 unauthorized reinsurers and $ 0 certified reinsurers)			0	0
20. Reinsurance in unauthorized and certified ($) companies			0	0
21. Net adjustments in assets and liabilities due to foreign exchange rates			0	0
22. Liability for amounts held under uninsured plans	160,795,779		160,795,779	115,103,480
23. Aggregate write-ins for other liabilities (including $ 42,755,394 current)	60,201,725	0	60,201,725	108,713,660
24. Total liabilities (Lines 1 to 23)	1,911,825,867	32,012,779	1,943,838,646	1,760,359,595
25. Aggregate write-ins for special surplus funds	XXX	XXX	1,427,769	1,931,686
26. Common capital stock	XXX	XXX	1,142,307	1,142,307
27. Preferred capital stock	XXX	XXX		
28. Gross paid in and contributed surplus	XXX	XXX	395,393,523	395,393,523
29. Surplus notes	XXX	XXX	0	
30. Aggregate write-ins for other than special surplus funds	XXX	XXX	0	0
31. Unassigned funds (surplus)	XXX	XXX	1,219,552,795	942,155,993
32. Less treasury stock, at cost:				
32.1 shares common (value included in Line 26 $)	XXX	XXX		
32.2 shares preferred (value included in Line 27 $)	XXX	XXX		
33. Total capital and surplus (Lines 25 to 31 minus Line 32)	XXX	XXX	1,617,516,394	1,340,623,509
34. Total liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	3,561,355,040	3,100,983,104
DETAILS OF WRITE-INS				
2301. Escheat liabilities	33,540,399		33,540,399	39,533,928
2302. Other accrued expenses - non trade	14,639,126		14,639,126	13,658,207
2303. Performance guaranty	12,022,200		12,022,200	6,233,650
2398. Summary of remaining write-ins for Line 23 from overflow page	0	0	0	49,287,875
2399. Totals (Lines 2301 thru 2303 plus 2398)(Line 23 above)	60,201,725	0	60,201,725	108,713,660
2501. Deferred gain on sale-leaseback transactions	XXX	XXX	1,427,769	1,931,686
2502.	XXX	XXX		
2503.	XXX	XXX		
2598. Summary of remaining write-ins for Line 25 from overflow page	XXX	XXX	0	0
2599. Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	XXX	XXX	1,427,769	1,931,686
3001.	XXX	XXX		
3002.	XXX	XXX		
3003.	XXX	XXX		
3098. Summary of remaining write-ins for Line 30 from overflow page	XXX	XXX	0	0
3099. Totals (Lines 3001 thru 3003 plus 3098)(Line 30 above)	XXX	XXX	0	0

STATEMENT OF REVENUE AND EXPENSES

		Current Year		Prior Year
		1 Uncovered	2 Total	3 Total
1.	Member Months	XXX	27,483,025	31,631,604
2.	Net premium income (including $ .... non-health premium income)	XXX	9,890,936,370	9,236,280,911
3.	Change in unearned premium reserves and reserve for rate credits	XXX	(39,134,498)	(18,096,727)
4.	Fee-for-service (net of $ .... medical expenses)	XXX	0	
5.	Risk revenue	XXX	0	444,917,409
6.	Aggregate write-ins for other health care related revenues	XXX	0	0
7.	Aggregate write-ins for other non-health revenues	XXX	0	0
8.	Total revenues (Lines 2 to 7)	XXX	9,851,801,872	9,663,101,593
	Hospital and Medical:			
9.	Hospital/medical benefits		5,615,823,184	5,945,387,197
10.	Other professional services		753,863,481	646,337,141
11.	Outside referrals	255,225,262	255,569,720	188,590,748
12.	Emergency room and out-of-area	39,329,692	506,342,670	698,056,876
13.	Prescription drugs		855,941,579	1,121,399,820
14.	Aggregate write-ins for other hospital and medical	0	0	0
15.	Incentive pool, withhold adjustments and bonus amounts		246,779,617	135,967,439
16.	Subtotal (Lines 9 to 15)	294,554,954	8,234,320,251	8,735,739,221
	Less:			
17.	Net reinsurance recoveries		(39,194,870)	350,629,565
18.	Total hospital and medical (Lines 16 minus 17)	294,554,954	8,273,515,121	8,385,109,656
19.	Non-health claims (net)			
20.	Claims adjustment expenses, including $ 157,150,766 cost containment expenses		285,538,794	308,987,451
21.	General administrative expenses		721,445,883	718,844,908
22.	Increase in reserves for life and accident and health contracts (including $ .... increase in reserves for life only)		(1,171,602)	(1,833,857)
23.	Total underwriting deductions (Lines 18 through 22)	294,554,954	9,279,328,196	9,411,108,158
24.	Net underwriting gain or (loss) (Lines 8 minus 23)	XXX	572,473,676	251,993,435
25.	Net investment income earned (Exhibit of Net Investment Income, Line 17)		118,300,489	67,996,600
26.	Net realized capital gains (losses) less capital gains tax of $ (6,675,829)		(28,607,688)	(30,579,326)
27.	Net investment gains (losses) (Lines 25 plus 26)	0	89,692,801	37,417,274
28.	Net gain or (loss) from agents' or premium balances charged off [(amount recovered $ ....) (amount charged off $ 886,146)]		(886,146)	(771,084)
29.	Aggregate write-ins for other income or expenses	0	32,858,635	27,956,437
30.	Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus 27 plus 28 plus 29)	XXX	694,138,966	316,596,062
31.	Federal and foreign income taxes incurred	XXX	176,853,345	45,356,132
32.	Net income (loss) (Lines 30 minus 31)	XXX	517,285,621	271,239,930
	DETAILS OF WRITE-INS			
0601.		XXX		
0602.		XXX		
0603		XXX		
0698.	Summary of remaining write-ins for Line 6 from overflow page	XXX	0	0
0699.	Totals (Lines 0601 thru 0603 plus 0698)(Line 6 above)	XXX	0	0
0701.		XXX		
0702.		XXX		
0703		XXX		
0798.	Summary of remaining write-ins for Line 7 from overflow page	XXX	0	0
0799.	Totals (Lines 0701 thru 0703 plus 0798)(Line 7 above)	XXX	0	0
1401.				
1402.				
1403.				
1498.	Summary of remaining write-ins for Line 14 from overflow page	0	0	0
1499.	Totals (Lines 1401 thru 1403 plus 1498)(Line 14 above)	0	0	0
2901.	Change in cash surrender value of investment in corporate-owned life insurance		20,829,570	22,679,427
2902.	Miscellaneous income (expense)		12,029,065	5,277,010
2903				
2998.	Summary of remaining write-ins for Line 29 from overflow page	0	0	0
2999.	Totals (Lines 2901 thru 2903 plus 2998)(Line 29 above)	0	32,858,635	27,956,437

STATEMENT OF REVENUE AND EXPENSES (Continued)

		1 Current Year	2 Prior Year
	CAPITAL AND SURPLUS ACCOUNT		
33.	Capital and surplus prior reporting year	1,340,623,509	1,004,922,702
34.	Net income or (loss) from Line 32	517,285,621	271,239,930
35.	Change in valuation basis of aggregate policy and claim reserves		
36.	Change in net unrealized capital gains (losses) less capital gains tax of $ 3,732,403	14,040,943	(27,798,552)
37.	Change in net unrealized foreign exchange capital gain or (loss)		
38.	Change in net deferred income tax	32,697,106	8,819,458
39.	Change in nonadmitted assets	(14,766,534)	(116,056,111)
40	Change in unauthorized and certified reinsurance	0	0
41.	Change in treasury stock	0	0
42.	Change in surplus notes	0	0
43.	Cumulative effect of changes in accounting principles		
44.	Capital Changes:		
	44.1 Paid in	0	0
	44.2 Transferred from surplus (Stock Dividend)	0	0
	44.3 Transferred to surplus		
45.	Surplus adjustments:		
	45.1 Paid in	0	200,000,000
	45.2 Transferred to capital (Stock Dividend)		
	45.3 Transferred from capital		
46.	Dividends to stockholders	(271,200,000)	
47.	Aggregate write-ins for gains or (losses) in surplus	(1,164,251)	(503,918)
48.	Net change in capital and surplus (Lines 34 to 47)	276,892,885	335,700,807
49.	Capital and surplus end of reporting period (Line 33 plus 48)	1,617,516,394	1,340,623,509
	DETAILS OF WRITE-INS		
4701.	Change in Medicare supplement reserving methodology	(660,333)	
4702.	Deferred gain on sale-leaseback activity	(503,918)	(503,918)
4703.			
4798.	Summary of remaining write-ins for Line 47 from overflow page	0	0
4799.	Totals (Lines 4701 thru 4703 plus 4798)(Line 47 above)	(1,164,251)	(503,918)

CASH FLOW

		1 Current Year	2 Prior Year
	Cash from Operations		
1.	Premiums collected net of reinsurance	9,764,482,656	9,124,622,351
2.	Net investment income	110,805,417	69,824,967
3.	Miscellaneous income	0	444,917,409
4.	Total (Lines 1 through 3)	9,875,288,073	9,639,364,727
5.	Benefit and loss related payments	8,234,314,392	8,103,332,074
6.	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts		
7.	Commissions, expenses paid and aggregate write-ins for deductions	940,326,804	930,562,508
8.	Dividends paid to policyholders		
9.	Federal and foreign income taxes paid (recovered) net of $ (6,675,829) tax on capital gains (losses)	158,957,242	50,931,774
10.	Total (Lines 5 through 9)	9,333,598,438	9,084,826,356
11.	Net cash from operations (Line 4 minus Line 10)	541,689,635	554,538,371
	Cash from Investments		
12.	Proceeds from investments sold, matured or repaid:		
	12.1 Bonds	808,959,175	514,108,798
	12.2 Stocks	2,481,937	2,093,677
	12.3 Mortgage loans	0	319,500
	12.4 Real estate	0	0
	12.5 Other invested assets	2,512,907	9,328,726
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments	(248,533)	(72,966)
	12.7 Miscellaneous proceeds	2,634,604	0
	12.8 Total investment proceeds (Lines 12.1 to 12.7)	816,340,090	525,777,735
13.	Cost of investments acquired (long-term only):		
	13.1 Bonds	1,070,832,087	840,152,329
	13.2 Stocks	1,506,331	465,351
	13.3 Mortgage loans	136,595,000	66,280,000
	13.4 Real estate	0	0
	13.5 Other invested assets	2,234,126	400,106
	13.6 Miscellaneous applications	95,453,347	28,469,243
	13.7 Total investments acquired (Lines 13.1 to 13.6)	1,306,620,891	935,767,029
14.	Net increase/(decrease) in contract loans and premium notes	0	0
15.	Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)	(490,280,801)	(409,989,294)
	Cash from Financing and Miscellaneous Sources		
16.	Cash provided (applied):		
	16.1 Surplus notes, capital notes	0	0
	16.2 Capital and paid in surplus, less treasury stock	0	200,000,000
	16.3 Borrowed funds	0	0
	16.4 Net deposits on deposit-type contracts and other insurance liabilities	0	0
	16.5 Dividends to stockholders	271,200,000	0
	16.6 Other cash provided (applied)	121,640,129	(151,007,841)
17.	Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)	(149,559,871)	48,992,159
	RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS		
18.	Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	(98,151,037)	193,541,236
19.	Cash, cash equivalents and short-term investments:		
	19.1 Beginning of year	(171,672,743)	(365,213,979)
	19.2 End of year (Line 18 plus Line 19.1)	(269,823,780)	(171,672,743)

Note: Supplemental disclosures of cash flow information for non-cash transactions:

ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

	1	Comprehensive (Hospital & Medical)		4	5	6	7	8	9	10	11	12	13	14
	Total	2 Individual	3 Group	Medicare Supplement	Vision Only	Dental Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other Health	Other Non-Health
1. Net premium income	9,890,936,370	500,001,884	1,904,196,319	171,941,441	26,574,751	72,980,279	1,048,943,434	4,169,816,713	1,309,068,228				687,413,321	
2. Change in unearned premium reserves and reserve for rate credit	(39,134,498)		(7,463,529)	(47,653)				(28,201,937)	(3,421,379)					
3. Fee-for-service (net of $ medical expenses)	0													XXX
4. Risk revenue	0													XXX
5. Aggregate write-ins for other health care related revenues	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
6. Aggregate write-ins for other non-health care related revenues	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
7. Total revenues (Lines 1 to 6)	9,851,801,872	500,001,884	1,896,732,790	171,893,788	26,574,751	72,980,279	1,048,943,434	4,141,614,776	1,305,646,849	0	0	0	687,413,321	0
8. Hospital/medical benefits	5,615,823,184	267,264,859	861,380,028	110,783,855			954,113,513	2,743,912,106	525,410,666				152,958,157	XXX
9. Other professional services	753,863,481	20,159,336	81,808,776	22,556,589	20,600,588	34,555,474	104,893,549	285,407,070	183,882,099					XXX
10. Outside referrals	255,569,720	25,554,992	22,217,514		265,344	22,957,675	7,299,285	89,593,618	87,681,292					XXX
11. Emergency room and out-of-area	506,342,670	20,126,692	230,963,279	3,555,334			43,567,076	164,817,560	43,312,729					XXX
12. Prescription drugs	855,941,579	70,899,143	304,876,797	(2,322,062)			305,233,583	177,395,567	(738,726)				597,277	XXX
13. Aggregate write-ins for other hospital and medical	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
14. Incentive pool, withhold adjustments and bonus amounts	246,779,617	3,824,083	11,316,301				6,983,976	209,755,626	14,588,083				311,548	XXX
15. Subtotal (Lines 8 to 14)	8,234,320,251	407,829,105	1,512,562,695	134,573,716	20,865,932	57,513,149	1,422,090,982	3,670,881,547	854,136,143	0	0	0	153,866,982	XXX
16. Net reinsurance recoveries	(39,194,870)				2,990,880		426,658,891		(81,500,070)				(387,344,571)	XXX
17. Total medical and hospital (Lines 15 minus 16)	8,273,515,121	407,829,105	1,512,562,695	134,573,716	17,875,052	57,513,149	995,432,091	3,670,881,547	935,636,213	0	0	0	541,211,553	XXX
18. Non-health claims (net)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
19. Claims adjustment expenses including $ 157,150,766 cost containment expenses	285,538,796	19,775,283	49,926,515	10,443,236	1,206,304	5,358,021	15,255,485	136,787,715	45,836,050				950,187	
20. General administrative expenses	721,445,883	57,788,817	145,899,010	30,518,009	3,525,151	15,657,611	44,580,722	399,731,328	133,945,545				(110,200,310)	
21. Increase in reserves for accident and health contracts	(1,171,602)			(1,171,602)										XXX
22. Increase in reserves for life contracts	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
23. Total underwriting deductions (Lines 17 to 22)	9,279,328,198	485,393,205	1,708,388,220	174,363,359	22,606,507	78,528,781	1,055,268,298	4,207,400,590	1,115,417,808	0	0	0	431,961,430	0
24. Net underwriting gain or (loss) (Line 7 minus Line 23)	572,473,674	14,608,679	188,344,570	(2,469,571)	3,968,244	(5,548,502)	(6,324,864)	(65,785,814)	190,229,041	0	0	0	255,451,891	0
DETAILS OF WRITE-INS														
0501.														XXX
0502.														XXX
0503.														XXX
0598. Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
0599. Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
0601.		XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0602.		XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0603.		XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0698. Summary of remaining write-ins for Line 6 from overflow page	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
0699. Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
1301.														XXX
1302.														XXX
1303.														XXX
1398. Summary of remaining write-ins for Line 13 from overflow page	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
1399. Totals (Lines 1301 thru 1303 plus 1398) (Line 13 above)	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX

UNDERWRITING AND INVESTMENT EXHIBIT

PART 1 - PREMIUMS

	Line of Business	1 Direct Business	2 Reinsurance Assumed	3 Reinsurance Ceded	4 Net Premium Income (Cols. 1 + 2 - 3)
1.	Comprehensive (hospital and medical) individual	500,001,884			500,001,884
2.	Comprehensive (hospital and medical) group	1,904,196,319			1,904,196,319
3.	Medicare Supplement	171,941,441			171,941,441
4.	Vision only	29,633,906		3,059,156	26,574,750
5.	Dental only	72,980,279			72,980,279
6.	Federal Employees Health Benefits Plan	1,498,490,621		449,547,186	1,048,943,435
7.	Title XVIII - Medicare	4,169,816,713			4,169,816,713
8.	Title XIX - Medicaid	1,220,449,032	88,827,172	207,977	1,309,068,227
9.	Credit A&H				0
10.	Disability Income				0
11.	Long-Term Care				0
12.	Other health	202,830,875	484,949,146	366,700	687,413,321
13.	Health subtotal (Lines 1 through 12)	9,770,341,070	573,776,318	453,181,019	9,890,936,369
14.	Life	0			0
15.	Property/casualty	0			0
16.	Totals (Lines 13 to 15)	9,770,341,070	573,776,318	453,181,019	9,890,936,369

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2 - CLAIMS INCURRED DURING THE YEAR

	1	Comprehensive (Hospital & Medical)		4	5	6	7	8	9	10	11	12	13	14
		2	3											
	Total	Individual	Group	Medicare Supplement	Vision Only	Dental Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other Health	Other Non-Health
1. Payments during the year:														
1.1 Direct	8,055,354,243	381,639,905	1,591,518,221	136,593,755	20,475,745	58,268,522	1,395,539,125	3,452,769,482	847,771,913				170,777,575	
1.2 Reinsurance assumed	415,282,641								79,070,265				336,212,376	
1.3 Reinsurance ceded	418,126,223				2,797,380		414,880,421		378,772				69,650	
1.4 Net	8,052,510,661	381,639,905	1,591,518,221	136,593,755	17,678,365	58,268,522	980,658,704	3,452,769,482	926,463,406	0	0	0	506,920,301	0
2. Paid medical incentive pools and bonuses	181,803,730	3,681,898	11,224,055				6,028,914	159,166,761	1,392,003				310,099	
3. Claim liability December 31, current year from Part 2A:														
3.1 Direct	924,291,352	59,698,610	174,559,590	14,270,706	1,344,166	3,735,331	200,116,096	287,334,250	159,557,203	0	0	0	23,675,400	0
3.2 Reinsurance assumed	58,245,732	0	0	0	0	0	0	0	7,177,946	0	0	0	51,067,786	0
3.3 Reinsurance ceded	60,494,754	0	0	0	206,527	0	60,034,830	0	122,110	0	0	0	131,287	0
3.4 Net	922,042,330	59,698,610	174,559,590	14,270,706	1,137,639	3,735,331	140,081,266	287,334,250	166,613,039	0	0	0	74,611,899	0
4. Claim reserve December 31, current year from Part 2D:														
4.1 Direct	0													
4.2 Reinsurance assumed	0													
4.3 Reinsurance ceded	0													
4.4 Net	0	0	0	0	0	0	0	0	0	0	0	0	0	0
5. Accrued medical incentive pools and bonuses, current year	144,239,823	1,698,791	1,575,282				1,825,850	125,940,772	13,196,080				3,048	
6. Net health care receivables (a)	(52,343,681)	3,136,299	2,402,272	(187,569)	11,354	18,754	1,700,477	(13,012,377)	424,407				(46,837,298)	
7. Amounts recoverable from reinsurers December 31, current year	37,035,703				361,973		36,654,480						19,250	
8. Claim liability December 31, prior year from Part 2A:														
8.1 Direct	1,044,448,644	34,197,194	262,429,145	16,478,315	942,625	4,471,951	178,847,739	291,990,189	167,356,648	0	0	0	87,734,838	0
8.2 Reinsurance assumed	4,247,260	0	0	0	0	0	0	0	4,247,260	0	0	0	0	0
8.3 Reinsurance ceded	53,944,970	0	0	0	0	0	53,654,020	0	0	0	0	0	290,950	0
8.4 Net	994,750,934	34,197,194	262,429,145	16,478,315	942,625	4,471,951	125,193,719	291,990,189	171,603,908	0	0	0	87,443,888	0
9. Claim reserve December 31, prior year from Part 2D:														
9.1 Direct	0													
9.2 Reinsurance assumed	0													
9.3 Reinsurance ceded	0													
9.4 Net	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10. Accrued medical incentive pools and bonuses, prior year	79,263,935	1,556,606	1,483,036				870,787	75,351,907					1,599	
11. Amounts recoverable from reinsurers December 31, prior year	31,625,464				375,000		31,256,819						(6,355)	
12. Incurred Benefits:														
12.1 Direct	7,987,540,632	404,005,022	1,501,246,394	134,573,715	20,865,932	57,513,148	1,415,107,005	3,461,125,920	839,548,061	0	0	0	153,555,435	0
12.2 Reinsurance assumed	469,281,113	0	0	0	0	0	0	0	82,000,951	0	0	0	387,280,162	0
12.3 Reinsurance ceded	430,086,246	0	0	0	2,990,880	0	426,658,892	0	500,882	0	0	0	(64,408)	0
12.4 Net	8,026,735,499	404,005,022	1,501,246,394	134,573,715	17,875,052	57,513,148	988,448,113	3,461,125,920	921,048,130	0	0	0	540,900,005	0
13. Incurred medical incentive pools and bonuses	246,779,618	3,824,083	11,316,301	0	0	0	6,983,977	209,755,626	14,588,083	0	0	0	311,548	0

(a) Excludes $ 16,527,049 loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

	1	Comprehensive (Hospital & Medical)		4	5	6	7	8	9	10	11	12	13	14
		2	3											
	Total	Individual	Group	Medicare Supplement	Vision Only	Dental Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other Health	Other Non-Health
1. Reported in Process of Adjustment:														
1.1 Direct	228,885,796	10,937,377	41,496,165	1,787,831	398,161	1,502,762	29,810,064	113,702,040	29,285,766	0	0	0	(34,370)	
1.2 Reinsurance assumed	8,177,930	0	0	0	0	0	0	0	2,189,124	0	0	0	5,988,806	
1.3 Reinsurance ceded	8,980,261	0	0	0	0	0	8,943,020	0	37,241	0	0	0	0	
1.4 Net	228,083,465	10,937,377	41,496,165	1,787,831	398,161	1,502,762	20,867,044	113,702,040	31,437,649	0	0	0	5,954,436	0
2. Incurred but Unreported:														
2.1 Direct	695,405,556	48,761,233	133,063,425	12,482,875	946,005	2,232,569	170,306,032	173,632,210	130,271,437	0	0	0	23,709,770	
2.2 Reinsurance assumed	50,067,802	0	0	0	0	0	0	0	4,988,822	0	0	0	45,078,980	
2.3 Reinsurance ceded	51,514,493	0	0	0	206,527	0	51,091,810	0	84,869	0	0	0	131,287	
2.4 Net	693,958,865	48,761,233	133,063,425	12,482,875	739,478	2,232,569	119,214,222	173,632,210	135,175,390	0	0	0	68,657,463	0
3. Amounts Withheld from Paid Claims and Capitations:														
3.1 Direct	0													
3.2 Reinsurance assumed	0													
3.3 Reinsurance ceded	0													
3.4 Net	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4. TOTALS:														
4.1 Direct	924,291,352	59,698,610	174,559,590	14,270,706	1,344,166	3,735,331	200,116,096	287,334,250	159,557,203	0	0	0	23,675,400	0
4.2 Reinsurance assumed	58,245,732	0	0	0	0	0	0	0	7,177,946	0	0	0	51,067,786	0
4.3 Reinsurance ceded	60,494,754	0	0	0	206,527	0	60,034,830	0	122,110	0	0	0	131,287	0
4.4 Net	922,042,330	59,698,610	174,559,590	14,270,706	1,137,639	3,735,331	140,081,266	287,334,250	166,613,039	0	0	0	74,611,899	0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

	Claims Paid During the Year		Claim Reserve and Claim Liability December 31 of Current Year		5	6
	1	2	3	4		
Line of Business	On Claims Incurred Prior to January 1 of Current Year	On Claims Incurred During the Year	On Claims Unpaid December 31 of Prior Year	On Claims Incurred During the Year	Claims Incurred In Prior Years (Columns 1 + 3)	Estimated Claim Reserve and Claim Liability December 31 of Prior Year
1. Comprehensive (hospital and medical) individual	17,272,562	364,367,342	2,308,950	57,389,660	19,581,512	34,197,194
2. Comprehensive (hospital and medical) group	143,493,648	1,448,024,573	9,575,563	164,984,027	153,069,211	262,429,145
3. Medicare Supplement	14,866,363	121,727,392	21,915	14,248,792	14,888,278	16,478,315
4. Vision Only	1,157,344	16,534,047	2,313	1,135,326	1,159,657	942,625
5. Dental Only	3,477,027	54,791,496	159,074	3,576,258	3,636,101	4,471,951
6. Federal Employees Health Benefits Plan	139,867,654	835,393,388	4,622,587	135,458,680	144,490,241	125,193,718
7. Title XVIII - Medicare	167,895,720	3,284,873,761	2,434,633	284,899,618	170,330,353	291,990,189
8 Title XIX - Medicaid	108,389,523	818,073,883	4,738,212	161,874,828	113,127,735	171,603,908
9. Credit A&H	0	0	0	0	0	0
10. Disability Income	0	0	0	0	0	0
11. Long-Term Care	0	0	0	0	0	0
12. Other health	6,925,191	499,969,506	2,900,931	71,710,968	9,826,122	87,443,889
13. Health subtotal (Lines 1 to 12)	603,345,032	7,443,755,388	26,764,178	895,278,157	630,109,210	994,750,934
14. Health care receivables (a)	12,585,831	91,032,054	0	0	12,585,831	155,961,566
15. Other non-health	0	0	0	0	0	0
16. Medical incentive pools and bonus amounts	30,944,093	150,859,637	25,781,628	118,458,194	56,725,721	79,263,936
17. Totals (Lines 13 - 14 + 15 + 16)	621,703,294	7,503,582,971	52,545,806	1,013,736,351	674,249,100	918,053,304

(a) Excludes $ 16,527,049 loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

($000 Omitted)

Section A - Paid Health Claims - Comprehensive (Hospital & Medical)

	Year in Which Losses Were Incurred	Cumulative Net Amounts Paid 1 2019	2 2020	3 2021	4 2022	5 2023
1.	Prior	178,283	183,864	184,928	185,321	185,321
2.	2019	1,695,161	1,885,457	1,890,617	1,895,104	1,892,180
3.	2020	XXX	1,652,681	1,814,608	1,822,178	1,822,665
4.	2021	XXX	XXX	1,820,388	2,037,523	2,040,123
5.	2022	XXX	XXX	XXX	1,918,161	2,076,443
6.	2023	XXX	XXX	XXX	XXX	1,798,486

Section B - Incurred Health Claims - Comprehensive (Hospital & Medical)

	Year in Which Losses Were Incurred	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year 1 2019	2 2020	3 2021	4 2022	5 2023
1.	Prior	183,115	184,528	185,162	184,687	185,321
2.	2019	1,900,919	1,890,459	1,892,058	1,896,008	1,892,544
3.	2020	XXX	1,881,856	1,821,558	1,823,007	1,822,388
4.	2021	XXX	XXX	2,053,276	2,050,578	2,040,671
5.	2022	XXX	XXX	XXX	2,203,673	2,087,828
6.	2023	XXX	XXX	XXX	XXX	2,023,998

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Comprehensive (Hospital & Medical)

	Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Payments	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1.	2019	2,285,816	1,892,180	99,058	5.2	1,991,238	87.1	364	35	1,991,637	87.1
2.	2020	2,276,644	1,822,665	101,835	5.6	1,924,500	84.5	(277)	(34)	1,924,189	84.5
3.	2021	2,355,049	2,040,123	91,768	4.5	2,131,891	90.5	548	10	2,132,449	90.5
4.	2022	2,505,138	2,076,443	67,719	3.3	2,144,162	85.6	11,385	250	2,155,797	86.1
5.	2023	2,396,735	1,798,486	62,655	3.5	1,861,141	77.7	225,512	6,492	2,093,145	87.3

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

($000 Omitted)

Section A - Paid Health Claims - Medicare Supplement

	Year in Which Losses Were Incurred	Cumulative Net Amounts Paid 1 2019	2 2020	3 2021	4 2022	5 2023
1.	Prior	8,849	8,802	8,922	8,907	8,907
2.	2019	95,361	105,079	105,101	105,063	104,918
3.	2020	XXX	92,101	102,261	102,173	102,211
4.	2021	XXX	XXX	106,334	117,710	117,946
5.	2022	XXX	XXX	XXX	111,775	126,404
6.	2023	XXX	XXX	XXX	XXX	120,357

Section B - Incurred Health Claims - Medicare Supplement

	Year in Which Losses Were Incurred	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year 1 2019	2 2020	3 2021	4 2022	5 2023
1.	Prior	8,958	8,806	8,973	8,907	8,907
2.	2019	105,947	105,192	105,226	105,063	104,918
3.	2020	XXX	104,633	102,438	102,173	102,211
4.	2021	XXX	XXX	119,102	117,722	117,909
5.	2022	XXX	XXX	XXX	128,241	126,462
6.	2023	XXX	XXX	XXX	XXX	134,606

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Medicare Supplement

	Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Payments	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1.	2019	141,181	104,918	12,992	12.4	117,910	83.5	0	0	117,910	83.5
2.	2020	150,044	102,211	12,370	12.1	114,581	76.4	0	0	114,581	76.4
3.	2021	159,689	117,946	13,221	11.2	131,167	82.1	(37)	(1)	131,129	82.1
4.	2022	165,695	126,404	10,206	8.1	136,610	82.4	58	2	136,670	82.5
5.	2023	171,894	120,357	8,927	7.4	129,284	75.2	14,249	435	143,968	83.8

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

($000 Omitted)

Section A - Paid Health Claims - Dental Only

Year in Which Losses Were Incurred	Cumulative Net Amounts Paid 1 2019	2 2020	3 2021	4 2022	5 2023
1. Prior	2,664	2,705	2,724	2,725	2,725
2. 2019	42,355	45,040	45,117	45,123	45,128
3. 2020	XXX	38,500	42,697	42,775	42,785
4. 2021	XXX	XXX	53,456	57,254	57,352
5. 2022	XXX	XXX	XXX	58,874	62,183
6. 2023	XXX	XXX	XXX	XXX	54,687

Section B - Incurred Health Claims - Dental Only

Year in Which Losses Were Incurred	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year 1 2019	2 2020	3 2021	4 2022	5 2023
1. Prior	2,727	2,709	2,724	2,725	2,725
2. 2019	45,268	45,097	45,126	45,123	45,128
3. 2020	XXX	42,820	42,793	42,790	42,784
4. 2021	XXX	XXX	57,801	57,392	57,370
5. 2022	XXX	XXX	XXX	63,192	62,325
6. 2023	XXX	XXX	XXX	XXX	58,263

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Dental Only

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Payments	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1. 2019	59,008	45,128	5,835	12.9	50,963	86.4	0	0	50,963	86.4
2. 2020	62,545	42,785	6,150	14.4	48,935	78.2	(1)	0	48,934	78.2
3. 2021	74,521	57,352	6,925	12.1	64,277	86.3	18	0	64,295	86.3
4. 2022	80,082	62,183	5,846	9.4	68,029	84.9	142	3	68,174	85.1
5. 2023	72,980	54,687	4,716	8.6	59,403	81.4	3,576	86	63,065	86.4

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

($000 Omitted)

Section A - Paid Health Claims - Vision Only

Year in Which Losses Were Incurred	Cumulative Net Amounts Paid				
	1 2019	2 2020	3 2021	4 2022	5 2023
1. Prior	1,108	1,098	1,097	1,097	1,097
2. 2019	17,671	19,001	18,998	18,996	18,998
3. 2020	XXX	11,326	11,943	11,938	11,939
4. 2021	XXX	XXX	13,346	14,097	14,098
5. 2022	XXX	XXX	XXX	14,282	15,419
6. 2023	XXX	XXX	XXX	XXX	16,503

Section B - Incurred Health Claims - Vision Only

Year in Which Losses Were Incurred	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
	1 2019	2 2020	3 2021	4 2022	5 2023
1. Prior	1,104	1,098	1,097	1,097	1,097
2. 2019	19,117	19,001	18,998	18,996	18,998
3. 2020	XXX	12,112	11,944	11,938	11,939
4. 2021	XXX	XXX	14,284	14,097	14,098
5. 2022	XXX	XXX	XXX	15,224	15,421
6. 2023	XXX	XXX	XXX	XXX	17,638

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Vision Only

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Payments	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1. 2019	26,767	18,998	1,368	7.2	20,366	76.1	0	0	20,366	76.1
2. 2020	21,075	11,939	1,547	13.0	13,486	64.0	0	0	13,486	64.0
3. 2021	23,412	14,098	1,731	12.3	15,829	67.6	0	0	15,829	67.6
4. 2022	23,931	15,419	1,332	8.6	16,751	70.0	2	0	16,753	70.0
5. 2023	26,575	16,503	1,055	6.4	17,558	66.1	1,135	26	18,719	70.4

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

($000 Omitted)

Section A - Paid Health Claims - Federal Employees Health Benefits Plan Premium

	Year in Which Losses Were Incurred	Cumulative Net Amounts Paid				
		1 2019	2 2020	3 2021	4 2022	5 2023
1.	Prior	92,733	90,123	89,206	88,983	88,983
2.	2019	719,945	798,690	799,728	799,423	800,363
3.	2020	XXX	703,203	786,526	790,404	791,009
4.	2021	XXX	XXX	769,691	902,229	907,301
5.	2022	XXX	XXX	XXX	762,329	893,885
6.	2023	XXX	XXX	XXX	XXX	840,216

Section B - Incurred Health Claims - Federal Employees Health Benefits Plan Premium

	Year in Which Losses Were Incurred	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
		1 2019	2 2020	3 2021	4 2022	5 2023
1.	Prior	93,003	90,005	89,217	88,968	88,983
2.	2019	805,195	798,513	799,736	799,360	800,341
3.	2020	XXX	788,740	786,690	790,405	791,520
4.	2021	XXX	XXX	895,871	903,292	908,444
5.	2022	XXX	XXX	XXX	887,408	896,901
6.	2023	XXX	XXX	XXX	XXX	977,475

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Federal Employees Health Benefits Plan Premium

	Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Payments	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1.	2019	837,357	800,363	18,476	2.3	818,839	97.8	(22)	(1)	818,816	97.8
2.	2020	844,535	791,009	19,085	2.4	810,094	95.9	511	12	810,617	96.0
3.	2021	943,730	907,301	17,096	1.9	924,397	98.0	1,143	27	925,567	98.1
4.	2022	948,371	893,885	13,761	1.5	907,646	95.7	3,016	71	910,733	96.0
5.	2023	1,048,943	840,216	12,724	1.5	852,940	81.3	137,259	3,213	993,412	94.7

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS
($000 Omitted)

Section A - Paid Health Claims - Title XVIII

Year in Which Losses Were Incurred		Cumulative Net Amounts Paid 1 2019	2 2020	3 2021	4 2022	5 2023
1.	Prior	121,710	139,225	135,543	138,445	138,445
2.	2019	1,691,787	1,847,054	1,842,754	1,840,870	1,839,610
3.	2020	XXX	1,944,059	2,201,658	2,211,393	2,211,154
4.	2021	XXX	XXX	2,548,449	2,748,732	2,764,347
5.	2022	XXX	XXX	XXX	3,003,072	3,179,457
6.	2023	XXX	XXX	XXX	XXX	3,357,567

Section B - Incurred Health Claims - Title XVIII

Year in Which Losses Were Incurred		Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year 1 2019	2 2020	3 2021	4 2022	5 2023
1.	Prior	135,901	137,933	137,746	138,449	138,445
2.	2019	1,846,552	1,840,148	1,842,599	1,840,859	1,839,583
3.	2020	XXX	2,268,820	2,208,371	2,209,844	2,211,135
4.	2021	XXX	XXX	2,830,551	2,755,038	2,765,225
5.	2022	XXX	XXX	XXX	3,365,664	3,206,682
6.	2023	XXX	XXX	XXX	XXX	3,742,786

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XVIII

Years in which Premiums were Earned and Claims were Incurred		1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Payments	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1.	2019	2,195,015	1,839,610	117,260	6.4	1,956,870	89.2	(27)	(1)	1,956,842	89.1
2.	2020	2,692,863	2,211,154	142,463	6.4	2,353,617	87.4	(19)	(1)	2,353,597	87.4
3.	2021	3,182,183	2,764,347	156,957	5.7	2,921,304	91.8	878	(12)	2,922,170	91.8
4.	2022	3,845,992	3,179,457	138,411	4.4	3,317,868	86.3	27,225	85	3,345,178	87.0
5.	2023	4,141,615	3,357,567	120,477	3.6	3,478,044	84.0	385,219	8,382	3,871,645	93.5

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

($000 Omitted)

Section A - Paid Health Claims - Title XIX

Year in Which Losses Were Incurred	Cumulative Net Amounts Paid 1 2019	2 2020	3 2021	4 2022	5 2023
1. Prior	0	0	0	0	0
2. 2019	0	0	0	(73)	(30)
3. 2020	XXX	20,799	25,888	21,084	20,933
4. 2021	XXX	XXX	35,412	44,387	44,023
5. 2022	XXX	XXX	XXX	1,010,977	1,119,839
6. 2023	XXX	XXX	XXX	XXX	819,041

Section B - Incurred Health Claims - Title XIX

Year in Which Losses Were Incurred	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year 1 2019	2 2020	3 2021	4 2022	5 2023
1. Prior	0	0	0	0	0
2. 2019	0	0	0	(73)	(30)
3. 2020	XXX	26,739	26,739	21,084	20,933
4. 2021	XXX	XXX	38,042	44,282	44,023
5. 2022	XXX	XXX	XXX	1,182,686	1,124,577
6. 2023	XXX	XXX	XXX	XXX	994,112

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XIX

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Payments	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1. 2019		(30)	(1)	3.3	(31)	0.0	0	0	(31)	0.0
2. 2020	22,311	20,933	34	0.2	20,967	94.0	0	0	20,967	94.0
3. 2021	47,130	44,023	8,337	18.9	52,360	111.1	0	0	52,360	111.1
4. 2022	1,404,019	1,119,839	61,341	5.5	1,181,180	84.1	4,738	110	1,186,028	84.5
5. 2023	1,305,647	819,041	38,968	4.8	858,009	65.7	175,071	3,770	1,036,850	79.4

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

($000 Omitted)

Section A - Paid Health Claims - Other

	Year in Which Losses Were Incurred	Cumulative Net Amounts Paid				
		1 2019	2 2020	3 2021	4 2022	5 2023
1.	Prior	18,884	19,212	19,209	19,215	19,215
2.	2019	279,240	320,081	320,194	320,246	319,095
3.	2020	XXX	350,879	399,563	399,755	398,607
4.	2021	XXX	XXX	422,998	484,535	481,022
5.	2022	XXX	XXX	XXX	524,558	537,242
6.	2023	XXX	XXX	XXX	XXX	496,724

Section B - Incurred Health Claims - Other

	Year in Which Losses Were Incurred	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
		1 2019	2 2020	3 2021	4 2022	5 2023
1.	Prior	18,988	19,225	19,209	19,215	19,215
2.	2019	323,727	318,840	320,200	320,249	319,095
3.	2020	XXX	410,303	400,099	399,913	399,189
4.	2021	XXX	XXX	492,919	487,944	481,395
5.	2022	XXX	XXX	XXX	608,433	539,188
6.	2023	XXX	XXX	XXX	XXX	568,438

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Other

	Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Payments	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1.	2019	229,635	319,095	15,238	4.8	334,333	145.6	0	(4)	334,329	145.6
2.	2020	233,608	398,607	17,778	4.5	416,385	178.2	582	(4)	416,963	178.5
3.	2021	235,887	481,022	19,546	4.1	500,568	212.2	373	(12)	500,929	212.4
4.	2022	244,956	537,242	1,714	0.3	538,956	220.0	1,946	43	540,945	220.8
5.	2023	687,413	496,724	84	0.0	496,808	72.3	71,714	1,679	570,201	82.9

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

($000 Omitted)

Section A - Paid Health Claims - Grand Total

	Year in Which Losses Were Incurred	Cumulative Net Amounts Paid 1 2019	2 2020	3 2021	4 2022	5 2023
1.	Prior	424,231	445,029	441,629	444,693	444,693
2.	2019	4,541,520	5,020,402	5,022,509	5,024,752	5,020,262
3.	2020	XXX	4,813,548	5,385,144	5,401,700	5,401,303
4.	2021	XXX	XXX	5,770,074	6,406,467	6,426,212
5.	2022	XXX	XXX	XXX	7,404,028	8,010,872
6.	2023	XXX	XXX	XXX	XXX	7,503,581

Section B - Incurred Health Claims - Grand Total

	Year in Which Losses Were Incurred	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year 1 2019	2 2020	3 2021	4 2022	5 2023
1.	Prior	443,796	444,304	444,128	444,048	444,693
2.	2019	5,046,725	5,017,250	5,023,943	5,025,585	5,020,577
3.	2020	XXX	5,536,023	5,400,632	5,401,154	5,402,099
4.	2021	XXX	XXX	6,501,846	6,430,345	6,429,135
5.	2022	XXX	XXX	XXX	8,454,521	8,059,384
6.	2023	XXX	XXX	XXX	XXX	8,517,316

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

	Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Payments	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1.	2019	5,774,779	5,020,262	270,226	5.4	5,290,488	91.6	315	29	5,290,832	91.6
2.	2020	6,303,625	5,401,303	301,262	5.6	5,702,565	90.5	796	(27)	5,703,334	90.5
3.	2021	7,021,601	6,426,212	315,581	4.9	6,741,793	96.0	2,923	12	6,744,728	96.1
4.	2022	9,218,184	8,010,872	300,330	3.7	8,311,202	90.2	48,512	564	8,360,278	90.7
5.	2023	9,851,802	7,503,581	249,606	3.3	7,753,187	78.7	1,013,735	24,083	8,791,005	89.2

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

	1	Comprehensive (Hospital & Medical)		4	5	6	7	8	9	10	11	12	13
		2	3										
	Total	Individual	Group	Medicare Supplement	Vision Only	Dental Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other
1. Unearned premium reserves	5,716,399			5,716,399									
2. Additional policy reserves (a)	14,221,690			14,221,690									
3. Reserve for future contingent benefits	0												
4. Reserve for rate credits or experience rating refunds (including $ .... for investment income)	46,671,316		13,056,155	150,490				30,043,292	3,421,379				
5. Aggregate write-ins for other policy reserves	51,451,709	37,143,725	1,717,879	0	0	0	0	12,590,105	0	0	0	0	0
6. Totals (gross)	118,061,114	37,143,725	14,774,034	20,088,579	0	0	0	42,633,397	3,421,379	0	0	0	0
7. Reinsurance ceded	0												
8. Totals (Net)(Page 3, Line 4)	118,061,114	37,143,725	14,774,034	20,088,579	0	0	0	42,633,397	3,421,379	0	0	0	0
9. Present value of amounts not yet due on claims	0												
10. Reserve for future contingent benefits	0												
11. Aggregate write-ins for other claim reserves	0	0	0	0	0	0	0	0	0	0	0	0	0
12. Totals (gross)	0	0	0	0	0	0	0	0	0	0	0	0	0
13. Reinsurance ceded	0												
14. Totals (Net)(Page 3, Line 7)	0	0	0	0	0	0	0	0	0	0	0	0	0
DETAILS OF WRITE-INS													
0501. Policy reserves subject to redetermination	51,451,709	37,143,725	1,717,879					12,590,105					
0502.													
0503.													
0598. Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	0	0	0	0	0
0599. Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	51,451,709	37,143,725	1,717,879	0	0	0	0	12,590,105	0	0	0	0	0
1101.													
1102.													
1103.													
1198. Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0	0	0	0	0	0	0	0	0	0
1199. Totals (Lines 1101 thru 1103 plus 1198) (Line 11 above)	0	0	0	0	0	0	0	0	0	0	0	0	0

(a) Includes $ .... premium deficiency reserve.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 3 - ANALYSIS OF EXPENSES

	Claim Adjustment Expenses		3	4	5
	1 Cost Containment Expenses	2 Other Claim Adjustment Expenses	General Administrative Expenses	Investment Expenses	Total
1. Rent ($ .... for occupancy of own building)	2,290,180	2,022,549	2,314,180	0	6,626,909
2. Salary, wages and other benefits	109,211,393	64,616,565	452,058,843	0	625,886,801
3. Commissions (less $ .... ceded plus $ .... assumed)	0	0	244,862,376	0	244,862,376
4. Legal fees and expenses	58,321	285,257	13,032,734	0	13,376,312
5. Certifications and accreditation fees	0	0	0	0	0
6. Auditing, actuarial and other consulting services	11,279,998	6,940,619	73,035,099	0	91,255,716
7. Traveling expenses	277,831	62,066	3,743,880	0	4,083,777
8. Marketing and advertising	1,148,908	939,503	52,418,225	0	54,506,636
9. Postage, express and telephone	718,771	1,546,790	26,063,354	0	28,328,915
10. Printing and office supplies	259,764	46,523	6,343,871	0	6,650,158
11. Occupancy, depreciation and amortization	0	0	0	0	0
12. Equipment	2,430	7,575	2,041,535	0	2,051,540
13. Cost or depreciation of EDP equipment and software	(5,842,446)	1,063,083	61,760,477	0	56,981,114
14. Outsourced services including EDP, claims, and other services	20,741,015	11,439,047	164,965,142	0	197,145,204
15. Boards, bureaus and association fees	31,719	1,405	2,570,553	0	2,603,677
16. Insurance, except on real estate	0	0	2,954,463	0	2,954,463
17. Collection and bank service charges	1,672	0	2,629,751	0	2,631,423
18. Group service and administration fees	986,073	3,442,805	66,641,495	0	71,070,373
19. Reimbursements by uninsured plans	0	0	(710,243,109)	0	(710,243,109)
20. Reimbursements from fiscal intermediaries	0	0	0	0	0
21. Real estate expenses	208	2,303	9,312,554	0	9,315,065
22. Real estate taxes	0	0	24,860	0	24,860
23. Taxes, licenses and fees:					
23.1 State and local insurance taxes	(4,664,095)	(3,139,904)	96,070,435	0	88,266,436
23.2 State premium taxes	0	0	36,813,096	0	36,813,096
23.3 Regulatory authority licenses and fees	458,374	58,248	1,244,311	0	1,760,933
23.4 Payroll taxes	10,713,932	6,890,468	18,397,979	0	36,002,379
23.5 Other (excluding federal income and real estate taxes)	0	0	14,851,439	0	14,851,439
24. Investment expenses not included elsewhere	0	0	0	3,703,136	3,703,136
25. Aggregate write-ins for expenses	9,476,718	32,163,126	77,538,340	0	119,178,184
26. Total expenses incurred (Lines 1 to 25)	157,150,766	128,388,028	721,445,883	3,703,136	(a) 1,010,687,813
27. Less expenses unpaid December 31, current year	0	24,663,216	133,598,892	0	158,262,108
28. Add expenses unpaid December 31, prior year	0	26,057,642	121,503,016	0	147,560,658
29. Amounts receivable relating to uninsured plans, prior year			377,359,439		377,359,439
30. Amounts receivable relating to uninsured plans, current year	0	0	397,591,046	0	397,591,046
31. Total expenses paid (Lines 26 minus 27 plus 28 minus 29 plus 30)	157,150,766	129,782,454	729,581,614	3,703,136	1,020,217,970
DETAILS OF WRITE-INS					
2501. Miscellaneous expenses	9,476,718	32,163,126	77,538,340		119,178,184
2502.					
2503.					
2598. Summary of remaining write-ins for Line 25 from overflow page	0	0	0	0	0
2599. Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	9,476,718	32,163,126	77,538,340	0	119,178,184

(a) Includes management fees of $ 1,160,913,801 to affiliates and $ .... to non-affiliates.

EXHIBIT OF NET INVESTMENT INCOME

		1 Collected During Year	2 Earned During Year
1.	U.S. government bonds	(a) 5,347,123	5,528,360
1.1	Bonds exempt from U.S. tax	(a)	
1.2	Other bonds (unaffiliated)	(a) 79,241,613	81,428,175
1.3	Bonds of affiliates	(a) 0	0
2.1	Preferred stocks (unaffiliated)	(b) 0	0
2.11	Preferred stocks of affiliates	(b) 0	0
2.2	Common stocks (unaffiliated)	218,160	218,160
2.21	Common stocks of affiliates	0	0
3.	Mortgage loans	(c) 6,151,605	6,777,205
4.	Real estate	(d) 0	0
5	Contract Loans	0	0
6	Cash, cash equivalents and short-term investments	(e) 23,508,279	23,508,803
7	Derivative instruments	(f) 0	0
8.	Other invested assets	4,409,213	4,409,213
9.	Aggregate write-ins for investment income	143,977	133,710
10.	Total gross investment income	119,019,969	122,003,625
11.	Investment expenses		(g) 3,703,136
12.	Investment taxes, licenses and fees, excluding federal income taxes		(g) 0
13.	Interest expense		(h)
14.	Depreciation on real estate and other invested assets		(i)
15.	Aggregate write-ins for deductions from investment income		0
16.	Total deductions (Lines 11 through 15)		3,703,136
17.	Net investment income (Line 10 minus Line 16)		118,300,489
	DETAILS OF WRITE-INS		
0901.	Miscellaneous Income	(143,828)	(143,828)
0902.	Securities Lending	287,804	277,538
0903.			
0998.	Summary of remaining write-ins for Line 9 from overflow page	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	143,977	133,710
1501.			
1502.			
1503.			
1598.	Summary of remaining write-ins for Line 15 from overflow page		0
1599.	Totals (Lines 1501 thru 1503 plus 1598) (Line 15, above)		0

(a) Includes $ 9,224,398 accrual of discount less $ 4,786,627 amortization of premium and less $ 6,468,997 paid for accrued interest on purchases.

(b) Includes $ 0 accrual of discount less $ 0 amortization of premium and less $ 0 paid for accrued dividends on purchases.

(c) Includes $ 0 accrual of discount less $ 0 amortization of premium and less $ .... paid for accrued interest on purchases.

(d) Includes $ .... for company's occupancy of its own buildings; and excludes $ .... interest on encumbrances.

(e) Includes $ 1,188,237 accrual of discount less $ 425 amortization of premium and less $ 4,408 paid for accrued interest on purchases.

(f) Includes $ 0 accrual of discount less $ 0 amortization of premium.

(g) Includes $. .... investment expenses and $ .... investment taxes, licenses and fees, excluding federal income taxes, attributable to segregated and Separate Accounts.

(h) Includes $ .... interest on surplus notes and $ .... interest on capital notes.

(i) Includes $ 0 depreciation on real estate and $ .... depreciation on other invested assets.

EXHIBIT OF CAPITAL GAINS (LOSSES)

		1 Realized Gain (Loss) On Sales or Maturity	2 Other Realized Adjustments	3 Total Realized Capital Gain (Loss) (Columns 1 + 2)	4 Change in Unrealized Capital Gain (Loss)	5 Change in Unrealized Foreign Exchange Capital Gain (Loss)
1.	U.S. Government bonds	(3,534,729)	0	(3,534,729)	0	0
1.1	Bonds exempt from U.S. tax			0		
1.2	Other bonds (unaffiliated)	(29,648,430)	(2,191,948)	(31,840,378)	22,371,528	0
1.3	Bonds of affiliates	0	0	0	0	0
2.1	Preferred stocks (unaffiliated)	0	0	0	0	0
2.11	Preferred stocks of affiliates	0	0	0	0	0
2.2	Common stocks (unaffiliated)	529,323	(654,084)	(124,761)	41,419	1,725
2.21	Common stocks of affiliates	0	0	0	0	0
3.	Mortgage loans		0	0	0	0
4.	Real estate		0	0		0
5.	Contract loans	0	0	0		
6.	Cash, cash equivalents and short-term investments	(294)	(248,239)	(248,533)	0	
7.	Derivative instruments	0	0	0	0	
8.	Other invested assets	0	0	0	(4,679,137)	0
9.	Aggregate write-ins for capital gains (losses)	(1,223)	466,108	464,885	39,536	37,810
10.	Total capital gains (losses)	(32,655,353)	(2,628,163)	(35,283,516)	17,773,346	39,535
	DETAILS OF WRITE-INS					
0901.	Gain on sale-leaseback activity		503,918	503,918		
0902.	Foreign exchange investments	(1,223)	(37,810)	(39,033)	39,536	37,810
0903.						
0998.	Summary of remaining write-ins for Line 9 from overflow page	0	0	0	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	(1,223)	466,108	464,885	39,536	37,810

EXHIBIT OF NON-ADMITTED ASSETS

	1 Current Year Total Nonadmitted Assets	2 Prior Year Total Nonadmitted Assets	3 Change in Total Nonadmitted Assets (Col. 2 - Col. 1)
1. Bonds (Schedule D)			0
2. Stocks (Schedule D):			
2.1 Preferred stocks			0
2.2 Common stocks			0
3. Mortgage loans on real estate (Schedule B):			
3.1 First liens	712,122		(712,122)
3.2 Other than first liens			0
4. Real estate (Schedule A):			
4.1 Properties occupied by the company			0
4.2 Properties held for the production of income			0
4.3 Properties held for sale			0
5. Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments (Schedule DA)			0
6. Contract loans			0
7. Derivatives (Schedule DB)			0
8. Other invested assets (Schedule BA)			0
9. Receivables for securities	818,369	316,685	(501,684)
10. Securities lending reinvested collateral assets (Schedule DL)			0
11. Aggregate write-ins for invested assets	0	0	0
12. Subtotals, cash and invested assets (Lines 1 to 11)	1,530,491	316,685	(1,213,806)
13. Title plants (for Title insurers only)			0
14. Investment income due and accrued	11,633	16,049	4,416
15. Premiums and considerations:			
15.1 Uncollected premiums and agents' balances in the course of collection	2,653,217	3,444,098	790,881
15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due			0
15.3 Accrued retrospective premiums and contracts subject to redetermination			0
16. Reinsurance:			
16.1 Amounts recoverable from reinsurers			0
16.2 Funds held by or deposited with reinsured companies			0
16.3 Other amounts receivable under reinsurance contracts			0
17. Amounts receivable relating to uninsured plans	37,537,768	31,244,514	(6,293,254)
18.1 Current federal and foreign income tax recoverable and interest thereon			0
18.2 Net deferred tax asset	20,958,645	13,733,786	(7,224,859)
19. Guaranty funds receivable or on deposit			0
20. Electronic data processing equipment and software			0
21. Furniture and equipment, including health care delivery assets	22,402,820	10,868,998	(11,533,822)
22. Net adjustment in assets and liabilities due to foreign exchange rates			0
23. Receivable from parent, subsidiaries and affiliates			0
24. Health care and other amounts receivable	71,251,418	62,740,746	(8,510,672)
25. Aggregate write-ins for other than invested assets	71,020,434	90,235,016	19,214,582
26. Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	227,366,426	212,599,892	(14,766,534)
27. From Separate Accounts, Segregated Accounts and Protected Cell Accounts			0
28. Total (Lines 26 and 27)	227,366,426	212,599,892	(14,766,534)
DETAILS OF WRITE-INS			
1101.			
1102.			
1103.			
1198. Summary of remaining write-ins for Line 11 from overflow page	0	0	0
1199. Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0
2501. Intangibles	53,119,074	70,328,911	17,209,837
2502. Prepaid expenses	15,123,785	16,564,124	1,440,339
2503. Other miscellaneous accounts receivable	2,777,575	3,341,982	564,407
2598. Summary of remaining write-ins for Line 25 from overflow page	0	0	0
2599. Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	71,020,434	90,235,016	19,214,582

EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

Source of Enrollment	Total Members at End of 1 Prior Year	2 First Quarter	3 Second Quarter	4 Third Quarter	5 Current Year	6 Current Year Member Months
1. Health Maintenance Organizations	569,329	621,105	615,221	600,686	588,107	7,284,702
2. Provider Service Organizations						
3. Preferred Provider Organizations	1,562,431	1,381,332	1,360,130	1,323,531	1,271,552	15,021,464
4. Point of Service	288	281	282	281	306	3,388
5. Indemnity Only	79,235	79,209	77,835	76,827	77,018	933,107
6. Aggregate write-ins for other lines of business	428,940	358,564	349,986	350,055	299,662	4,240,364
7. Total	2,640,223	2,440,491	2,403,454	2,351,380	2,236,645	27,483,025
DETAILS OF WRITE-INS						
0601. Consumer Driven Health Plans	417,983	345,594	337,788	340,088	289,590	4,103,764
0602. Supplemental Health Products	10,957	12,970	12,198	9,967	10,072	136,600
0603.						
0698. Summary of remaining write-ins for Line 6 from overflow page	0	0	0	0	0	0
0699. Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	428,940	358,564	349,986	350,055	299,662	4,240,364

NOTES TO FINANCIAL STATEMENTS

1. Summary of Significant Accounting Policies and Going Concern

A. Accounting Practices

The accompanying financial statements of Community Insurance Company (the "Company") have been prepared in conformity with the National Association of Insurance Commissioners' ("NAIC") *Annual Statement Instructions* and in accordance with accounting practices prescribed by the NAIC *Accounting Practices and Procedures Manual* ("NAIC SAP"), subject to any deviations prescribed or permitted by the Ohio Insurance Department (the "Department").

A reconciliation of the Company's net income (loss) and capital and surplus between NAIC SAP and practices prescribed and permitted by the Department is shown below:

	SSAP #	F/S Page	F/S Line #	2023	2022
Net Income					
(1) Community Insurance Company state basis (Page 4, Line 32, Columns 2 & 3)	XXX	XXX	XXX	$ 517,285,621	$ 271,239,930
(2) State Prescribed Practices that is an increase/(decrease) from NAIC SAP:				—	—
(3) State Permitted Practices that is an increase/(decrease) from NAIC SAP:				—	—
(4) NAIC SAP (1-2-3=4)	XXX	XXX	XXX	$ 517,285,621	$ 271,239,930
Surplus					
(5) Community Insurance Company state basis (Page 3, Line 33, Columns 3 & 4)	XXX	XXX	XXX	$1,617,516,394	$1,340,623,509
(6) State Prescribed Practices that is an increase/(decrease) from NAIC SAP:				—	—
(7) State Permitted Practices that is an increase/(decrease) from NAIC SAP:				—	—
(8) NAIC SAP (5-6-7=8)	XXX	XXX	XXX	$1,617,516,394	$1,340,623,509

B. Use of Estimates in the Preparation of the Financial Statements

Preparation of financial statements requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

C. Accounting Policies

Health premiums are earned over the term of the related insurance policies and reinsurance contracts. Premiums written are reported net of excess loss reinsurance ceded and experience rating refunds. Unearned premium reserves are established to cover the unexpired portion of premiums written and are computed by pro rata methods for direct business and based on reports received from ceding companies for reinsurance. Premiums paid by subscribers prior to the effective date are recorded on the balance sheet as premiums received in advance and are subsequently credited to income as earned during the coverage period. Premium rates for certain lines of business are subject to approval by the Department or the Center for Medicare and Medicaid Services. Expenses

NOTES TO FINANCIAL STATEMENTS

incurred in connection with acquiring new insurance business, including acquisition costs such as sales commissions, are charged to operations as incurred. All other costs, including underwriting expenses, are charged to operations as incurred.

The Company provides administrative services to various customers on an uninsured basis. Under these arrangements, the customer retains the risk of funding payments for health benefits provided, and the Company may be subject to credit risk of the customer from the time of the Company's claim payment until the Company receives the claim reimbursement. In accordance with SSAP No. 47, *Uninsured Plans*, these claims payments and subsequent reimbursements are excluded from the Company's statutory statement of revenue and expenses. Administrative fees for administering these arrangements are recognized as administrative services are performed and recorded as a reduction to operating expenses.

In addition, the Company uses the following accounting policies:

(1) Short-term investments include investments with maturities of less than one year and more than three months at the date of acquisition and are reported at amortized cost, which approximates fair value. Non-investment grade short-term investments are stated at the lower of amortized cost or fair value.
(2) Investment grade bonds not backed by other loans are stated at amortized cost, with amortization calculated based on the modified scientific method, using lower of yield to call or yield to maturity. Non-investment grade bonds are stated at the lower of amortized cost or fair value as determined by various third-party pricing sources.
(3) Common stocks of unaffiliated companies are stated at fair value based upon security ratings prescribed by various third-party pricing sources.
(4) The Company has no investments in preferred stocks.
(5) Mortgage loans held for investment are reported on the balance sheet at their amortized cost basis, which is the amount at which the loan is originated, adjusted for accrued interest, amortization of premium, discount and net deferred fees or costs, collection of cash, and write-offs.
(6) Loan-backed securities are stated at amortized cost. Prepayment assumptions for loan-backed securities and structured securities were obtained from broker-dealer survey values or internal estimates. These assumptions are consistent with the current interest rate and economic environment. The retrospective adjustment method is used to value all loan-backed securities. Non-investment grade loan-backed securities are stated at the lower of amortized cost or fair value.
(7) The Company has no investments in subsidiaries, controlled and affiliated companies.
(8) The Company has ownership interests in unaffiliated joint ventures and limited liability companies. The Company reports these interests as Other Long-Term Invested Assets on Schedule BA. The Company carries these investments at their underlying GAAP equity value. The Company reports the net change in the equity, excluding changes in capital contributions and distributions received in excess of undistributed earnings, as a change in net unrealized capital gains and losses in unassigned surplus.
(9) The Company has no derivative instruments.
(10) The Company recognizes losses from other-than-temporary impairments ("OTTI") of investments in accordance with Statements of Standard Accounting Practice ("SSAP") No. 26R, *Bonds*; and SSAP No. 30, *Common Stock*; and SSAP No. 32R, *Preferred Stock*.
(11) The Company does not anticipate investment income as a factor in premium deficiency calculations.

NOTES TO FINANCIAL STATEMENTS

(12) Unpaid claims and claims adjustment expenses include management's best estimate of amounts based on historical claim development patterns and certain individual case estimates. The established liability considers health benefit provisions, business practices, economic conditions and other factors that may materially affect the cost, frequency and severity of claims. Liabilities for unpaid claims and claim adjustment expenses are based on assumptions and estimates, and while management believes such estimates are reasonable, the ultimate liability may be in excess of or less than the amount provided. The methods for making such estimates and for establishing the resulting liabilities are continually reviewed and changes in estimates are incorporated into current period estimates.

(13) The Company has not modified its capitalization policy from the prior period.

(14) Pharmacy rebate receivables are recorded when earned based upon actual rebate receivables billed and an estimate of receivables based upon current utilization of specific pharmaceuticals and provider contract terms.

(15) Service fees earned from providing administrative services to self-insured customers are deducted from operating expenses, and related claim payments and subsequent reimbursements of those claim payments are excluded from net income.

(16) The Company records a liability for future policy benefits relating to certain Medicare supplement and individual product contracts. The liability represents the present value of future benefits to be paid to or on behalf of policy holders and related expenses less the present value of future net premiums. Changes in the liability for future benefits are reported as a component of net income in the period in which the change occurs.

(17) The Company sells policies where premiums vary based on loss experience or premium stabilization programs. Retrospectively rated refunds include minimum medical loss ratio ("MLR") rebates per the Affordable Care Act ("ACA"). Risk adjustment programs transfer premiums from insurers that enroll members with relatively lower health risks to insurers that enroll members with relatively higher health risks. Reserves for rate credits, risk adjustment programs or policy rating refunds are reported in aggregate policy reserves. Accrued retrospective premiums are reported in premiums receivable.

(18) Premium under the Federal Employee Program ("FEP") is earned when chargeable benefit costs, allowable expenses and retentions are incurred. Deferred premiums are recorded to offset the FEP liabilities for incurred claims but not reported and claims adjustment expenses that are due from the Office of Personnel Management ("OPM") when the claims are ultimately paid.

(19) For investments in corporate-owned life insurance ("COLI"), the amount that could be realized on a life insurance policy as of the date to which premiums have been paid is reported as an admitted asset. The change in the cash surrender value, or contract value, of COLI during the period is treated as income.

(20) A discount rate is applied to guaranty fund liabilities and assets related to assessments from insolvencies of entities that wrote long-term care contracts.

(21) Investments in non-rated residual tranches in bonds are reported as other invested assets valued on Schedule BA at the lower of cost or fair value.

D. Going Concern

Not applicable.

2. Accounting Changes and Corrections of Errors

Effective January 1, 2023, the Company adopted GAAP Accounting Standard Update (ASU) Number 2020-11 and 2018-18, *Targeted Improvements to the Accounting for Long-Duration Contracts*. The adoption of this new GAAP accounting guidance resulted in a reduction in GAAP active life reserves for Medicare Supplement products, which were previously used for statutory reporting purposes as the GAAP calculated reserves exceeded statutory reserve minimums. These reserves are now below the reserves required under NAIC SAP, therefore, the calculation for statutory active life reserves has been updated for these products to use the

NOTES TO FINANCIAL STATEMENTS

prescribed two-year preliminary term methodology. The financial impact of moving from the previous net level premium to the current two-year preliminary term method is $660,333 increase in Aggregate Health Policy Reserves at January 1, 2023. This change in reserving methodology represents a change in accounting principle and was recorded to unassigned surplus in accordance with SSAP 3, *Accounting Changes and Corrections of Errors*.

3. Business Combinations and Goodwill

A. Statutory Purchase Method

Not applicable.

B. Statutory Merger

Not applicable.

C. Assumption Reinsurance

Not applicable.

D. Impairment Loss

Not applicable.

E. Subcomponents and Calculation of Adjusted Surplus and Total Admitted Goodwill

Not applicable.

4. Discontinued Operations

The Company had no operations that were discontinued during 2023 or 2022.

5. Investments

A. Mortgage Loans, including Mezzanine Real Estate Loans

(1) The maximum and minimum lending rates for mortgage loans during 2023 were:

Farm loans 0.0% and 0.0%, City loans 0.0% and 0.0%, Purchase money mortgages 6.2% and 3.8%.

(2) The maximum percentage of any one loan to the value of security at the time of the loan, exclusive of insured or guaranteed or purchase money mortgages was: 83.9%

	Current Year	Prior Year
(3) Taxes, assessments and any amounts advanced and not included in the mortgage loan total:	$ —	—

NOTES TO FINANCIAL STATEMENTS

(4) Age Analysis of Mortgage Loans and Identification of Mortgage Loans in Which the Insurer is Participant or Co-lender in a Mortgage Loan Agreement:

	Farm	Residential		Commercial		Mezzanine	Total
		Insured	All Other	Insured	All Other		
a. Current Year							
1. Recorded Investment (All)							
(a) Current	$ —	$ —	$ —	$ —	$212,575,00	$ —	$212,575,00
(b) 30-59 Days Past Due	—	—	—	—	—	—	—
(c) 60-89 Days Past Due	—	—	—	—	—	—	—
(d) 90-179 Days Past Due	—	—	—	—	—	—	—
(e) 180+ Days Past Due	—	—	—	—	—	—	—
2. Accruing Interest 90-179 Days Past Due							
(a) Recorded Investment	$ —	$ —	$ —	$ —	$ —	$ —	$ —
(b) Interest Accrued	—	—	—	—	—	—	—
3. Accruing Interest 180+ Days Past Due							
(a) Recorded Investment	$ —	$ —	$ —	$ —	$ —	$ —	$ —
(b) Interest Accrued	—	—	—	—	—	—	—
4. Interest Reduced							
(a) Recorded Investment	$ —	$ —	$ —	$ —	$ —	$ —	$ —
(b) Number of Loans	—	—	—	—	—	—	—
(c) Percent Reduced	— %	— %	— %	— %	— %	— %	— %
5. Participant or Co-lender in a Mortgage Loan Agreement							
(a) Recorded Investment	$ —	$ —	$ —	$ —	$ —	$ —	$ —
b. Prior Year							
1. Recorded Investment (All)							
(a) Current	$ —	$ —	$ —	$ —	$75,980,000	$ —	$75,980,000
(b) 30-59 Days Past Due	—	—	—	—	—	—	—
(c) 60-89 Days Past Due	—	—	—	—	—	—	—
(d) 90-179 Days Past Due	—	—	—	—	—	—	—
(e) 180+ Days Past Due	—	—	—	—	—	—	—
2. Accruing Interest 90-179 Days Past Due							
(a) Recorded Investment	$ —	$ —	$ —	$ —	$ —	$ —	$ —
(b) Interest Accrued	—	—	—	—	—	—	—
3. Accruing Interest 180+ Days Past Due							
(a) Recorded Investment	$ —	$ —	$ —	$ —	$ —	$ —	$ —
(b) Interest Accrued	—	—	—	—	—	—	—
4. Interest Reduced							
(a) Recorded Investment	$ —	$ —	$ —	$ —	$ —	$ —	$ —
(b) Number of Loans	—	—	—	—	—	—	—
(c) Percent Reduced	— %	— %	— %	— %	— %	— %	— %
5. Participant or Co-lender in a Mortgage Loan Agreement							
(a) Recorded Investment	$ —	$ —	$ —	$ —	$ —	$ —	$ —

NOTES TO FINANCIAL STATEMENTS

(5) Investment in Impaired Loans With or Without Allowance for Credit Losses and Impaired Loans Subject to a Participant or Co-lender Mortgage Loan Agreement for Which the Reporting Entity is Restricted from Unilaterally Foreclosing on the Mortgage Loan:

	Farm	Residential		Commercial		Mezzanine	Total
		Insured	All Other	Insured	All Other		
a. Current Year							
1. With Allowance for Credit Losses	$ —	$ —	$ —	$ —	$ —	$ —	$ —
2. No Allowances for Credit Losses	—	—	—	—	—	—	—
3. Total (1+2)	—	—	—	—	—	—	—
4. Subject to a participant or co-lender mortgage loan agreement for which the reporting entity is restricted from unilaterally foreclosing on the mortgage loan.	—	—	—	—	—	—	—
b. Prior Year							
1. With Allowance for Credit Losses	$ —	$ —	$ —	$ —	$ —	$ —	$ —
2. No Allowances for Credit Losses	—	—	—	—	—	—	—
3. Total (1+2)	—	—	—	—	—	—	—
4. Subject to a participant or co-lender mortgage loan agreement for which the reporting entity is restricted from unilaterally foreclosing on the mortgage loan.	—	—	—	—	—	—	—

(6) Investment in Impaired Loans - Average Recorded Investment, Interest Income Recognized, Recorded Investment on Nonaccrual Status and Amount of Interest Income Recognized Using a Cash-Basis Method of Accounting:

	Farm	Residential		Commercial		Mezzanine	Total
		Insured	All Other	Insured	All Other		
a. Current Year							
1. Average Recorded Investment	$ —	$ —	$ —	$ —	$ —	$ —	$ —
2. Interest Income Recognized	—	—	—	—	—	—	—
3. Recorded Investments on Nonaccrual Status	—	—	—	—	—	—	—
4. Amount of Interest Income Recognized Using a Cash-Basis Method of Accounting	—	—	—	—	—	—	—
b. Prior Year							
1. Average Recorded Investment	$ —	$ —	$ —	$ —	$ —	$ —	$ —
2. Interest Income Recognized	—	—	—	—	—	—	—
3. Recorded Investments on Nonaccrual Status	—	—	—	—	—	—	—
4. Amount of Interest Income Recognized Using a Cash-Basis Method of Accounting	—	—	—	—	—	—	—

(7) Allowance for Credit Losses:

	Current Year	Prior Year
a. Balance at beginning of period	$ —	$ —
b. Additions charged to operations	$ —	$ —
c. Direct write-downs charged against the allowances	$ —	$ —
d. Recoveries of amounts previously charged off	$ —	$ —
e. Balance at end of period	$ —	$ —

NOTES TO FINANCIAL STATEMENTS

(8) Mortgage Loans Derecognized as a Result of Foreclosure:

			Current Year
a.	Aggregate amount of mortgage loans derecognized	$	—
b.	Real estate collateral recognized	$	—
c.	Other collateral recognized	$	—
d.	Receivables recognized from a government guarantee of the foreclosed mortgage loan	$	—

(9) The company recognizes interest income on its impaired loans upon receipt.

B. Debt Restructuring

The Company did not have invested assets that were restructured debt at December 31, 2023 or 2022.

C. Reverse Mortgages

The Company did not have investments in reverse mortgages at December 31, 2023 or 2022.

D. Loan-Backed Securities

(1) Prepayment assumptions for single-class and multi-class mortgage-backed and asset-backed securities were obtained from broker-dealer survey values or internal estimates. The Company used various third-party pricing sources in determining the market value of its loan-backed securities.
(2) The Company did not recognize OTTI on its loan-backed securities during the years ended December 31, 2023 and 2022.
(3) The Company did not recognize OTTI on its loan-backed securities at December 31, 2023 and 2022.
(4) All impaired securities (fair value is less than cost or amortized cost) for which an other-than-temporary impairment has not been recognized in earnings as a realized loss (including securities with a recognized other-than-temporary impairment for non-interest related declines when a non-recognized interest related impairment remains):

a.	The aggregate amount of unrealized losses:				
		1.	Less than 12 Months	$	(2,019,830)
		2.	12 Months or Longer	$	(38,238,020)
b.	The aggregate related fair value of securities with unrealized losses:				
		1.	Less than 12 Months	$	135,691,432
		2.	12 Months or Longer	$	432,966,368

(5) The Company's bond portfolio is sensitive to interest rate fluctuations, which impact the fair value of individual securities. Unrealized losses on bonds were primarily caused by the effects of the interest rate environment and the widening of credit spreads on certain securities. The Company currently has the ability and intent to hold these securities until their full cost can be recovered. Therefore, the Company does not believe the unrealized losses represent an OTTI at December 31, 2023 or 2022.

E. Dollar Repurchase Agreements and/or Securities Lending Transactions

(1) The Company did not enter into repurchase agreements at December 31, 2023 or 2022.

NOTES TO FINANCIAL STATEMENTS

(2) The Company participates in a securities lending program whereby marketable securities in its investment portfolio are transferred to independent brokers or dealers based on, among other things, their creditworthiness in exchange for collateral initially equal to at least 102% of the market value of the loaned securities. The Company receives the collateral in cash or securities, and if cash is received the cash collateral is thereafter invested according to guidelines of the Company's Investment Policy.

(3) Collateral Received

a. Aggregate amount collateral received

			Fair Value
1.	Securities Lending		
	(a) Open	$	128,545,439
	(b) 30 days or less		—
	(c) 31 to 60 days		—
	(d) 61 to 90 days		—
	(e) Greater than 90 days		—
	(f) Sub-total	$	128,545,439
	(g) Securities received		34,182,908
	(h) Total collateral received	$	162,728,347

2. Dollar repurchase agreement - Not applicable.

b. The fair value of that collateral and of the portion of that collateral that it has sold or repledged	$	162,728,347

c. The Company receives cash collateral in an amount in excess of fair value of the securities lent. The Company reinvests the cash collateral according to guidelines of the Company's Investment Policy.

(4) Not applicable.

(5) Collateral Reinvestment

a. Aggregate amount collateral reinvested

				Amortized Cost		Fair Value
1.	Securities Lending					
	(a)	Open	$	—	$	—
	(b)	30 days or less		52,483,508		52,500,284
	(c)	31 to 60 days		28,953,643		28,981,370
	(d)	61 to 90 days		10,122,454		10,164,461
	(e)	91 to 120 days		11,013,258		11,022,382
	(f)	121 to 180 days		17,317,480		17,324,142
	(g)	181 to 365 days		8,545,084		8,552,799
	(k)	Sub-total		128,435,427		128,545,439
	(l)	Securities received		34,182,908		34,182,908
	(m)	Total collateral reinvested	$	162,618,335	$	162,728,347

2. Dollar repurchase agreement - Not applicable.

b. Not applicable.

(6) Not applicable.

(7) Not applicable.

NOTES TO FINANCIAL STATEMENTS

F. Repurchase Agreements Transactions Accounted for as Secured Borrowing

The Company did not enter into repurchase agreement transactions accounted for as secured borrowing at December 31, 2023 or 2022.

G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing

(1) The Company allows investment managers to engage in reverse repurchase agreements, in accordance with our investment policy. Investment managers participate in overnight reverse repurchase trading where they provide cash in exchange for a US Treasury (or other high quality collateral) with an initial fair value equal to at least 102% of the amount lent.

(2) Type of Repo Trades Used

	FIRST QUARTER	SECOND QUARTER	THIRD QUARTER	FOURTH QUARTER
a. Bilateral (YES/NO)	YES	YES	YES	YES
b. Tri-Party (YES/NO)	NO	NO	NO	NO

(3) Original (Flow) & Residual Maturity

	FIRST QUARTER	SECOND QUARTER	THIRD QUARTER	FOURTH QUARTER
a. Maximum Amount				
1. Open - No Maturity	$ —	$ —	$ —	$ —
2. Overnight	$ 24,800,000	$ 27,300,000	$ 29,600,000	$ 7,700,000
3. 2 Days to 1 Week	$ —	$ —	$ —	$ —
4. >1 Week to 1 Month	$ —	$ —	$ —	$ —
5. >1 Month to 3 Months	$ —	$ —	$ —	$ —
6. >3 Months to 1 Year	$ —	$ —	$ —	$ —
7. >1 Year	$ —	$ —	$ —	$ —

	FIRST QUARTER	SECOND QUARTER	THIRD QUARTER	FOURTH QUARTER
b. Ending Balance				
1. Open - No Maturity	$ —	$ —	$ —	$ —
2. Overnight	$ 14,000,000	$ 8,000,000	$ 7,600,000	$ 2,900,000
3. 2 Days to 1 Week	$ —	$ —	$ —	$ —
4. >1 Week to 1 Month	$ —	$ —	$ —	$ —
5. >1 Month to 3 Months	$ —	$ —	$ —	$ —
6. >3 Months to 1 Year	$ —	$ —	$ —	$ —
7. >1 Year	$ —	$ —	$ —	$ —

(4) Aggregate Narrative Disclosure of Fair Value of Securities Sold and/or Acquired That Resulted in Default

Not applicable.

(5) Fair Value of Securities Acquired Under Repo-Secured Borrowing

	FIRST QUARTER	SECOND QUARTER	THIRD QUARTER	FOURTH QUARTER
a. Maximum Amount	$ 25,172,574	$ 27,717,765	$ 30,058,448	$ 7,977,248
b. Ending Balance	$ 14,317,315	$ 8,144,336	$ 7,768,891	$ 2,952,338

NOTES TO FINANCIAL STATEMENTS

(6) Securities Acquired Under Repo - Secured Borrowing by NAIC Designation

ENDING BALANCE

	1 NONE	2 NAIC 1	3 NAIC 2	4 NAIC 3
a. Bonds - FV	$ —	$ 2,952,338	$ —	$ —
b. LB & SS - FV	$ —	$ —	$ —	$ —
c. Preferred Stock - FV	$ —	$ —	$ —	$ —
d. Common Stock	$ —	$ —	$ —	$ —
e. Mortgage Loans - FV	$ —	$ —	$ —	$ —
f. Real Estate - FV	$ —	$ —	$ —	$ —
g. Derivatives - FV	$ —	$ —	$ —	$ —
h. Other Invested Assets - FV	$ —	$ —	$ —	$ —
i. Total Assets - FV (Sum of a through h)	$ —	$ 2,952,338	$ —	$ —

ENDING BALANCE

	5 NAIC 4	6 NAIC 5	7 NAIC 6	8 DOES NOT QUALIFY AS ADMITTED
a. Bonds - FV	$ —	$ —	$ —	$ —
b. LB & SS - FV	$ —	$ —	$ —	$ —
c. Preferred Stock - FV	$ —	$ —	$ —	$ —
d. Common Stock	$ —	$ —	$ —	$ —
e. Mortgage Loans - FV	$ —	$ —	$ —	$ —
f. Real Estate - FV	$ —	$ —	$ —	$ —
g. Derivatives - FV	$ —	$ —	$ —	$ —
h. Other Invested Assets - FV	$ —	$ —	$ —	$ —
i. Total Assets - FV (Sum of a through h)	$ —	$ —	$ —	$ —

(7) Collateral Pledged - Secured Borrowing

	FIRST QUARTER	SECOND QUARTER	THIRD QUARTER	FOURTH QUARTER
a. Maximum Amount				
1. Cash	$ 24,800,000	$ 27,300,000	$ 29,600,000	$ 7,700,000
2. Securities (FV)	$ —	$ —	$ —	$ —
3. Securities (BACV)	XXX	XXX	XXX	XXX
4. Nonadmitted Subset (BACV)	XXX	XXX	XXX	XXX
b. Ending Balance				
1. Cash	$ 14,000,000	$ 8,000,000	$ 7,600,000	$ 2,900,000
2. Securities (FV)	$ —	$ —	$ —	$ —
3. Securities (BACV)	$ —	$ —	$ —	$ —
4. Nonadmitted Subset (BACV)	$ —	$ —	$ —	$ —

(8) Allocation of Aggregate Collateral Pledged by Remaining Contractual Maturity

	AMORTIZED COST	FAIR VALUE
a. Overnight and Continuous	$ 2,900,000	$ 2,952,338
b. 30 Days or Less	$ —	$ —
c. 31 to 90 Days	$ —	$ —
d. >90 Days	$ —	$ —

NOTES TO FINANCIAL STATEMENTS

(9) Recognized Receivable for Return of Collateral - Secured Borrowing

	FIRST QUARTER	SECOND QUARTER	THIRD QUARTER	FOURTH QUARTER
a. Maximum Amount				
1. Cash	$ —	$ —	$ —	$ —
2. Securities (FV)	$ —	$ —	$ —	$ —
b. Ending Balance				
1. Cash	$ —	$ —	$ —	$ —
2. Securities (FV)	$ —	$ —	$ —	$ —

(10) Recognized Liability to Return Collateral - Secured Borrowing (Total)

	FIRST QUARTER	SECOND QUARTER	THIRD QUARTER	FOURTH QUARTER
a. Maximum Amount				
1. Repo Securities Sold/Acquired with Cash Collateral	$ —	$ —	$ —	$ —
2. Repo Securities Sold/Acquired with Securities Collateral (FV)	$ —	$ —	$ —	$ —
b. Ending Balance				
1. Repo Securities Sold/Acquired with Cash Collateral	$ —	$ —	$ —	$ —
2. Repo Securities Sold/Acquired with Securities Collateral (FV)	$ —	$ —	$ —	$ —

H. Repurchase Agreements Transactions Accounted for as a Sale

The Company did not enter into repurchase agreement transactions accounted for as a sale at December 31, 2023 or 2022.

I. Reverse Repurchase Agreements Transactions Accounted for as a Sale

The Company did not enter into reverse repurchase agreement transactions accounted for as a sale at December 31, 2023 or 2022.

J. Real Estate

The Company did not have investments in real estate and did not engage in retail land sales operations during 2023 or 2022.

K. Investments in Low-Income Housing Tax Credits

The Company did not invest in properties generating low-income housing tax credits during 2023 or 2022.

NOTES TO FINANCIAL STATEMENTS

L. Restricted Assets

(1) Restricted assets (including pledged)

		1	2	3	4	5	6	7
	Restricted Asset Category	Total Gross (Admitted & Nonadmitted) Restricted from Current Year	Total Gross (Admitted & Nonadmitted) Restricted from Prior Year	Increase/ (Decrease) (1 minus 2)	Total Current Year Nonadmitted Restricted	Total Current Year Admitted Restricted (1 minus 4)	Gross Admitted and Nonadmitted Restricted to Total Assets (a)	Admitted Restricted to Total Admitted Assets (b)
a.	Subject to contractual obligation for which liability is not shown	$ —	$ —	$ —	$ —	$ —	— %	— %
b.	Collateral held under security lending agreements	162,618,335	72,724,060	89,894,275	—	162,618,335	4.29 %	4.57 %
c.	Subject to repurchase agreements	—	—	—	—	—	— %	— %
d.	Subject to reverse repurchase agreements	2,900,000	—	2,900,000	—	2,900,000	0.08 %	0.08 %
e.	Subject to dollar repurchase agreements	—	—	—	—	—	— %	— %
f.	Subject to dollar reverse repurchase agreements	—	—	—	—	—	— %	— %
g.	Placed under option contracts	—	—	—	—	—	— %	— %
h.	Letter stock or securities restricted as to sale-excluding FHLB capital stock	—	—	—	—	—	— %	— %
i.	FHLB capital stock	2,480,800	3,836,000	(1,355,200)	—	2,480,800	0.07 %	0.07 %
j.	On deposit with states	4,237,666	4,344,989	(107,324)	—	4,237,666	0.11 %	0.12 %
k.	On deposit with other regulatory bodies	—	—	—	—	—	— %	— %
l.	Pledged as collateral to FHLB (including assets backing funding agreements)	255,026,294	269,467,255	(14,440,961)	—	255,026,294	6.73 %	7.16 %
m.	Pledged as collateral not captured in other categories	—	—	—	—	—	— %	— %
n.	Other restricted assets	—	—	—	—	—	— %	— %
o.	Total Restricted Assets	$ 427,263,095	$ 350,372,304	$ 76,890,790	$ —	$427,263,095	11.28 %	12.00 %

(a) Column 1 divided by Asset Page, Column 1, Line 28

(b) Column 5 divided by Asset Page, Column 3, Line 28

(2) Not applicable.

(3) Not applicable.

NOTES TO FINANCIAL STATEMENTS

(4) Collateral Received and Reflected as Assets Within the Reporting Entity's Financial Statements

		1	2	3	4
	Collateral Assets	Book/Adjusted Carrying Value (BACV)	Fair Value	% of BACV to Total Assets (Admitted and Nonadmitted*)	% of BACV to Total Admitted Assets **
a.	Cash	$ —	$ —	— %	— %
b.	Schedule D, Part 1	—	—	—	—
c.	Schedule D, Part 2 Section 1	—	—	—	—
d.	Schedule D, Part 2 Section 2	—	—	—	—
e.	Schedule B	—	—	—	—
f.	Schedule A	—	—	—	—
g.	Schedule BA, Part 1	—	—	—	—
h.	Schedule DL, Part 1	162,618,335	162,728,347	4.29 %	4.57 %
i.	Other	—	—	—	—
j.	Total Collateral Assets (a+b+c+d+e+f+g+h+i)	$ 162,618,335	$162,728,347	4.29 %	4.57 %

* Column 1 divided by Asset Page, Line 26 (Column 1)

** Column 1 divided by Asset Page, Line 26 (Column 3)

		1	2
		Amount	% of Liability to Total Liabilities *
k.	Recognized Obligation to Return Collateral Asset	$ 162,618,335	8.37 %

* Column 1 divided by Liability Page, Line 24 (Column 3)

M. Working Capital Finance Investments

The Company did not have any working capital finance investments at December 31, 2023 and 2022.

N. Offsetting and Netting of Assets and Liabilities

The Company did not have any offsetting or netting of assets and liabilities at December 31, 2023 and 2022.

O. 5GI Securities

The Company has no 5GI Securities as of December 31, 2023 and 2022.

P. Short Sales

The Company did not have any short sales at December 31, 2023 and 2022.

NOTES TO FINANCIAL STATEMENTS

Q. Prepayment Penalty and Acceleration Fees

		General Account
(1) Number of CUSIPs		8
(2) Aggregate Amount of Investment Income	$	(274,802)

R. Reporting Entity's Share of Cash Pool by Asset Type

The Company did not participate in a cash pool at December 31, 2023 or 2022.

6. Joint Ventures, Partnerships and Limited Liability Companies

A. The Company has no investments in joint ventures, partnerships or limited liability companies that exceeded 10% of its admitted assets at December 31, 2023 or 2022.

B. The Company did not recognize any impairment write downs for its investments in joint ventures, partnerships, or limited liability companies during 2023 or 2022.

7. Investment Income

A. All investment income due and accrued with amounts that are over 90 days past due is non-admitted.

B. At December 31, 2023 and 2022 there was $11,633 and $16,049 of nonadmitted accrued investment income, respectively.

C. At December 31, 2023 and 2022 the gross, nonadmitted and admitted amounts for interest income due and accrued are as follows:

Interest Income Due and Accrued		2023		2022
1. Gross	$	16,520,888	$	13,537,232
2. Nonadmitted	$	11,633	$	16,049
3. Admitted	$	16,509,255	$	13,521,183

D. At December 31, 2023 and 2022 the Company had no aggregate deferred interest.

E. At December 31, 2023 and 2022 the Company had cumulative amounts of paid-in-kind (“PIK”) interest included in the current principal balance as follows:

		2023		2022
Cumulative amounts of PIK interest included in the current principal balance	$	20,844	$	123,592

8. Derivative Instruments

The Company has no derivative instruments.

NOTES TO FINANCIAL STATEMENTS

9. Income Taxes

A. The components of net deferred tax assets (liabilities):

(1) The components of net deferred tax asset (liabilities) are as follows:

		12/31/2023		
		(1) Ordinary	(2) Capital	(3) (Col 1+2) Total
(a)	Gross Deferred Tax Assets	$ 105,850,533	$ —	$ 105,850,533
(b)	Statutory Valuation Allowance Adjustments	—	—	—
(c)	Adjusted Gross Deferred Tax Assets (1a - 1b)	105,850,533	—	105,850,533
(d)	Deferred Tax Assets Nonadmitted	20,958,645	—	20,958,645
(e)	Subtotal Net Admitted Deferred Tax Asset (1c - 1d)	84,891,888	—	84,891,888
(f)	Deferred Tax Liabilities	573,397	5,419,305	5,992,702
(g)	Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability) (1e - 1f)	$ 84,318,491	$ (5,419,305)	$ 78,899,186

		12/31/2022		
		(4) Ordinary	(5) Capital	(6) (Col 4+5) Total
(a)	Gross Deferred Tax Assets	$ 75,679,188	$ 5,771,921	$ 81,451,109
(b)	Statutory Valuation Allowance Adjustments	—	—	—
(c)	Adjusted Gross Deferred Tax Assets (1a - 1b)	75,679,188	5,771,921	81,451,109
(d)	Deferred Tax Assets Nonadmitted	13,733,786	—	13,733,786
(e)	Subtotal Net Admitted Deferred Tax Asset (1c - 1d)	61,945,402	5,771,921	67,717,323
(f)	Deferred Tax Liabilities	1,165,611	9,392,370	10,557,981
(g)	Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability) (1e - 1f)	$ 60,779,791	$ (3,620,449)	$ 57,159,342

		Change		
		(7) (Col 1-4) Ordinary	(8) (Col 2-5) Capital	(9) (Col 7+8) Total
(a)	Gross Deferred Tax Assets	$ 30,171,345	$ (5,771,921)	$ 24,399,424
(b)	Statutory Valuation Allowance Adjustments	—	—	—
(c)	Adjusted Gross Deferred Tax Assets (1a - 1b)	30,171,345	(5,771,921)	24,399,424
(d)	Deferred Tax Assets Nonadmitted	7,224,859	—	7,224,859
(e)	Subtotal Net Admitted Deferred Tax Asset (1c - 1d)	22,946,486	(5,771,921)	17,174,565
(f)	Deferred Tax Liabilities	(592,214)	(3,973,065)	(4,565,279)
(g)	Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability) (1e - 1f)	$ 23,538,700	$ (1,798,856)	$ 21,739,844

NOTES TO FINANCIAL STATEMENTS

(2) The amount of admitted adjusted gross deferred tax assets under each component of SSAP No. 101, *Income Taxes* ("SSAP No. 101") are as follows:

Admission Calculation Components SSAP No. 101	12/31/2023 (1) Ordinary	 (2) Capital	 (3) (Col 1+2) Total
(a) Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks.	$ 76,384,088	$ —	$ 76,384,088
(b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below)	2,515,098	—	2,515,098
1. Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date.	2,515,098	—	2,515,098
2. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.	XXX	XXX	230,792,581
(c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities.	5,992,702	—	5,992,702
(d) Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c))	$ 84,891,888	$ —	$ 84,891,888

Admission Calculation Components SSAP No. 101	12/31/2022 (4) Ordinary	 (5) Capital	 (6) (Col 4+5) Total
(a) Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks.	$ 50,665,933	$ 2,788,574	$ 53,454,507
(b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below)	2,164,468	1,540,367	3,704,835
1. Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date.	2,164,468	1,540,367	3,704,835
2. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.	XXX	XXX	192,519,625
(c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities.	9,115,001	1,442,980	10,557,981
(d) Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c))	$ 61,945,402	$ 5,771,921	$ 67,717,323

Admission Calculation Components SSAP No. 101	Change (7) (Col 1-4) Ordinary	 (8) (Col 2-5) Capital	 (9) (Col 7+8) Total
(a) Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks.	$ 25,718,155	$ (2,788,574)	$ 22,929,581
(b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below)	350,630	(1,540,367)	(1,189,737)
1. Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date.	350,630	(1,540,367)	(1,189,737)
2. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.	XXX	XXX	38,272,956
(c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities.	(3,122,299)	(1,442,980)	(4,565,279)
(d) Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c))	$ 22,946,486	$ (5,771,921)	$ 17,174,565

NOTES TO FINANCIAL STATEMENTS

(3)

		2023	2022
(a)	Ratio Percentage Used To Determine Recovery Period And Threshold Limitation Amount.	482.84 %	373.13 %
(b)	Amount Of Adjusted Capital And Surplus Used To Determine Recovery Period And Threshold Limitation In 2(b)2 Above.	$ 1,538,617,208	$ 1,283,464,167

(4)

	12/31/2023		12/31/2022		Change	
	(1) Ordinary	(2) Capital	(3) Ordinary	(4) Capital	(5) (Col 1-3) Ordinary	(6) (Col 2-4) Capital
Impact of Tax-Planning Strategies						
(a) Determination of Adjusted Gross Deferred Tax Assets and Net Admitted Deferred Tax Assets, By Tax Character As A Percentage.						
1. Adjusted Gross DTAs Amount From Note 9A1(c)	$105,850,533	$ —	$75,679,188	$5,771,921	$30,171,345	$(5,771,921)
2. Percentage of Adjusted Gross DTAs By Tax Character Attributable To The Impact Of Tax Planning Strategies	— %	— %	— %	— %	— %	— %
3. Net Admitted Adjusted Gross DTAs Amount From Note 9A1(e)	$84,891,888	$ —	$61,945,402	$5,771,921	$22,946,486	$(5,771,921)
4. Percentage of Net Admitted Adjusted Gross DTAs By Tax Character Admitted Because Of The Impact Of Tax Planning Strategies	— %	— %	— %	— %	— %	— %

(b) Does the Company's tax-planning strategies include the use of reinsurance? Yes ______ No X

B. The Company has no unrecognized deferred tax liabilities at December 31, 2023 and 2022.

C. Current income taxes incurred consist of the following major components:

	(1) 12/31/2023	(2) 12/31/2022	(3) (Col 1-2) Change
(1) Current Income Tax			
(a) Federal	$ 176,853,345	$ 45,356,132	$ 131,497,213
(b) Foreign	—	—	—
(c) Subtotal	176,853,345	45,356,132	131,497,213
(d) Federal income tax expense on net capital gains	(6,675,829)	(219,720)	(6,456,109)
(e) Utilization of capital loss carry-forwards	—	—	—
(f) Other	—	—	—
(g) Federal and foreign income taxes incurred	$ 170,177,516	$ 45,136,412	$ 125,041,104

NOTES TO FINANCIAL STATEMENTS

	(1) 12/31/2023	(2) 12/31/2022	(3) (Col 1-2) Change
(2) Deferred Tax Assets:			
(a) Ordinary			
(1) Discounting of unpaid losses	$ 2,742,227	$ 2,745,909	$ (3,682)
(2) Unearned premium reserve	2,916,130	2,443,441	472,689
(3) Policyholder reserves	5,594,052	5,082,000	512,052
(4) Investments	—	—	—
(5) Deferred acquisition costs	2,751,907	2,781,305	(29,398)
(6) Policyholder dividends accrual	—	—	—
(7) Fixed assets	4,531,017	1,924,074	2,606,943
(8) Compensation and benefits accrual	—	2,332,551	(2,332,551)
(9) Pension accrual	—	—	—
(10) Receivables - nonadmitted	20,511,104	18,926,857	1,584,247
(11) Net operating loss carry-forward	—	—	—
(12) Tax credit carry-forward	—	—	—
(13) Other	66,804,096	39,443,051	27,361,045
(99) Subtotal (sum of 2a1 through 2a13)	105,850,533	75,679,188	30,171,345
(b) Statutory valuation allowance adjustment	—	—	—
(c) Nonadmitted	20,958,645	13,733,786	7,224,859
(d) Admitted ordinary deferred tax assets (2a99 - 2b - 2c)	84,891,888	61,945,402	22,946,486
(e) Capital			
(1) Investments	—	5,771,921	(5,771,921)
(2) Net capital loss carry-forward	—	—	—
(3) Real estate	—	—	—
(4) Other	—	—	—
(99) Subtotal (2e1+2e2+2e3+2e4)	—	5,771,921	(5,771,921)
(f) Statutory valuation allowance adjustment	—	—	—
(g) Nonadmitted	—	—	—
(h) Admitted capital deferred tax assets (2e99 - 2f - 2g)	—	5,771,921	(5,771,921)
(i) Admitted deferred tax assets (2d + 2h)	$ 84,891,888	$ 67,717,323	$ 17,174,565
(3) Deferred Tax Liabilities:			
(a) Ordinary			
(1) Investments	—	—	—
(2) Fixed assets	—	—	—
(3) Deferred and uncollected premium	—	—	—
(4) Policyholder reserves	—	—	—
(5) Other	573,397	1,165,611	(592,214)
(99) Subtotal (3a1+3a2+3a3+3a4+3a5)	573,397	1,165,611	(592,214)
(b) Capital			
(1) Investments	727,378	—	727,378
(2) Real estate	529,114	423,291	105,823
(3) Other	4,162,813	8,969,079	(4,806,266)
(99) Subtotal (3b1+3b2+3b3)	5,419,305	9,392,370	(3,973,065)
(c) Deferred tax liabilities (3a99 + 3b99)	5,992,702	10,557,981	(4,565,279)
(4) Net deferred tax assets/liabilities (2i - 3c)	$ 78,899,186	$ 57,159,342	$ 21,739,844

NOTES TO FINANCIAL STATEMENTS

D. The Company's income tax expense and change in deferred income taxes differs from the amount obtained by applying the federal statutory income tax rate of 21% for the year ended December 31 as follows:

	2023	2022
Tax expense computed using federal statutory rate	$ 144,367,259	$ 66,439,032
Change in nonadmitted assets	(1,583,752)	(21,487,688)
Tax exempt income and dividend received deduction net of proration	(839,624)	(1,370,141)
Prior year true-up and adjustments	(92,925)	(4,306,699)
Tax settlements and contingencies	(17,859)	1,758,479
Other, net	(4,352,689)	(4,716,029)
Total	$ 137,480,410	$ 36,316,954
Federal income taxes incurred	170,177,516	45,136,412
Change in net deferred income taxes	(32,697,106)	(8,819,458)
Total statutory income taxes	$ 137,480,410	$ 36,316,954

E. Operating loss carryforwards:

(1) The Company has no operating loss carryforwards and no corporate alternative minimum tax ("AMT") credit carryforwards as of December 31, 2023 or 2022.

(2) The following are income taxes incurred in the current and prior year(s) that will be available for recoupment in the event of future net losses:

	Ordinary	Capital	Total
2023	$ 166,485,516	$ —	$ 166,485,516
2022	54,652,134	48,777	54,700,911
2021	N/A	2,256,170	2,256,170

(3) The Company has no protective tax deposits reported as admitted assets under Section 6603 of the Internal Revenue Service Code as of December 31, 2023 and 2022.

F. The following companies will be included in the consolidated federal income tax return with their parent Elevance Health, Inc. ("Elevance Health") as of December 31, 2023 and either are current members of the consolidated tax sharing agreement or are in the process of being added to the consolidated tax sharing agreement. Allocation of federal income taxes, including corporate AMT, with affiliates subject to the tax sharing agreement is based upon separate income tax return calculations, including separate corporate AMT calculations, with credit for net operating losses and capital losses that can be used on a consolidated basis. Pursuant to this agreement, the Company has the enforceable right to recoup federal income taxes paid in prior years in the event of future net losses, which it may incur, or to recoup its net losses carried forward as an offset to future net income subject to federal income taxes. Intercompany income tax balances are settled based on the Internal Revenue Service due dates.

Alliance Care Management, LLC
AMERIGROUP Community Care of New Mexico, Inc.
Amerigroup District of Columbia, Inc.
Amerigroup Mississippi, Inc.
Amerigroup Oklahoma, Inc.
Amerigroup Pennsylvania, Inc.
AMGP Georgia Managed Care Company, Inc.
Anthem Blue Cross Life and Health Insurance Company
Anthem Financial, Inc.
Anthem Health Plans of Kentucky, Inc.
Anthem Health Plans of Maine, Inc.
Anthem Health Plans of New Hampshire, Inc.
Anthem Health Plans of Virginia, Inc.
DeCare Dental, LLC
Designated Agent Company, Inc.
EHC Benefits Agency, Inc.
Elevance Health Inc
Empire HealthChoice Assurance, Inc.
Empire HealthChoice HMO, Inc.
Federal Government Solutions, LLC
FHC Health Systems, Inc.
Freedom Health, Inc.
Freedom SPV, Inc.
Golden West Health Plan, Inc.
Healthkeepers, Inc.
HealthLink Administrators, Inc.

NOTES TO FINANCIAL STATEMENTS

Anthem Health Plans, Inc.
Anthem Holding Corp.
Anthem Insurance Companies, Inc.
Anthem Kentucky Managed Care Plan, Inc.
Anthem Southeast, Inc.
APR, LLC
Arcus Enterprises, Inc.
Aspire Health, Inc.
Associated Group, Inc.
AUMSI UM Services, Inc.
Beacon Health Financing, LLC
Beacon Health Options Holdco, Inc.
Beacon Health Vista Parent, Inc.
BioPlus Parent, LLC
Blue Cross Blue Shield Healthcare Plan of Georgia, Inc.
Blue Cross Blue Shield of Wisconsin
Blue Cross of California
Blue Cross of California Partnership Plan, Inc.
Carelon Behavioral Care, Inc.
Carelon Behavioral Health, Inc.
Carelon Behavioral Health IPA, Inc.
Carelon Behavioral Health of California, Inc.
Carelon Behavioral Health Strategies IPA, LLC
Carelon Digital Platforms, Inc.
Carelon Global Solutions U.S., Inc.
Carelon Health Federal Services, Inc.
Carelon Health of New Jersey, Inc.
Carelon Health of Pennsylvania, Inc.
Carelon Health Solutions, Inc.
Carelon Holdings, Inc.
Carelon Holdings I, Inc.
Carelon Insights, Inc.
Carelon Medical Benefits Management, Inc.
Carelon PharmacyRx, Inc.
Carelon Post Acute Solutions, Inc.
Carelon Research, Inc.
CarelonRx, Inc.
CareMore Health IPA of New York, Inc.
CareMore Health of Arizona, Inc.
CareMore Health Plan
CareMore Health Plan of Arizona, Inc.
CareMore Health Plan of Nevada, Inc.
CareMore Health Plan of Texas, Inc.
CareMore Health System
Cerulean Companies, Inc.
Claim Management Services, Inc.
Community Care Health Plan of Kansas, Inc.
Community Care Health Plan of Nebraska, Inc.
Community Care Health Plan of Nevada, Inc.
Community Insurance Company
Compcare Health Services Insurance Corporation
Crossroads Acquisition Corp.
DeCare Analytics, LLC
DeCare Dental Health International, LLC
DeCare Dental Networks, LLC
HealthLink, Inc.
HealthPlus HP, LLC
HealthSun Health Plan, Inc.
Healthy Alliance Life Insurance Company
HEP AP Holdings, Inc.
HMO Colorado, Inc.
HMO Missouri, Inc.
IEC Group Holdings, Inc.
IEC Group, Inc. d/b/a AmeriBen
Imaging Management Holdings, LLC
Living Complete Technologies, Inc.
Massachusetts Behavioral Health Partnership
Matthew Thornton Health Plan, Inc.
Missouri Care, Incorporated
myNEXUS Holdings, Inc.
myNEXUS Management, Inc.
Nash Holding Company, LLC
National Government Services, Inc.
New England Research Institutes, Inc.
Optimum Healthcare, Inc.
OPTIONS Health Care, Inc.
RightCHOICE Managed Care, Inc.
Rocky Mountain Hospital and Medical Service, Inc.
SellCore, Inc.
Simply Healthcare Plans, Inc.
Southeast Services, Inc.
State Sponsored Services, Inc.
The Elevance Health Companies, Inc.
The Elevance Health Companies of California, Inc.
TrustSolutions, LLC
UNICARE Health Plan of West Virginia, Inc.
UNICARE Illinois Services, Inc.
UNICARE National Services, Inc.
UNICARE Specialty Services, Inc.
ValueOptions Texas, Inc.
WellPoint California Services, Inc.
Wellpoint Corporation
Wellpoint Delaware, Inc.
WellPoint Dental Services, Inc.
Wellpoint Federal Corporation
WellPoint Health Solutions, Inc.
WellPoint Holding Corporation
WellPoint Information Technology Services, Inc.
Wellpoint Insurance Company
WellPoint Insurance Services, Inc.
Wellpoint Iowa, Inc.
Wellpoint Life and Health Insurance Company
Wellpoint Maryland, Inc.
Wellpoint New Jersey, Inc.
Wellpoint Ohio, Inc.
Wellpoint South Carolina, Inc.
Wellpoint Tennessee, Inc.
Wellpoint Texas, Inc.
Wellpoint Washington, Inc.
Wisconsin Collaborative Insurance Company

G. Not applicable.

H. Repatriation Transition Tax (RTT)

Not applicable.

NOTES TO FINANCIAL STATEMENTS

I. Alternative Minimum Tax (AMT) Credit

(1) On August 16, 2022, the U.S. government enacted the Inflation Reduction Act which includes a new corporate AMT of 15% on the adjusted financial statement of income ("AFSI") of corporations with average AFSI exceeding $1.0 billion over a three-year period. The corporate AMT is effective beginning after December 31, 2022. The controlled group of corporations, of which the Company is a member, has determined it is an applicable corporation for purposes of determining if the corporate AMT exceeds the regular federal income tax payable. The controlled group has determined that it does not expect to be subject to the corporate AMT in 2023.

The Company is an applicable reporting entity, not individually as an unaffiliated corporation, but as a member of a tax-controlled group of corporations. The Company does not expect to be subject to the corporate AMT in 2023.

(2) An accounting policy election has been made to disregard corporate AMT when evaluating the need for a valuation allowance for its regular tax deferred tax assets.

(3) The controlled group of corporations, of which the Company is a member, has not made any material modifications to the methodology used to project the corporate AMT liability.

(4) Does the Company’s tax-planning strategies include the use of corporate AMT? Yes_____ No __X__

10. Information Concerning Parent, Subsidiaries, Affiliates and Other Related Parties

A. Nature of the Relationship

The Company is an Ohio domiciled stock insurance company and is a wholly-owned subsidiary of ATH Holding Company, LLC (“ATH Holding”), which is a wholly-owned subsidiary of Elevance Health, a publicly traded company.

B. Significant Transactions for Each Period

The following significant transactions took place between the Company and its affiliates:

The Board of Directors of the Company declared an ordinary dividend in the amount of $271,200,000 on August 23, 2023. The Company paid the dividend to its parent company, ATH Holding, on September 5, 2023.

On December 22, 2022, ATH Holding authorized a capital contribution to the Company in the amount of $200,000,000 which was paid on December 29, 2022.

Effective July 1, 2022, the Company entered into an excess of loss reinsurance agreement for its Medicaid business with Anthem Insurance Companies, Inc., a subsidiary of the Company's ultimate parent, Elevance Health.

For changes to the intercompany management and service arrangements see Note 10E. The amounts of transactions under such agreements are presented in Schedule Y, Part 2.

C. Transactions with Related Parties who are not Reported on Schedule Y

The Company has no transactions with related parties who are not reported on Schedule Y.

NOTES TO FINANCIAL STATEMENTS

D. Amounts Due to or from Related Parties

At December 31, 2023 and 2022, the Company reported $123,679,454 and $203,926,445 due from affiliates, respectively. At December 31, 2023 and 2022, the Company reported no amounts due to affiliates. The receivable and payable balances represent intercompany transactions that will be settled in accordance with the settlement terms of the intercompany agreement.

E. Management and Service Contracts and Cost Sharing Arrangements

The Company entered into risk sharing arrangements with affiliated companies within Elevance Health's Carelon Services division in 2023. The Company reported $51,296,147 of incentive payments as claims expense under these arrangements in 2023.

The Company has entered into administrative services agreements with its affiliated companies. Pursuant to these agreements, various administrative, management and support services are provided to or provided by the Company. The costs and expenses related to these administrative management and support services are allocated to or allocated by the Company in an amount equal to the direct and indirect costs and expenses incurred in providing these services. Costs include expenses such as salaries, employee benefits, information technology, pharmacy benefits administration, communications, advertising, consulting services, rent, utilities, billing, accounting, underwriting, and product development, which support the Company's operations. These costs are allocated based on various utilization statistics.

In addition, the Company is party to the Fair Market Value ("FMV") Services Attachment, to the master administrative services agreement with affiliates, the costs and expenses related to certain services including behavioral health, palliative care, utilization management, payment integrity services, subrogation services as well as health and wellness programs are allocated to or allocated by the Company in an amount equal to the fair market value of the services provided. These costs are allocated based on various utilization statistics.

The FMV Services Attachment was amended to add BioPlus Specialty Pharmacy Services, LLC and BioPlus Parent, LLC as a provider effective August 1, 2023.

The Company is party to a cash concentration agreement with its affiliated companies. Under this agreement, any of the Company's affiliates may be designated as a cash manager to handle the collection and/or payment of funds on behalf of the Company. Conversely, the Company may be designated as a cash manager to handle the collection and/or payment of funds on behalf of its affiliates. Cash services covered under this agreement include the collection of premiums and other revenue, the collection of benefit and administrative expense reimbursements, the payment of policy benefits, payroll expense, general and administrative expense, and accounts payable disbursements.

There were no changes to the intercompany management and service arrangements, and there were no additional arrangements entered into during 2023 or 2022. The amounts of transactions under such agreements are presented in Schedule Y, Part 2.

F. Guarantees or Contingencies for Related Parties

The Company did not enter into guarantees or undertakings for the benefit of an affiliate which would result in a material contingent exposure of the Company's or any affiliated insurer's assets or liabilities.

G. Nature of Control Relationships that Could Affect Operations or Financial Position

ATH Holding owns all outstanding shares of the Company. The Company's ultimate parent is Elevance Health.

NOTES TO FINANCIAL STATEMENTS

H. Amount Deducted for Investment in Upstream Company

The Company and its subsidiary do not own shares of upstream intermediate entities or Elevance Health.

I. Detail of Investments in Affiliates Greater than 10% of Admitted Assets

The Company does not have investments in affiliates greater than 10% of admitted assets.

J. Write-down for Impairments of Investments in Subsidiaries, Controlled or Affiliated ("SCA") Companies

Not applicable.

K. Investment in a Foreign Insurance Subsidiary

The Company does not have investments in foreign insurance subsidiaries.

L. Investment in Downstream Non-insurance Holding Companies

The Company does not have investments in downstream non-insurance holding companies.

M. All SCA Investments

The Company has no SCA Investments.

N. Investment in Insurance SCAs

The Company does not have investments in Insurance SCAs.

O. SCA or SSAP 48 Entity Loss Tracking

The Company does not have losses on investments in Insurance SCAs and/or joint ventures, partnerships or LLCs.

11. Debt

A. Capital Notes and Other Debt

The Company had no capital notes or other debt outstanding at December 31, 2023 and 2022.

B. FHLB (Federal Home Loan Bank) Agreements

(1) The Company is a member of the Federal Home Loan Bank of Cincinnati (“FHLBC”). Through its membership, the Company has conducted business activity (borrowings) with the FHLBC. It is part of the Company’s strategy to utilize these funds as working capital. The Company has determined the actual maximum borrowing capacity as $213,798,454. The Company calculated this amount in accordance with current FHLBC capital stock.

NOTES TO FINANCIAL STATEMENTS

(2) FHLB Capital Stock

a. Aggregate Totals

1. Current year

		Total
(a)	Membership stock - Class A	$ —
(b)	Membership stock - Class B	2,480,786
(c)	Activity stock	—
(d)	Excess stock	14
(e)	Aggregate total (a+b+c+d)	$ 2,480,800
(f)	Actual or estimated borrowing capacity as determined by the insurer	$ 213,798,454

2. Prior year-end

		Total
(a)	Membership stock - Class A	$ —
(b)	Membership stock - Class B	1,883,924
(c)	Activity stock	—
(d)	Excess stock	1,952,076
(e)	Aggregate total (a+b+c+d)	$ 3,836,000
(f)	Actual or estimated borrowing capacity as determined by the insurer	$ 231,627,746

11B(2)a1(f) should be equal to or greater than 11B(4)a1(d)

11B(2)a2(f) should be equal to or greater than 11B(4)a2(d)

b. Membership Stock (Class A and B) Eligible and Not Eligible for Redemption

			Eligible for Redemption			
	1	2	3	4	5	6
Membership Stock	Current Year Total (2+3+4+5+6)	Not Eligible for Redemption	Less Than 6 Months	6 Months to Less Than 1 Year	1 to Less Than 3 Years	3 to 5 Years
1. Class A	$ —	$ —	$ —	$ —	$ —	$ —
2. Class B	$ 2,480,786	$ 2,480,786	$ —	$ —	$ —	$ —

11B(2)b1 Current Year Total (Column 1) should equal 11B(2)a1(a) Total (Column 1)

11B(2)b2 Current Year Total (Column 1) should equal 11B(2)a1(b) Total (Column 1)

NOTES TO FINANCIAL STATEMENTS

(3) Collateral Pledged to FHLB

a. Amount pledged as of reporting date

	1 Fair Value	2 Carrying Value	3 Aggregate Total Borrowing
1. Current Year Total Collateral Pledged	$ 227,888,166	$ 255,026,294	$ —
2. Prior Year-end Total Collateral Pledged	$ 237,588,705	$ 269,467,255	$ —

11B(3)a1 (Columns 1, 2 and 3) should be equal to or less than 11B(3)b1 (Columns 1, 2 and 3 respectively)

11B(3)a2 (Columns 1, 2 and 3) should be equal to or less than 11B(3)b2 (Columns 1, 2 and 3 respectively)

b. Maximum amount pledged during reporting period

	1 Fair Value	2 Carrying Value	3 Amount Borrowed at Time of Maximum Collateral
1. Current Year Total Maximum Collateral Pledged	$ 245,255,703	$ 272,938,241	$ —
2. Prior Year-end Total Maximum Collateral Pledged	$ 251,552,140	$ 269,467,255	$ —

NOTES TO FINANCIAL STATEMENTS

(4) Borrowing from FHLB

a. Amount as of the reporting date

	Total	Funding Agreements Reserves Established
1. Current year		
(a) Debt	$ —	XXX
(b) Funding agreements	—	$ —
(c) Other	—	XXX
(d) Aggregate total (a+b+c)	$ —	$ —
2. Prior year-end		
(a) Debt	$ —	XXX
(b) Funding agreements	—	$ —
(c) Other	—	XXX
(d) Aggregate total (a+b+c)	$ —	$ —

b. Maximum amount during reporting period (current year)

	Total
1. Debt	$ —
2. Funding agreements	—
3. Other	—
4. Aggregate total (Lines 1+2+3)	$ —

c. FHLB - Prepayment obligations

	Does the Company have prepayment obligations under the following arrangements (YES/NO)?
1. Debt	No
2. Funding agreements	No
3. Other	No

C. All Other Debt

The Company had no other debt outstanding at December 31, 2023 and 2022.

12. Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans

A. Defined Benefit Plan

Not applicable - See Note 12G.

B. Not applicable - See Note 12G.

C. Not applicable - See Note 12G.

D. Not applicable - See Note 12G.

E. Defined Contribution Plans

Not applicable - See Note 12G.

F. Multiemployer Plans

The Company does not participate in a multiemployer plan.

NOTES TO FINANCIAL STATEMENTS

G. Consolidated/Holding Company Plans

The Company participates in the Elevance Health Cash Balance Plan A and the Elevance Health Cash Balance Plan B, collectively referred to as "the Cash Balance Plans." The Cash Balance Plans are frozen non-contributory defined benefit pension plans sponsored by ATH Holding, covering certain eligible employees of Elevance Health and its subsidiaries. ATH Holding allocates a share of the total accumulated costs of the plans to the Company based on the number of allocated employees. The Company has no legal obligation for benefits under these plans.

The Company participates in a postretirement medical benefit plan, sponsored by ATH Holding, providing certain medical, vision and dental benefits to eligible retirees. ATH Holding allocates a share of the total accumulated costs of this plan to the Company based on the number of allocated employees. The Company has no legal obligation for benefits under this plan.

The Company participates in a nonqualified deferred compensation plans sponsored by Elevance Health which covers certain employees once the participant reaches the maximum contribution amount for the Elevance Health 401(k) Plan (the "401(k) Plan"). The deferred amounts are payable according to the terms and subject to the conditions of the deferred compensation plan. Elevance Health allocates a share of the total accumulated costs of this plan to the Company based on the number of allocated employees subject to the deferred compensation plan. The Company has no legal obligation for benefits under this plan.

The Company participates in the 401(k) Plan, sponsored by ATH Holding and covering substantially all employees. Voluntary employee contributions are matched by ATH Holding subject to certain limitations. ATH Holding allocates a share of the total accumulated costs of this plan to the Company based on the number of allocated employees. The Company has no legal obligation for benefits under this plan.

The Company participates in a stock incentive compensation plan, sponsored by Elevance Health, providing incentive awards to non-employee directors and employees, consisting of Elevance Health stock options, restricted stock, restricted stock units, stock appreciation rights, performance shares, and performance units. Elevance Health allocates a share of the total share-based compensation expense of this plan to the Company based on the number of allocated employees. The Company has no legal obligation for benefits under this plan.

During 2023 and 2022, the Company was allocated the following costs or (credits) for these retirement benefits:

	2023	2022
Defined benefit pension plan	$ 362,819	$ (1,110,555)
Postretirement medical benefit plan	(530,690)	(691,480)
Deferred compensation plan	163,409	102,623
Defined contribution plan	14,897,728	10,574,151
Stock incentive compensation plan	15,953,059	10,461,123

H. Post Employment Benefits and Compensated Absences

Not applicable.

I. Impact of Medicare Modernization Act on Postretirement Benefits (INT 04-17)

Not applicable.

NOTES TO FINANCIAL STATEMENTS

13. Capital and Surplus, Shareholders' Dividend Restrictions and Quasi-Reorganizations

A. Outstanding Shares

As of December 31, 2023, the Company has 750 shares of $10,000 par value common stock authorized. The number of shares issued and outstanding is 114.23.

B. Preferred Stock

The Company has no preferred stock outstanding.

C. Dividend Restrictions

The maximum amount of dividends which can be paid by State of Ohio insurance companies to shareholders without prior approval of the Insurance Commissioner is subject to restrictions relating to statutory surplus and net income. Within any 12 month period, cumulative dividends may not exceed the greater of 10% of statutory surplus at the prior December 31, or net income for the 12 month period ending at the prior December 31. Also, any dividend paid from other than earned surplus shall be considered an extraordinary dividend.

D. Dividends Paid

See Footnote 10B.

E. Maximum Ordinary Dividend During 2024

Within the limitations of (C) above, the Company may pay $517,285,621 in ordinary dividends during 2024 without restrictions, other than state notification requirements.

F. Unassigned Surplus Restrictions

Unassigned surplus funds are not restricted at December 31, 2023.

G. Mutual Surplus Advances

Not applicable.

H. Company Stock Held for Special Purpose

There are no shares of stock held for special purposes at December 31, 2023.

I. Changes in Special Surplus Funds

The change in balances of special surplus funds from the prior year are due to changes in the amounts segregated for the deferred gain on the Company’s sale-leaseback transaction.

J. Changes in Unassigned Funds

The portion of unassigned funds represented by cumulative unrealized investment gains and losses was ($2,299,169) at December 31, 2023.

K. Surplus Notes

The Company has not issued any surplus notes or debentures or similar obligations.

NOTES TO FINANCIAL STATEMENTS

L. Restatement due to Prior Quasi-reorganizations

The Company had no restatements due to prior quasi-reorganizations.

M. Quasi-reorganizations over Prior 10 Years

The Company has not been involved in a quasi-reorganization during the past 10 years.

14. Liabilities, Contingencies and Assessments

A. Contingent Commitments

(1) The Company has a commitment to contribute an additional $17,260,581, in subsequent years, related to the Company's investments in joint ventures, limited partnerships, limited liability companies and residual tranches.

(2) Not applicable.

(3) Not applicable.

B. Assessments

(1) The Company is subject to guaranty fund and other assessments by the state(s) in which it writes business. Guaranty fund assessments are accrued at the time of covered insurer insolvencies. Other assessments are accrued at the time the assessment obligation is incurred.

(2) Guaranty Fund Assets Recognized Reconciliation

a.	Guaranty fund assets recognized from paid and accrued premium tax offsets and policy surcharges prior year-end	$ 1,675,629
b.	Decreases current year:	
	Policy surcharges collected	—
	Policy surcharges charged off	—
	Premium tax offset applied	—
	Recovery adjustment	—
c.	Increases current year:	
	Policy surcharges recognized	—
	Premium tax offset recognized	—
d.	Guaranty fund assets recognized from paid and accrued premium tax offsets and policy surcharges current year-end	$ 1,675,629

(3) Guaranty Fund Liabilities and Assets Related to Insolvencies of Entities That Wrote Long-Term Care Contracts

a. Discount Rate Applied 3.5%

b. The Undiscounted and Discounted Amount of the Guaranty Fund Assessments and Related Assets by Insolvency:

	Guaranty Fund Assessment		Related Assets	
Name of the Insolvency	Undiscounted	Discounted	Undiscounted	Discounted
Penn Treaty Network America Insurance Company and its subsidiary, American Network Insurance Company (collectively "Penn Treaty")	$ 14,193,960	$ 9,859,565	$ 4,151,883	$ 1,675,629

NOTES TO FINANCIAL STATEMENTS

c. Number of Jurisdictions, Ranges of Years Used to Discount and Weighted Average Number of Years of the Discounting Time Period for Payables and Recoverables by Insolvency:

	Payables			Recoverables		
Name of the Insolvency	**Number of Jurisdictions**	**Range of Years**	**Weighted Average Number of Years**	**Number of Jurisdictions**	**Range of Years**	**Weighted Average Number of Years**
Penn Treaty	1	1 - 16	8.5	1	1 - 22	7.9

C. Gain Contingencies

The Company has no gain contingencies at December 31, 2023 or 2022.

D. Claims-Related Extra Contractual Obligation and the Bad Faith Losses Stemming From Lawsuits

Not applicable.

E. Joint and Several Liabilities

Not applicable.

F. All Other Contingencies

Litigation and regulatory proceedings

Blue Cross Blue Shield Antitrust Litigation

Elevance Health, Inc. is a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or Blue Shield licensees (the "Blue plans") across the country. Cases filed in twenty-eight states were consolidated into a single, multi-district proceeding captioned *In re Blue Cross Blue Shield Antitrust Litigation* that is pending in the U.S. District Court for the Northern District of Alabama (the "Court"). Generally, the suits allege that the BCBSA and the Blue plans have conspired to horizontally allocate geographic markets through license agreements, best efforts rules that limit the percentage of non-Blue revenue of each plan, restrictions on acquisitions, rules governing the BlueCard® and National Accounts programs and other arrangements in violation of the Sherman Antitrust Act ("Sherman Act") and related state laws. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers.

In April 2018, the Court issued an order on the parties' cross motions for partial summary judgment, determining that the defendants' aggregation of geographic market allocations and output restrictions are to be analyzed under a per se standard of review, and the BlueCard® program and other alleged Section 1 Sherman Act violations are to be analyzed under the rule of reason standard of review. With respect to whether the defendants operate as a single entity with regard to the enforcement of the Blue Cross Blue Shield trademarks, the Court found that summary judgment was not appropriate due to the existence of genuine issues of material fact. In April 2019, the plaintiffs filed motions for class certification, which defendants opposed.

The BCBSA and Blue plans approved a settlement agreement and release with the subscriber plaintiffs (the "Subscriber Settlement Agreement"), which agreement required the Court's approval to become effective. The Subscriber Settlement Agreement requires the defendants to make a monetary settlement payment and contains certain terms imposing non- monetary obligations including (i) eliminating the "national best efforts" rule in the BCBSA license agreements (which rule limits the percentage of non-Blue revenue permitted for each Blue plan) and (ii) allowing for some large national employers

NOTES TO FINANCIAL STATEMENTS

with self-funded benefit plans to request a bid for insurance coverage from a second Blue plan in addition to the local Blue plan.

In November 2020, the Court issued an order preliminarily approving the Subscriber Settlement Agreement, following which members of the subscriber class were provided notice of the Subscriber Settlement Agreement and an opportunity to opt out of the class. A small number of subscribers submitted valid opt-outs by the July 2021 opt-out deadline.

In August 2022, the Court issued a final order approving the Subscriber Settlement Agreement (the "Final Approval Order"). The Court amended its Final Approval Order in September 2022, further clarifying the injunctive relief that may be available to subscribers who submitted valid opt-outs. In September 2022, an objector filed a motion to amend the Final Approval Order, which the Court denied. In compliance with the Subscriber Settlement Agreement, Elevance Health paid $506,000,000 into an escrow account in September 2022, for an aggregate and full settlement payment by Elevance Health of $596,000,000, which amount was accrued in 2020.

Four notices of appeal of the Final Approval Order were filed by the September 2022 appeal deadline. Those appeals were heard by a panel of the United States Court of Appeals for the Eleventh Circuit in September 2023. In October 2023, the Eleventh Circuit affirmed the District Court’s order approver the subscriber settlement. Certain appellants filed petitions for rehearing in November 2023 and December 2023. In the event that all appellate rights are exhausted in a manner that affirms the Court’s Final Approval Order, the defendants’ payment and non-monetary obligations under the Subscriber Settlement Agreement will become effective and the funds held in escrow will be distributed in accordance with the Subscriber Settlement Agreement.

In October 2020, after the Court lifted the stay as to the provider litigation, provider plaintiffs filed a renewed motion for class certification, which defendants opposed. In March 2021, the Court issued an order terminating the pending motion for class certification until the Court determined the standard of review applicable to the providers’ claims. In response to that order, the parties filed renewed standard of review motions in May 2021. In June 2021, the parties filed summary judgment motions not critically dependent on class certification. In February 2022, the Court issued orders (i) granting certain defendants’ motion for partial summary judgment against the provider plaintiffs who had previously released claims against such defendants, and (ii) granting the provider plaintiffs’ motion for partial summary judgment, holding that *Ohio v. American Express Co*. does not affect the standard of review in this case. In August 2022, the Court issued orders (i) granting in part the defendants’ motion regarding the antitrust standard of review, holding that for the period of time after the elimination of the “national best efforts” rule, the rule of reason applies to the provider plaintiffs’ market allocation conspiracy claims, and (ii) denying the provider plaintiffs’ motion for partial summary judgment on the standard of review, reaffirming its prior holding that the providers’ group boycott claims are subject to the rule of reason. In December 2023, the Court denied Defendants’ Motion for Summary Judgment on Providers’ Damage Claims as Time-Barred and Speculative and Provider Plaintiffs’ Motion for partial Summary Judgment on the Defendants’ Single Entity Defense due to the existence of genuine issues of material fact. Providers Plaintiffs’ motion for class certification remain pending. Elevance Health intends to continue to vigorously defend the provider litigation, which they believe is without merit, however, its ultimate outcome cannot be presently determined.

A number of follow-on cases involving entities that opted out of the Subscriber Settlement Agreement have been filed. Those actions are: *Alaska Air Group, Inc., et al. v. Anthem, Inc., et al.,* No. 2:21-cv-01209-AMM (N.D. Ala.); *JetBlue Airways Corp., et al. v. Anthem, Inc., et al.*, No. 2:22-cv-00558-GMB (N.D. Ala.); *Metropolitan Transportation Authority v. Blue Cross and Blue Shield of Alabama et al.*, No. 2:22-cv-00265-RDP (N.D. Ala.) (dismissed without prejudice on June 27, 2023); *Bed Bath &*

NOTES TO FINANCIAL STATEMENTS

Beyond Inc. v. Anthem, Inc., No. 2:22-cv-01256-SGC (N.D. Ala.); *Hoover, et al. v. Blue Cross Blue Shield Association, et al.*, No. 2:22-cv-00261-RDP (N.D. Ala.); and *VHS Liquidating Trust v. Blue Cross of California, et al.*, No. RG21106600 (Cal. Super.). In February 2023, the Court denied the defendents' motion to dismiss based on a statute of limitations defense in *Alaska Air* and *Jet* Blue. On September 14, 2023, the *VHS* Court upheld its prior order granting in part Defendants' motion to strike based on the statute of limitations. Elevance Health intends to continue to vigorously defend these follow-on cases, which they believe are without merit; however, their ultimate outcome cannot be presently determined.

Express Scripts, Inc. Pharmacy Benefit Management Litigation

In March 2016, Elevance Health, Inc. filed a lawsuit against Express Scripts, Inc. ("Express Scripts"), their vendor at the time for PBM services, captioned *Anthem, Inc. v. Express Scripts, Inc.*, in the U.S. District Court for the Southern District of New York (the "District Court"). The lawsuit seeks to recover over $14,800,000,000 in damages for pharmacy pricing that is higher than competitive benchmark pricing under the agreement between the parties (the "ESI Agreement"), over $158,000,000 in damages related to operational breaches, as well as various declarations under the ESI Agreement, including that Express Scripts: (i) breached its obligation to negotiate in good faith and to agree in writing to new pricing terms; (ii) was required to provide competitive benchmark pricing to Elevance Health through the term of the ESI Agreement; (iii) has breached the ESI Agreement; and (iv) is required under the ESI Agreement to provide post-termination services, at competitive benchmark pricing, for one year following any termination.

Express Scripts has disputed Elevance Health's contractual claims and is seeking declaratory judgments: (i) regarding the timing of the periodic pricing review under the ESI Agreement, and (ii) that it has no obligation to ensure that Elevance Health receives any specific level of pricing, that Elevance Health has no contractual right to any change in pricing under the ESI Agreement and that its sole obligation is to negotiate proposed pricing terms in good faith. In the alternative, Express Scripts claims that Elevance Health has been unjustly enriched by its payment of $4,675,000,000 at the time they entered into the ESI Agreement. In March 2017, the District Court granted Elevance Health's motion to dismiss Express Scripts' counterclaims for (i) breach of the implied covenant of good faith and fair dealing, and (ii) unjust enrichment with prejudice. After such ruling, Express Scripts' only remaining claims were for breach of contract and declaratory relief. In August 2021, Express Scripts filed a motion for summary judgment, which Elevance Health opposed. In March 2022, the District Court granted in part and denied in part Express Scripts' motion for summary judgment. The District Court dismissed Elevance Health's declaratory judgment claim, Elevance Health's breach of contract claim for failure to prove damages and most of Elevance Health's operational breach claims. As a result of the summary judgment decision, the only remaining claims as of the filing of this Annual Report are (i) Elevance Health's operational breach claim based on Express Scripts' prior authorization processes and (ii) Express Scripts' counterclaim for breach of the market check provision of the ESI Agreement. Express Scripts filed a second motion for summary judgment in June 2022, challenging Elevance Health's remaining operational breach claims, which Elevance Health opposed, and the District Court denied in March 2023, allowing Elevance Health's operational breach claim to proceed. In November 2023, the Court issued an Order ending the lawsuit as a result of the parties entering into a settlement agreement. In December 2023, Elevance Health filed a notice of appeal with the United States Court of Appeal for the Second Circuit, regarding the pricing case. The Appellate Court recently ordered the parties to mediate the pricing case in February 2024. The ultimate outcome of this appeal cannot be presently determined.

Medicare Risk Adjustment Litigation

In March 2020, the U.S. Department of Justice ("DOJ") filed a civil lawsuit against Elevance Health, Inc. in the U.S. District Court for the Southern District of New York

NOTES TO FINANCIAL STATEMENTS

(the "New York District Court") in a case captioned *United States v. Anthem, Inc*. The DOJ's suit alleges, among other things, that Elevance Health falsely certified the accuracy of the diagnosis data they submitted to the Centers for Medicare and Medicaid Services ("CMS") for risk-adjustment purposes under Medicare Part C and knowingly failed to delete inaccurate diagnosis codes. The DOJ further alleges that, as a result of these purported acts, Elevance Health caused CMS to calculate the risk-adjustment payments based on inaccurate diagnosis information, which enabled Elevance Health to obtain unspecified amounts of payments in Medicare funds in violation of the False Claims Act. The DOJ filed an amended complaint in July 2020, alleging the same causes of action but revising some of its factual allegations. In September 2020, Elevance Health filed a motion to transfer the lawsuit to the Southern District of Ohio, a motion to dismiss part of the lawsuit, and a motion to strike certain allegations in the amended complaint, all of which the New York District Court denied in October 2022. In November 2022, Elevance Health filed an answer. In March 2023, discovery commenced, and an initial case management conference was held in April 2023. The Court entered a scheduling order requiring fact discovery to be completed by June 2024 and expert discovery to be complete by February 2025. Elevance Health intends to continue to vigorously defend this suit, which they believe is without merit; however, the ultimate outcome cannot be presently determined.

Other Contingencies

From time to time, the Company and certain of its subsidiaries are parties to various legal proceedings, many of which involve claims for coverage encountered in the ordinary course of business. The Company, like Health Maintenance Organizations ("HMOs") and health insurers generally, exclude certain healthcare and other services from coverage under their HMO, Preferred Provider Organizations and other plans. The Company is, in the ordinary course of business, subject to the claims of their enrollees arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results in a significant punitive damage award, could have a material adverse effect on the Company. In addition, the risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage claims.

In addition to the lawsuits described above, the Company is also involved in other pending and threatened litigation of the character incidental to their business and is from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings. These investigations, audits, reviews and administrative proceedings include routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on the Company's business operations. Any liability that may result from any one of these actions, or in the aggregate, could have a material adverse effect on the Company's consolidated financial position or results of operations.

The Company has no other known material contingencies.

Provisions for uncollectible amounts

At December 31, 2023 and 2022, the Company reported admitted assets of $917,780,597 and $743,772,677, respectively, in premium receivables and receivables due from uninsured plans. Based upon the Company's experience, any uncollectible receivables are not expected to exceed $40,190,984 that was nonadmitted at December 31, 2023; therefore, no additional provision for uncollectible amounts has been recorded. The potential for any additional loss is not believed to be material to the Company's financial condition.

NOTES TO FINANCIAL STATEMENTS

15. Leases

A. Lessee Operating Lease

(1) The Company leases office space, office equipment, EDP equipment, and software under various noncancelable operating leases. Related lease expense for 2023 and 2022 was $2,687,140 and $4,245,878, respectively.

The Company reevaluated its future office space needs and determined that it would permanently cease use of space under certain operating leases. At December 31, 2023 and 2022, the Company has lease exit costs liabilities of $9,872,267 and $13,135,975, respectively, included in general expenses due or accrued on the balance sheet.

(2) At December 31, 2023, the minimum aggregate rental commitments are as follows:

	Year Ending December 31	Operating Leases	
1.	2024	$	6,814,231
2.	2025		6,700,792
3.	2026		5,909,934
4.	2027		3,762,599
5.	2028		3,079,139
6.	Thereafter		9,514,749
7.	Total (sum of 1 through 6)	$	35,781,444

(3)

a. During 2014, the Company entered into a sale-leaseback transaction with an unaffiliated entity to lease the Mason, Ohio building for 12 years.

b. Not applicable.

B. Lessor Leases

(1) The Company has not entered into any operating leases as a lessor.

(2) The Company has not entered into any leveraged leases.

16. Information About Financial Instruments With Off-Balance Sheet Risk and Financial Instruments With Concentrations of Credit Risk

The Company has no significant financial instruments with off-balance sheet risk.

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of investment securities. All investment securities are managed by professional investment managers within policies authorized by the board of directors. Such policies limit the amounts that may be invested in any one issuer and prescribe certain investee company criteria. As of December 31, 2023, there were no significant concentrations.

17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities

A. Transfers of Receivables Reported as Sales

Not applicable at December 31, 2023 and 2022.

B. Transfer and Servicing of Financial Assets

(1) The Company participates in a securities lending program whereby marketable securities in its investment portfolio are transferred to independent brokers or

NOTES TO FINANCIAL STATEMENTS

dealers. At December 31, 2023 the fair value of securities loaned was $158,840,606, and the carrying value of securities loaned was $153,211,131.

(2) - (7) Not applicable.

C. Wash Sales

(1) In the course of the Company's asset management, securities may be sold and reacquired within 30 days of the sale date to enhance the yield on the investments.

(2) At December 31, 2023 and 2022, there were no wash sales involving securities with an NAIC designation of 3 or below or unrated.

18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans

A. Administrative Services Only ("ASO") Plans

The gain or (loss) from operations from ASO uninsured plans and the uninsured portion of partially insured plans during 2023 was:

		ASO Uninsured Plans	Uninsured Portion of Partially Insured Plans	Total ASO
a.	Net reimbursement for administrative expenses (including administrative fees) in excess of (less than) actual expenses	$ 15,239,535	$ (76)	$ 15,239,459
b.	Total net other income or expenses (including interest paid to or received from plans)	—	—	—
c.	Net gain or (loss) from operations	$ 15,239,535	$ (76)	$ 15,239,459
d.	Total claim payment volume	$ 1,510,246,275	$ —	$ 1,510,246,275

B. Administrative Services Contract ("ASC") Plans

The gain or (loss) from operations from ASC uninsured plans and the uninsured portion of partially insured plans during 2023 was:

		ASC Uninsured Plans	Uninsured Portion of Partially Insured Plans	Total ASC
a.	Gross reimbursement for medical cost incurred	$ 8,242,819,693	$ —	$ 8,242,819,693
b.	Gross administrative fees accrued	539,432,976	—	539,432,976
c.	Other income or expenses (including interest paid to or received from plans)	—	—	—
d.	Gross expenses incurred (claims and administrative)	(8,674,094,662)	—	(8,674,094,662)
e.	Total gain or (loss) from operations	$ 108,158,007	$ —	$ 108,158,007

C. Medicare or Other Similarly Structured Cost-Based Reimbursement Contract

(1) The Company does not record revenue explicitly attributable to the cost share and reinsurance components of administered Medicare products.

(2)

Receivable from	Related to	2023	2022
Federal government	ACA and Medicare cost sharing and reinsurance programs	$ 42,074,537	$ 42,240,286
Uninsured plans	Uninsured business, not including pharmaceutical rebate or provider receivables	$ 279,163,239	$ 241,016,471

(3) As no revenue is recorded in connection with the cost share and reinsurance components of the Company's Medicare and ACA products, the Company has recorded no allowances and reserves for the adjustment of recorded revenues and receivables.

(4) The Company has made no adjustment to revenue resulting from the audit of cost-reimbursement receivables related to revenues recorded in the prior period.

19. Direct Premium Written/Produced by Managing General Agents/Third Party Administrators

No premiums were written by managing general agents or third party administrators during the years ended December 31, 2023 and 2022.

20. Fair Value Measurements

A.

(1) Fair Value Measurements at Reporting Date:

Description for each class of asset or liability	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Total
a. Assets at fair value					
Bonds					
Industrial and misc	$ —	$ 5,004,273	$ 10,053,833	$ —	$ 15,058,106
Bank Loans	—	1,942,727	—	—	1,942,727
Total bonds	$ —	$ 6,947,000	$ 10,053,833	$ —	$ 17,000,833
Common stock					
Industrial and misc	$ 30,344	$ 1,263,940	$ 2,747,155	$ —	$ 4,041,439
Total common stocks	$ 30,344	$ 1,263,940	$ 2,747,155	$ —	$ 4,041,439
Total assets at fair value/NAV	$ 30,344	$ 8,210,940	$ 12,800,988	$ —	$ 21,042,272

NOTES TO FINANCIAL STATEMENTS

(2) Fair Value Measurements in (Level 3) of the Fair Value Hierarchy

Description	Beginning Balance at 01/01/2023	Transfers into Level 3	Transfers out of Level 3	Total gains and (losses) included in Net Income	Total gains and (losses) included in Surplus	Purchases	Issuances	Sales	Settlements	Ending Balance at 12/31/2023
a. Assets										
Common Stock										
Industrial and misc	$4,657,100	—	—	(428,830)	169,491	315,635	—	(1,966,241)	—	$ 2,747,155
Bonds										
Industrial and misc	8,531,646	—	—	—	5,060	1,517,127	—	—	—	10,053,833
Bank loans	2,616,881	—	(496,529)	(123,309)	74,919	—	—	(2,062,713)	(9,249)	—
Total assets	$15,805,627	—	(496,529)	(552,139)	249,470	1,832,762	—	(4,028,954)	(9,249)	$12,800,988

(3) The Company’s policy is to recognize transfers between Levels, if any, as of the beginning of the reporting period.

(4) Fair values of bonds are based on quoted market prices, where available. These fair values are obtained primarily from third party pricing services, which generally use Level 1 or Level 2 inputs, for the determination of fair value to facilitate fair value measurements and disclosures. Level 2 securities primarily include United States government securities, corporate securities, securities from states, municipalities and political subdivisions, mortgage-backed securities and certain other asset-backed securities. For securities not actively traded, the pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. The Company has controls in place to review the pricing services' qualifications and procedures used to determine fair values. In addition, the Company periodically reviews the pricing services' pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable.

Certain bonds, primarily corporate debt securities, are designated Level 3. For these securities, the valuation methodologies may incorporate broker quotes or discounted cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit spreads, default rates and prepayment speeds that are not observable in the markets.

Fair values of common and preferred stock are generally designated as Level 1 and are based on quoted market prices. For certain common and preferred stock, quoted market prices for the identical security are not always available and the fair value is estimated by reference to similar securities for which quoted prices are available. These securities are designated as Level 2. Certain equity securities, including private equity securities, for which the fair value is estimated based on each security’s current condition and future cash flow projections. Such securities are designated as Level 3. The fair values of these private equity securities are generally based on either broker quotes, or discounted cash flow projections using assumptions for inputs such as the weighted-average cost of capital, long-term revenue growth rates and earnings before interest, taxes, depreciation and amortization, and/or revenue multiples that are not observable in the markets.

Cash equivalents primarily consist of highly rated money market funds or bonds with original maturities of three months or less. Due to the high ratings and short-term nature, these investments are designated as Level 1. The Company also holds bonds purchased with less than three months to maturity. Fair value of these bonds are based on quoted market prices obtained from third party pricing services which generally use Level 1 or Level 2 inputs.

Fair values of investments in residual bond tranches are based on the quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value, to facilitate fair value measurements and disclosures. Certain residual bond tranches are designated Level III. For these securities, the valuation methodology may incorporate broker quotes or discounted cash flows using internal modeling and assumptions.

Mortgage loans on real estate are measured using discounted cash flows benchmarked against the 10 Year U.S. Treasury plus a market rate spread. Fair value for these investments are designated as Level III.

There have been no significant changes in the valuation techniques during the current period.

B. Fair Value Measurements Under Other Accounting Pronouncements

Not applicable at December 31, 2023 and 2022.

C. Financial Instruments

Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Not Practicable (Carrying Value)
Bonds	$1,876,555,898	$1,906,490,617	$ —	$ 1,800,034,484	$ 76,521,414	$ —	$ —
Unaffiliated common stock	4,041,439	4,041,439	30,344	1,263,940	2,747,155	—	—
Cash equivalents	2,900,000	2,900,000	—	2,900,000	—	—	—
Short-term investments	443,778	259,752	—	318,664	125,114	—	—
Securities lending collateral asset	162,728,347	162,618,335	—	162,728,347	—	—	—
Mortgage Loans	197,988,675	211,862,878	—	—	197,988,675	—	—
Residual Tranche securities	12,913,664	12,913,664	—	—	12,913,664	—	—

D. Not Practicable to Estimate Fair Value

There are no financial instruments that were not practicable to estimate fair value.

E. Investments Measured at Net Asset Value

The Company has no investments measured at net asset value.

21. Other Items

A. Unusual or Infrequent Items

On February 11, 2022, the Company completed the acquisition of the Medicaid contract held by Paramount Advantage ("Paramount") to serve Ohio Medicaid enrollees for $93,300,000. The contract added approximately 270,000 Medicaid members in the state of Ohio. The Company began administering benefits for these members through a transition services agreement with Paramount immediately upon close through the start of the re-imagined Medicaid program that began February 1, 2023. This was to ensure continuity of care and help individuals maintain access to their preferred providers as they transitioned to the Company.

As a result of the acquisition, the Company recorded $53,119,074 and $70,328,911 of an intangible asset as of December 31, 2023 and 2022, respectively, which has been reported in aggregate write-ins for other invested assets. This intangible contract asset was assigned a five-year life and charged to surplus as a non-admitted asset. The intangible

NOTES TO FINANCIAL STATEMENTS

asset amortization expense was $40,486,987 and $28,958,964 in 2023 and 2022, respectively.

In addition, at the time of the closing of the acquisition, the Company paid $50,000,000 in cash and recorded a contingent purchase price liability of $49,287,875 as of December 31, 2022, which was reported in aggregate write-ins for other liabilities. The final payment of the transaction is based on membership retention and was paid on May 1, 2023, which was 90 days after the Company began Medicaid membership administration.

B. Troubled Debt Restructuring: Debtors

Not applicable at December 31, 2023 and 2022.

C. Other Disclosures

The Company participates in the Federal Employee Health Benefits Program ("FEHBP") with other Blue Cross Blue Shield Plans. This program includes a fully-insured experience-rated contract, commonly known as the FEP, between the OPM and BCBSA, which acts as an agent for the participating Blue Cross Blue Shield plans. In addition, each participating plan, including the Company, executes a contract with BCBSA which obligates each participating plan to underwrite FEP benefits in its service area.

FEP premium is earned when chargeable benefit costs, allowable expenses or retentions are incurred. Deferred premiums are recorded to offset the FEP liabilities for incurred claims but not reported and claims adjustment expenses that are due from the OPM, when the claims are ultimately paid. Premium rates are developed by BCBSA and negotiated with OPM annually. These rates determine the funds that will be available to the participating Blue Cross Blue Shield plans to provide insurance to Federal employees that enroll with the Blue Cross Blue Shield FEP. The excess of gross premiums for the life of the program over the charges for the life of the program on an accrual basis is accounted for as a rate stabilization reserve (commonly referred to as the special reserve), as required by the contract between OPM and BCBSA. Each year, OPM also allocates a portion of the premiums to a contingency reserve, which may be utilized by the participating plans in the event that annual premiums paid to the insurance carrier are insufficient or the rate stabilization reserve falls below certain levels prescribed by OPM. Premiums paid to the carrier and available to each participating Blue Cross Blue Shield plan, including the special reserve and the contingency reserve, are held at the U.S. Treasury, including amounts unused from prior periods. Any premiums that remain in the rate stabilization reserve upon termination of the BCBSA contract after the claims run-out and reimbursement of allowable administrative expenses would be returned to OPM for the benefit of the FEHBP. The FEP contract renews automatically each year unless written notice of termination is given by either party.

In accordance with the FEP contract, premium funds that exceed daily operating needs are held on behalf of the Company in letter of credit accounts at the U.S. Treasury to provide funding for claims, administrative expenses, and other charges to the contract. The Company, along with other Blue Cross Blue Shield plans who participate in the FEHBP contract, have an unrestricted right to draw funds being held in the U.S. Treasury, other than those allocated to the contingency reserve, for any valid claim or expense. If the balance of the special reserve is exhausted or falls below certain prescribed levels, OPM will transfer funds from the contingency reserve to the special reserve to the extent that funds are available in the contingency reserve. Amounts incurred in excess of the total reserves held at the U.S. Treasury for the FEP would not be reimbursed to the Company.

A rate stabilization reserve was not required for the Company at December 31, 2023 or 2022.

NOTES TO FINANCIAL STATEMENTS

FEP represented approximately 26.4% and 33.6% of premiums receivable as of December 31, 2023 and 2022, respectively. FEP represented approximately 10.6% and 10.3% of net premiums written for the years ended December 31, 2023 and 2022, respectively.

D. Business Interruption Insurance Recoveries

The Company has reported no recoveries for business interruption for the years ended December 31, 2023 and 2022.

E. State Transferable and Non-Transferable Tax Credits

(1) Carrying value of transferable and non-transferable state tax credits gross of any related tax liabilities and total unused transferable and non-transferable state tax credits by state and in total.

Description of State Transferable and Non-transferable Tax Credits	State	Carrying Value	Unused Amount
Premium Tax Credits	OH	$ 4,110,000	$ 4,110,000
Total		$ 4,110,000	$ 4,110,000

(2) Method of Estimating Utilization of Remaining Transferable and Non-transferable State Tax Credits

Utilization of remaining transferable state tax credits is estimated based on prior year information and current business trends.

(3) Impairment Loss

There were no impairment losses recognized on state tax credits during the years ended December 31, 2023 or 2022.

(4) State Tax Credits Admitted and Nonadmitted

	Total Admitted	Total Nonadmitted
a. Transferable	$ 4,110,000	$ —
b. Non-transferable	$ —	$ —

F. Subprime Mortgage-Related Risk Exposure

(1) The Company's investment strategy of providing safety and preservation of capital, sufficient liquidity to meet cash flow requirements and the attainment of a competitive after-tax investment return is supported by a well diversified portfolio consisting of many different types of investments. The portion of the Company's investment portfolio with subprime mortgage-related risk exposure is relatively small in comparison to the overall investment portfolio. All mortgage related investments are monitored closely as part of the quarterly investment review performed by the Elevance Health Investment Impairment Review Committee.

(2) The Company did not carry investments in subprime mortgage loans in its portfolio at December 31, 2023 or 2022.

NOTES TO FINANCIAL STATEMENTS

(3) At December 31, 2023, the Company's subprime mortgage-related risk exposure is detailed below:

	Actual Cost	Book/ Adjusted Carrying Value (excluding interest)	Fair Value	Other-Than-Temporary Impairment Losses Recognized
a. Residential mortgage-backed securities	$ 8,607,514	$ 8,554,967	$ 8,125,065	$ —
b. Commercial mortgage-backed securities	—	—	—	—
c. Collateralized debt obligations	—	—	—	—
d. Structured securities	—	—	—	—
e. Equity investments in SCAs	—	—	—	—
f. Other assets	—	—	—	—
g. Total	$ 8,607,514	$ 8,554,967	$ 8,125,065	$ —

(4) The Company did not underwrite Mortgage Guaranty or Financial Guaranty insurance coverage at December 31, 2023 or 2022.

G. Retained Assets

The Company does not have retained assets at December 31, 2023 and 2022.

H. Insurance-Linked Securities Contracts

Not applicable.

I. The Amount That Could Be Realized on Life Insurance Where the Reporting Entity is Owner and Beneficiary or Has Otherwise Obtained Rights to Control the Policy

(1) Amount of admitted balance that could be realized from an investment vehicle	$ 246,971,660
(2) Percentage bonds	7 %
(3) Percentage stocks	4 %
(4) Percentage mortgage loans	— %
(5) Percentage real estate	— %
(6) Percentage cash and short-term investments	3 %
(7) Percentage derivatives	— %
(8) Percentage other invested assets	86 %

22. Events Subsequent

Subsequent events have been considered through February 27, 2024 for the statutory statement issued on February 28, 2024. There were no events occurring subsequent to December 31, 2023 requiring recognition or disclosure.

23. Reinsurance

A. Ceded Reinsurance Report

Section 1 - General Interrogatories

(1) Are any of the reinsurers that are listed in Schedule S as non-affiliated owned in excess of 10% or controlled, either directly or indirectly, by the Company or by any representative, officer, trustee, or director of the Company?

Yes ( ) No (X)

NOTES TO FINANCIAL STATEMENTS

If yes, give full details.

(2) Have any policies issued by the Company been reinsured with a company chartered in a country other than the United States (excluding U.S. Branches of such companies) that is owned in excess of 10% or controlled, directly or indirectly, by an insured, a beneficiary, a creditor or an insured or any other person not primarily engaged in the insurance business?

Yes ( ) No (X)

If yes, give full details.

Section 2 - Ceded Reinsurance Report - Part A

(1) Does the Company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than for nonpayment of premium or other similar credits?

Yes ( ) No (X)

If yes, give full details.

(2) Does the reporting entity have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies?

Yes ( ) No (X)

If yes, give full details.

Section 3 - Ceded Reinsurance Report - Part B

(1) What is the estimated amount of the aggregate reduction in surplus, (for agreements other than those under which the reinsurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of ALL reinsurance agreements, by either party, as of the date of this statement? Where necessary, the Company may consider the current or anticipated experience of the business reinsured in making this estimate.

$4,919,530

(2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or which had existing reserves established by the Company as of the effective date of the agreement?

Yes ( ) No (X)

If yes, give full details.

B. Uncollectible Reinsurance

The Company has no uncollectible reinsurance at December 31, 2023 and 2022.

NOTES TO FINANCIAL STATEMENTS

C. Commutation of Ceded Reinsurance

The Company has not commuted ceded reinsurance during 2023 and 2022.

D. Certified Reinsurer Rating Downgraded or Status Subject Revocation

The Company has no downgraded certified reinsurer ratings or status subject to revocations during 2023 and 2022.

E. Reinsurance Credit

(1) The Company has the following reinsurance contracts subject to Life and Health Reinsurance Agreements Model Regulation Appendix A-791 (“A-791”) that includes a provision which limits the reinsurer’s assumption of risks, such as a deductible, a loss ratio corridor, a loss cap, or an aggregate limit, as defined in A-791:

Name of Reinsurer	Number of contracts to which such provisions apply	Was Deposit Accounting Applied (Yes or No)
Anthem Insurance Companies, Inc.	1	N

(2) Not applicable.

(3) Not applicable.

(4) Not applicable.

(5) Not applicable.

24. Retrospectively Rated Contracts & Contracts Subject to Redetermination

A. The Company sells accident and health policies for which the premiums vary based on loss experience. The Company estimates retrospective premium adjustments through the review of each retrospectively rated account, comparing the claim development with that anticipated in the policy contracts.

B. The Company records accrued retrospective premium as an adjustment to earned premium.

C. The amount of net premiums written by the Company at December 31, 2023 and 2022 that were subject to retrospective rating features was $9,097,456,895 and $8,887,312,437, respectively, which represented, 92.0% and 96.2%, respectively, of the total net premiums written.

D. In accordance with the NAIC SAP, medical loss ratio rebates in accordance with the Federal 2010 Patient Protection and Affordable Care Act and Public Health Service Act (“ACA Act” or “ACA”), are to be reported in accordance with SSAP No. 66 - *Retrospectively Rated Contracts* (“SSAP No. 66”). A retrospectively rated contract is one that has the final policy premium calculated based on the loss experience of the insured during the term of the policy (including loss development after the term of the policy) and the stipulated formula set forth in the policy, or in the case of medical loss ratio rebates, a formula required by law. The Company based the incurred and unpaid liability amounts reported below based on its underwriting experience; actuarial, tax, and accounting estimates and assumptions at the financial statement date; as well as regulations and guidance available that is not final and subject to change prior to settlement. Accordingly, the Company’s use of estimates and assumptions in the preparation of the statutory based financial statements and related footnote disclosures may differ from actual results. Hence, the amounts reported herein are for financial reporting purposes solely and not intended to be used for settlement purposes.

NOTES TO FINANCIAL STATEMENTS

Medical loss ratio rebates accrued pursuant to the ACA Act are as follows:

	Individual	Small Group Employer	Large Group Employer	Other Categories with Rebates	Total
Prior Year Reporting:					
(1) Medical loss ratio rebates incurred	$ (806,799)	$ 9,332,001	$ —	$ 375,639	$ 8,900,841
(2) Medical loss ratio rebates paid	320,063	4,555,873	—	—	4,875,936
(3) Medical loss ratio rebates unpaid	—	4,776,128	—	375,639	5,151,767
(4) Plus reinsurance assumed amounts	XXX	XXX	XXX	XXX	—
(5) Less reinsurance ceded amounts	XXX	XXX	XXX	XXX	—
(6) Rebates unpaid net of reinsurance	XXX	XXX	XXX	XXX	$ 5,151,767
Current Reporting Year-to-Date					
(7) Medical loss ratio rebates incurred	$ —	$ 8,885,176	$ —	$ (375,639)	$ 8,509,537
(8) Medical loss ratio rebates paid	—	6,141,602	—	—	6,141,602
(9) Medical loss ratio rebates unpaid	—	7,519,702	—	—	7,519,702
(10) Plus reinsurance assumed amounts	XXX	XXX	XXX	XXX	—
(11) Less reinsurance ceded amounts	XXX	XXX	XXX	XXX	—
(12) Rebates unpaid net of reinsurance	XXX	XXX	XXX	XXX	$ 7,519,702

E. Risk-Sharing Provisions of the ACA

(1) Did the reporting entity write accident and health insurance premium that is subject to the Affordable Care Act risk-sharing provisions (YES/NO)? Yes

(2) Impact of Risk-Sharing Provisions of the Affordable Care Act on Admitted Assets, Liabilities and Revenue for the Current Year

a. Permanent ACA Risk Adjustment Program		
Assets		
1. Premium adjustments receivable due to ACA Risk Adjustment (including high risk pool payments)	$	7,804,934
Liabilities		
2. Risk adjustment user fees payable for ACA Risk Adjustment	$	220,259
3. Premium adjustments payable due to ACA Risk Adjustment (including high risk pool premiums)	$	38,004,373
Operations (Revenue & Expense)		
4. Reported as revenue in premium for accident and health contracts (written/collected) due to ACA Risk Adjustment	$	(24,949,237)
5. Reported in expenses as ACA risk adjustment user fees (incurred/paid)	$	220,381
b. Transitional ACA Reinsurance Program		
Assets		
1. Amounts recoverable for claims paid due to ACA Reinsurance	$	—
2. Amounts recoverable for claims unpaid due to ACA Reinsurance (contra liability)	$	—
3. Amounts receivable relating to uninsured plans for contributions for ACA Reinsurance	$	—
Liabilities		
4. Liabilities for contributions payable due to ACA Reinsurance - not reported as ceded premium	$	—
5. Ceded reinsurance premiums payable due to ACA Reinsurance	$	—
6. Liability for amounts held under uninsured plans contributions for ACA Reinsurance	$	—
Operations (Revenue & Expense)		
7. Ceded reinsurance premiums due to ACA Reinsurance	$	—
8. Reinsurance recoveries (income statement) due to ACA Reinsurance payments or expected payments	$	—
9. ACA Reinsurance contributions - not reported as ceded premium	$	—
c. Temporary ACA Risk Corridors Program		
Assets		
1. Accrued retrospective premium due to ACA Risk Corridors	$	—
Liabilities		
2. Reserve for rate credits or policy experience rating refunds due to ACA Risk Corridors	$	—
Operations (Revenue & Expense)		
3. Effect of ACA Risk Corridors on net premium income (paid/received)	$	—
4. Effect of ACA Risk Corridors on change in reserves for rate credits	$	—

Line items where the amount is zero is due to no balance and/or no activity as of the reporting date.

NOTES TO FINANCIAL STATEMENTS

(3) Roll-forward of prior year ACA risk-sharing provisions for the following asset (gross of any nonadmission) and liability balances, along with the reasons for adjustments to prior year balance.

	Accrued During the Prior Year on Business Written Before December 31 of the Prior Year		Received or Paid as of the Current Year on Business Written Before December 31 of the Prior Year		Differences		Adjustments			Unsettled Balances as of the Reporting Date	
					Prior Year Accrued Less Payments (Col 1-3)	Prior Year Accrued Less Payments (Col 2-4)	To Prior Year Balances	To Prior Year Balances	Ref	Cumulative Balance from Prior Years (Col 1-3+7)	Cumulative Balance from Prior Years (Col 2-4+8)
	1	2	3	4	5	6	7	8		9	10
	Receivable	(Payable)	Receivable	(Payable)	Receivable	(Payable)	Receivable	(Payable)		Receivable	(Payable)
a. Permanent ACA Risk Adjustment Program											
1. Premium adjustments receivable	$ 5,434,340	$ —	$ 9,405,452	$ —	$ (3,971,112)	$ —	$ 3,986,198	$ —	A	$ 15,086	$ —
2. Premium adjustments (payable)	$ —	$16,495,450	$ —	$ 13,755,086	$ —	$ 2,740,364	$ —	$(2,740,364)	B	$ —	$ —
3. Subtotal ACA Permanent Risk Adjustment Program	$ 5,434,340	$16,495,450	$ 9,405,452	$ 13,755,086	$ (3,971,112)	$ 2,740,364	$ 3,986,198	$(2,740,364)		$ 15,086	$ —
b. Transitional ACA Reinsurance Program											
1. Amounts recoverable for claims paid	$ —	$ —	$ —	$ —	$ —	$ —	$ —	$ —	C	$ —	$ —
2. Amounts recoverable for claims unpaid (contra liability)	$ —	$ —	$ —	$ —	$ —	$ —	$ —	$ —	D	$ —	$ —
3. Amounts receivable relating to uninsured plans	$ —	$ —	$ —	$ —	$ —	$ —	$ —	$ —	E	$ —	$ —
4. Liabilities for contributions payable due to ACA Reinsurance - not reported as ceded premium	$ —	$ —	$ —	$ —	$ —	$ —	$ —	$ —	F	$ —	$ —
5. Ceded reinsurance premiums payable	$ —	$ —	$ —	$ —	$ —	$ —	$ —	$ —	G	$ —	$ —
6. Liability for amounts held under uninsured plans					$ —	$ —	$ —	$ —	H	$ —	$ —
7. Subtotal ACA Transitional Reinsurance Program	$ —	$ —	$ —	$ —	$ —	$ —	$ —	$ —		$ —	$ —
c. Temporary ACA Risk Corridors Program											
1. Accrued retrospective premium					$ —	$ —	$ —	$ —	I	$ —	$ —
2. Reserve for rate credits or policy experience rating refunds	$ —	$ —	$ —	$ —	$ —	$ —	$ —	$ —	J	$ —	$ —
3. Subtotal ACA Risk Corridors Program	$ —	$ —	$ —	$ —	$ —	$ —	$ —	$ —		$ —	$ —
d. Total for ACA Risk Sharing Provisions	$ 5,434,340	$16,495,450	$ 9,405,452	$ 13,755,086	$ (3,971,112)	$ 2,740,364	$ 3,986,198	$(2,740,364)		$ 15,086	$ —

Explanations of Adjustments

A Adjustments were made to reflect the ending balance in the Centers for Medicare & Medicaid Services "Summary Report on Permanent Risk Adjustment Transfers for the 2022 Benefit Year."

B Adjustments were made to reflect the ending balance in the Centers for Medicare & Medicaid Services "Summary Report on Permanent Risk Adjustment Transfers for the 2022 Benefit Year."

C Not applicable.

D Not applicable.

E Not applicable.

F Not applicable.

G Not applicable.

H Not applicable.

I Not applicable.

J Not applicable.

(4) Roll-forward of Risk Corridors Asset and Liability Balances by Program Benefit

Not applicable.

(5) ACA Risk Corridors Receivable as of Reporting Date

Not applicable.

25. Change in Incurred Claims and Claim Adjustment Expenses

A. The estimated cost of claims and claim adjustment expense attributable to insured events of prior years decreased by $231,830,288 during 2023. This is approximately 24.6% of unpaid claims and claim adjustment expenses, net of healthcare receivables, of $944,110,943 as of December 31, 2022. The redundancy reflects the decreases in estimated claims and claims adjustment expenses as a result of claims payment during the year, and as additional information is received regarding claims incurred prior to 2023. Recent claim development trends are also taken into account in evaluating the overall adequacy of unpaid claims and unpaid claim adjustment expense.

B. There were no significant changes in methodologies and assumptions used in calculating the liability for unpaid losses and loss adjustment expenses.

26. Intercompany Pooling Arrangements

Not applicable at December 31, 2023 and 2022.

NOTES TO FINANCIAL STATEMENTS

27. Structured Settlements

Not applicable at December 31, 2023 and 2022.

28. Health Care Receivables

A. Pharmaceutical Rebate Receivables

Quarter	Estimated Pharmacy Rebates as Reported on Financial Statements	Pharmacy Rebates as Billed or Otherwise Confirmed	Actual Rebates Received Within 90 Days of Billing	Actual Rebates Received Within 91 to 180 Days of Billing	Actual Rebates Received More Than 180 Days After Billing
12/31/2023	$ 56,412,712	$ 152,330,571	$ 95,917,859	$ —	$ —
9/30/2023	$ 61,572,286	$ 164,705,553	$ 153,971,497	$ —	$ —
6/30/2023	$ 59,750,774	$ 156,408,364	$ 145,521,047	$ 10,887,316	$ —
3/31/2023	$ 66,838,755	$ 150,593,984	$ 138,483,338	$ 12,110,646	$ —
12/31/2022	$ 55,771,261	$ 139,506,553	$ 129,435,672	$ 10,070,881	$ —
9/30/2022	$ 52,050,307	$ 136,006,211	$ 125,756,465	$ 10,249,746	$ —
6/30/2022	$ 51,550,942	$ 137,315,682	$ 127,541,011	$ 9,774,671	$ —
3/31/2022	$ 53,530,682	$ 125,153,621	$ 114,430,986	$ 10,722,635	$ —
12/31/2021	$ 43,793,115	$ 106,361,773	$ 99,443,209	$ 6,918,564	$ —
9/30/2021	$ 43,751,637	$ 105,277,452	$ 93,827,089	$ 11,450,363	$ —
6/30/2021	$ 8,594,772	$ 75,700,494	$ 66,881,620	$ 8,818,874	$ —
3/31/2021	$ 8,531,599	$ 102,938,361	$ 94,658,284	$ 8,280,078	$ —

Note: Amounts within column "Estimated pharmacy rebates as reported on financial statements" include $7,519,195 of uninsured admitted pharmacy rebate receivables at December 31, 2023 that are reported within Pg 2, Ln 17 "Amounts receivable relating to uninsured plans."

B. Risk Sharing Receivables

Not applicable at December 31, 2023 and 2022.

29. Participating Policies

Not applicable at December 31, 2023 and 2022.

30. Premium Deficiency Reserves

The Company had no liabilities related to premium deficiency reserves as of December 31, 2023 and 2022.

31. Anticipated Salvage and Subrogation

The Company took into account estimated anticipated subrogation and other recoveries in its determination of the liability for unpaid claims and reduced the liability by $2,796,444 and $11,477,000 at December 31, 2023 and 2022, respectively.

GENERAL INTERROGATORIES

PART 1 - COMMON INTERROGATORIES
GENERAL

1.1 Is the reporting entity a member of an Insurance Holding Company System consisting of two or more affiliated persons, one or more of which is an insurer? .... Yes [X] No [ ]
If yes, complete Schedule Y, Parts 1, 1A, 2 and 3.

1.2 If yes, did the reporting entity register and file with its domiciliary State Insurance Commissioner, Director or Superintendent or with such regulatory official of the state of domicile of the principal insurer in the Holding Company System, a registration statement providing disclosure substantially similar to the standards adopted by the National Association of Insurance Commissioners (NAIC) in its Model Insurance Holding Company System Regulatory Act and model regulations pertaining thereto, or is the reporting entity subject to standards and disclosure requirements substantially similar to those required by such Act and regulations? .... Yes [X] No [ ] N/A [ ]

1.3 State Regulating? .... Ohio

1.4 Is the reporting entity publicly traded or a member of a publicly traded group? .... Yes [X] No [ ]

1.5 If the response to 1.4 is yes, provide the CIK (Central Index Key) code issued by the SEC for the entity/group. 0001156039

2.1 Has any change been made during the year of this statement in the charter, by-laws, articles of incorporation, or deed of settlement of the reporting entity? .... Yes [ ] No [X]

2.2 If yes, date of change: ....

3.1 State as of what date the latest financial examination of the reporting entity was made or is being made. 12/31/2022

3.2 State the as of date that the latest financial examination report became available from either the state of domicile or the reporting entity. This date should be the date of the examined balance sheet and not the date the report was completed or released. 12/31/2017

3.3 State as of what date the latest financial examination report became available to other states or the public from either the state of domicile or the reporting entity. This is the release date or completion date of the examination report and not the date of the examination (balance sheet date). 05/23/2019

3.4 By what department or departments?
Ohio Department of Insurance ....

3.5 Have all financial statement adjustments within the latest financial examination report been accounted for in a subsequent financial statement filed with Departments? .... Yes [ ] No [ ] N/A [X]

3.6 Have all of the recommendations within the latest financial examination report been complied with? .... Yes [ ] No [ ] N/A [X]

4.1 During the period covered by this statement, did any agent, broker, sales representative, non-affiliated sales/service organization or any combination thereof under common control (other than salaried employees of the reporting entity), receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business measured on direct premiums) of:
4.11 sales of new business? .... Yes [ ] No [X]
4.12 renewals? .... Yes [ ] No [X]

4.2 During the period covered by this statement, did any sales/service organization owned in whole or in part by the reporting entity or an affiliate, receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business measured on direct premiums) of:
4.21 sales of new business? .... Yes [ ] No [X]
4.22 renewals? .... Yes [ ] No [X]

5.1 Has the reporting entity been a party to a merger or consolidation during the period covered by this statement? .... Yes [ ] No [X]
If yes, complete and file the merger history data file with the NAIC.

5.2 If yes, provide the name of the entity, NAIC Company Code, and state of domicile (use two letter state abbreviation) for any entity that has ceased to exist as a result of the merger or consolidation.

1 Name of Entity	2 NAIC Company Code	3 State of Domicile
....	....	....

6.1 Has the reporting entity had any Certificates of Authority, licenses or registrations (including corporate registration, if applicable) suspended or revoked by any governmental entity during the reporting period? .... Yes [ ] No [X]

6.2 If yes, give full information:
....

7.1 Does any foreign (non-United States) person or entity directly or indirectly control 10% or more of the reporting entity? .... Yes [ ] No [X]

7.2 If yes,
7.21 State the percentage of foreign control; .... %
7.22 State the nationality(s) of the foreign person(s) or entity(s); or if the entity is a mutual or reciprocal, the nationality of its manager or attorney-in-fact and identify the type of entity(s) (e.g., individual, corporation, government, manager or attorney-in-fact).

1 Nationality	2 Type of Entity
....	....

GENERAL INTERROGATORIES

8.1 Is the company a subsidiary of a depository institution holding company (DIHC) or a DIHC itself, regulated by the Federal Reserve Board? ...... Yes [ ] No [X]

8.2 If the response to 8.1 is yes, please identify the name of the DIHC.

....

8.3 Is the company affiliated with one or more banks, thrifts or securities firms? .... Yes [ ] No [X]

8.4 If response to 8.3 is yes, please provide below the names and location (city and state of the main office) of any affiliates regulated by a federal regulatory services agency [i.e. the Federal Reserve Board (FRB), the Office of the Comptroller of the Currency (OCC), the Federal Deposit Insurance Corporation (FDIC) and the Securities Exchange Commission (SEC)] and identify the affiliate's primary federal regulator.

1 Affiliate Name	2 Location (City, State)	3 FRB	4 OCC	5 FDIC	6 SEC
....	....	....	....	....	....

8.5 Is the reporting entity a depository institution holding company with significant insurance operations as defined by the Board of Governors of Federal Reserve System or a subsidiary of the depository institution holding company? .... Yes [ ] No [X]

8.6 If response to 8.5 is no, is the reporting entity a company or subsidiary of a company that has otherwise been made subject to the Federal Reserve Board's capital rule? .... Yes [ ] No [X] N/A [ ]

9. What is the name and address of the independent certified public accountant or accounting firm retained to conduct the annual audit?

Ernst & Young LLP 111 Monument Circle, Suite 4000, Indianapolis, IN 46204 ....

10.1 Has the insurer been granted any exemptions to the prohibited non-audit services provided by the certified independent public accountant requirements as allowed in Section 7H of the Annual Financial Reporting Model Regulation (Model Audit Rule), or substantially similar state law or regulation? .... Yes [ ] No [X]

10.2 If the response to 10.1 is yes, provide information related to this exemption:

....

10.3 Has the insurer been granted any exemptions related to the other requirements of the Annual Financial Reporting Model Regulation as allowed for in Section 18A of the Model Regulation, or substantially similar state law or regulation? .... Yes [ ] No [X]

10.4 If the response to 10.3 is yes, provide information related to this exemption:

....

10.5 Has the reporting entity established an Audit Committee in compliance with the domiciliary state insurance laws? .... Yes [X] No [ ] N/A [ ]

10.6 If the response to 10.5 is no or n/a, please explain.

....

11. What is the name, address and affiliation (officer/employee of the reporting entity or actuary/consultant associated with an actuarial consulting firm) of the individual providing the statement of actuarial opinion/certification?

Christine Valdez (employee), FSA, MAAA, Director & Actuary III, 20458 Napa St., Winnetka, CA 91306 ....

12.1 Does the reporting entity own any securities of a real estate holding company or otherwise hold real estate indirectly? .... Yes [ ] No [X]

12.11 Name of real estate holding company ...

12.12 Number of parcels involved ....

12.13 Total book/adjusted carrying value ....$ ....

12.2 If yes, provide explanation

....

13. **FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTITIES ONLY:**

13.1 What changes have been made during the year in the United States manager or the United States trustees of the reporting entity?

....

13.2 Does this statement contain all business transacted for the reporting entity through its United States Branch on risks wherever located? .... Yes [ ] No [ ]

13.3 Have there been any changes made to any of the trust indentures during the year? .... Yes [ ] No [ ]

13.4 If answer to (13.3) is yes, has the domiciliary or entry state approved the changes? .... Yes [ ] No [ ] N/A [ ]

14.1 Are the senior officers (principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions) of the reporting entity subject to a code of ethics, which includes the following standards? .... Yes [X] No [ ]

a. Honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships;

b. Full, fair, accurate, timely and understandable disclosure in the periodic reports required to be filed by the reporting entity;

c. Compliance with applicable governmental laws, rules and regulations;

d. The prompt internal reporting of violations to an appropriate person or persons identified in the code; and

e. Accountability for adherence to the code.

14.11 If the response to 14.1 is No, please explain:

....

14.2 Has the code of ethics for senior managers been amended? .... Yes [ ] No [X]

14.21 If the response to 14.2 is yes, provide information related to amendment(s).

....

14.3 Have any provisions of the code of ethics been waived for any of the specified officers? .... Yes [ ] No [X]

14.31 If the response to 14.3 is yes, provide the nature of any waiver(s).

....

GENERAL INTERROGATORIES

15.1 Is the reporting entity the beneficiary of a Letter of Credit that is unrelated to reinsurance where the issuing or confirming bank is not on the SVO Bank List? .... Yes [ ] No [X]

15.2 If the response to 15.1 is yes, indicate the American Bankers Association (ABA) Routing Number and the name of the issuing or confirming bank of the Letter of Credit and describe the circumstances in which the Letter of Credit is triggered.

1 American Bankers Association (ABA) Routing Number	2 Issuing or Confirming Bank Name	3 Circumstances That Can Trigger the Letter of Credit	4 Amount

BOARD OF DIRECTORS

16. Is the purchase or sale of all investments of the reporting entity passed upon either by the board of directors or a subordinate committee thereof? .... Yes [X] No [ ]

17. Does the reporting entity keep a complete permanent record of the proceedings of its board of directors and all subordinate committees thereof? .... Yes [X] No [ ]

18. Has the reporting entity an established procedure for disclosure to its board of directors or trustees of any material interest or affiliation on the part of any of its officers, directors, trustees or responsible employees that is in conflict or is likely to conflict with the official duties of such person? .... Yes [X] No [ ]

FINANCIAL

19. Has this statement been prepared using a basis of accounting other than Statutory Accounting Principles (e.g., Generally Accepted Accounting Principles)? .... Yes [ ] No [X]

20.1 Total amount loaned during the year (inclusive of Separate Accounts, exclusive of policy loans):
- 20.11 To directors or other officers........ $ 0
- 20.12 To stockholders not officers........ $ 0
- 20.13 Trustees, supreme or grand (Fraternal Only) .... $ 0

20.2 Total amount of loans outstanding at the end of year (inclusive of Separate Accounts, exclusive of policy loans):
- 20.21 To directors or other officers........ $ 0
- 20.22 To stockholders not officers........ $ 0
- 20.23 Trustees, supreme or grand (Fraternal Only) .... $ 0

21.1 Were any assets reported in this statement subject to a contractual obligation to transfer to another party without the liability for such obligation being reported in the statement? .... Yes [ ] No [X]

21.2 If yes, state the amount thereof at December 31 of the current year:
- 21.21 Rented from others........ $
- 21.22 Borrowed from others........ $
- 21.23 Leased from others .... $
- 21.24 Other .... $

22.1 Does this statement include payments for assessments as described in the Annual Statement Instructions other than guaranty fund or guaranty association assessments? .... Yes [ ] No [X]

22.2 If answer is yes:
- 22.21 Amount paid as losses or risk adjustment $
- 22.22 Amount paid as expenses .... $
- 22.23 Other amounts paid .... $

23.1 Does the reporting entity report any amounts due from parent, subsidiaries or affiliates on Page 2 of this statement? .... Yes [X] No [ ]

23.2 If yes, indicate any amounts receivable from parent included in the Page 2 amount: .... $ 123,679,454

24.1 Does the insurer utilize third parties to pay agent commissions in which the amounts advanced by the third parties are not settled in full within 90 days? .... Yes [ ] No [X]

24.2 If the response to 24.1 is yes, identify the third-party that pays the agents and whether they are a related party.

Name of Third-Party	Is the Third-Party Agent a Related Party (Yes/No)

INVESTMENT

25.01 Were all the stocks, bonds and other securities owned December 31 of current year, over which the reporting entity has exclusive control, in the actual possession of the reporting entity on said date? (other than securities lending programs addressed in 25.03)........ Yes [X] No [ ]

GENERAL INTERROGATORIES

25.02 If no, give full and complete information, relating thereto

25.03 For securities lending programs, provide a description of the program including value for collateral and amount of loaned securities, and whether collateral is carried on or off-balance sheet. (an alternative is to reference Note 17 where this information is also provided)
See Notes 5E and 17.

25.04 For the reporting entity's securities lending program, report amount of collateral for conforming programs as outlined in the Risk-Based Capital Instructions. $ 162,618,335

25.05 For the reporting entity's securities lending program, report amount of collateral for other programs. $

25.06 Does your securities lending program require 102% (domestic securities) and 105% (foreign securities) from the counterparty at the outset of the contract? Yes [X] No [ ] N/A [ ]

25.07 Does the reporting entity non-admit when the collateral received from the counterparty falls below 100%? Yes [X] No [ ] N/A [ ]

25.08 Does the reporting entity or the reporting entity's securities lending agent utilize the Master Securities lending Agreement (MSLA) to conduct securities lending? Yes [X] No [ ] N/A [ ]

25.09 For the reporting entity's securities lending program state the amount of the following as of December 31 of the current year:

25.091 Total fair value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2. $ 162,728,347
25.092 Total book/adjusted carrying value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2 $ 162,618,335
25.093 Total payable for securities lending reported on the liability page. $ 162,618,335

26.1 Were any of the stocks, bonds or other assets of the reporting entity owned at December 31 of the current year not exclusively under the control of the reporting entity or has the reporting entity sold or transferred any assets subject to a put option contract that is currently in force? (Exclude securities subject to Interrogatory 21.1 and 25.03). Yes [X] No [ ]

26.2 If yes, state the amount thereof at December 31 of the current year:

26.21 Subject to repurchase agreements $ 0
26.22 Subject to reverse repurchase agreements $ 2,900,000
26.23 Subject to dollar repurchase agreements $ 0
26.24 Subject to reverse dollar repurchase agreements $ 0
26.25 Placed under option agreements $ 0
26.26 Letter stock or securities restricted as to sale - excluding FHLB Capital Stock $ 0
26.27 FHLB Capital Stock $ 2,480,800
26.28 On deposit with states $ 4,237,666
26.29 On deposit with other regulatory bodies $ 0
26.30 Pledged as collateral - excluding collateral pledged to an FHLB $ 0
26.31 Pledged as collateral to FHLB - including assets backing funding agreements $ 255,026,294
26.32 Other $ 0

26.3 For category (26.26) provide the following:

1 Nature of Restriction	2 Description	3 Amount

27.1 Does the reporting entity have any hedging transactions reported on Schedule DB? Yes [ ] No [X]

27.2 If yes, has a comprehensive description of the hedging program been made available to the domiciliary state? Yes [ ] No [ ] N/A [ ]
If no, attach a description with this statement.

LINES 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY:

27.3 Does the reporting entity utilize derivatives to hedge variable annuity guarantees subject to fluctuations as a result of interest rate sensitivity? Yes [ ] No [ ]

27.4 If the response to 27.3 is YES, does the reporting entity utilize:
27.41 Special accounting provision of SSAP No. 108 Yes [ ] No [ ]
27.42 Permitted accounting practice Yes [ ] No [ ]
27.43 Other accounting guidance Yes [ ] No [ ]

27.5 By responding YES to 27.41 regarding utilizing the special accounting provisions of SSAP No. 108, the reporting entity attests to the following: Yes [ ] No [ ]
- The reporting entity has obtained explicit approval from the domiciliary state.
- Hedging strategy subject to the special accounting provisions is consistent with the requirements of VM-21.
- Actuarial certification has been obtained which indicates that the hedging strategy is incorporated within the establishment of VM-21 reserves and provides the impact of the hedging strategy within the Actuarial Guideline Conditional Tail Expectation Amount.
- Financial Officer Certification has been obtained which indicates that the hedging strategy meets the definition of a Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy is the hedging strategy being used by the company in its actual day-to-day risk mitigation efforts.

28.1 Were any preferred stocks or bonds owned as of December 31 of the current year mandatorily convertible into equity, or, at the option of the issuer, convertible into equity? Yes [ ] No [X]

28.2 If yes, state the amount thereof at December 31 of the current year. $

29. Excluding items in Schedule E - Part 3 - Special Deposits, real estate, mortgage loans and investments held physically in the reporting entity's offices, vaults or safety deposit boxes, were all stocks, bonds and other securities, owned throughout the current year held pursuant to a custodial agreement with a qualified bank or trust company in accordance with Section 1, III - General Examination Considerations, F. Outsourcing of Critical Functions, Custodial or Safekeeping Agreements of the NAIC Financial Condition Examiners Handbook? Yes [X] No [ ]

29.01 For agreements that comply with the requirements of the NAIC Financial Condition Examiners Handbook, complete the following:

1 Name of Custodian(s)	2 Custodian's Address
JP Morgan Chase Bank, N.A	383 Madison Ave, New York, NY 10179

GENERAL INTERROGATORIES

29.02 For all agreements that do not comply with the requirements of the NAIC Financial Condition Examiners Handbook, provide the name, location and a complete explanation:

1 Name(s)	2 Location(s)	3 Complete Explanation(s)

29.03 Have there been any changes, including name changes, in the custodian(s) identified in 29.01 during the current year? Yes [ ] No [X]

29.04 If yes, give full and complete information relating thereto:

1 Old Custodian	2 New Custodian	3 Date of Change	4 Reason

29.05 Investment management – Identify all investment advisors, investment managers, broker/dealers, including individuals that have the authority to make investment decisions on behalf of the reporting entity. For assets that are managed internally by employees of the reporting entity, note as such. ["…that have access to the investment accounts"; "…handle securities"]

1 Name of Firm or Individual	2 Affiliation
Elevance Health, Inc.	I
Ares Management LLC	U
Bain Capital Credit, LP	U
BlackRock Financial Management	U
Loomis, Sayles & Company, LP	U
NB Alternatives Advisers LLC	U
Pacific Investment Management Company	U
R4CF Mortgage	U
Western Asset Management	U

29.0597 For those firms/individuals listed in the table for Question 29.05, do any firms/individuals unaffiliated with the reporting entity (i.e. designated with a "U") manage more than 10% of the reporting entity's invested assets? Yes [X] No [ ]

29.0598 For firms/individuals unaffiliated with the reporting entity (i.e. designated with a "U") listed in the table for Question 29.05, does the total assets under management aggregate to more than 50% of the reporting entity's invested assets? Yes [X] No [ ]

29.06 For those firms or individuals listed in the table for 29.05 with an affiliation code of "A" (affiliated) or "U" (unaffiliated), provide the information for the table below.

1 Central Registration Depository Number	2 Name of Firm or Individual	3 Legal Entity Identifier (LEI)	4 Registered With	5 Investment Management Agreement (IMA) Filed
130074	Ares Management LLC	549300Z3CVOBET4MRT08	Securities Exchange Commission	NO
134852	Bain Capital Credit, LP	WBY05W75IL9CPDJW0453	Securities Exchange Commission	NO
107105	BlackRock Financial Management	549300LVXYIVJKE13M84	Securities Exchange Commission	NO
105377	Loomis, Sayles & Company, LP	JIZPN2RX3UMNOYIDI313	Securities Exchange Commission	NO
149822	NB Alternatives Advisers LLC	549300DBQULCAC1K1E25	Securities Exchange Commission	NO
104559	Pacific Investment Management Company	549300KGPYQZXGMYYN38	Securities Exchange Commission	NO
	R4CF Mortgage		Not a Registered Investment Advisor	NO
110441	Western Asset Management	549300C5A561UXUICN46	Securities Exchange Commission	NO

30.1 Does the reporting entity have any diversified mutual funds reported in Schedule D, Part 2 (diversified according to the Securities and Exchange Commission (SEC) in the Investment Company Act of 1940 [Section 5(b)(1)])? Yes [ ] No [X]

30.2 If yes, complete the following schedule:

1 CUSIP #	2 Name of Mutual Fund	3 Book/Adjusted Carrying Value
30.2999 - Total		0

30.3 For each mutual fund listed in the table above, complete the following schedule:

1 Name of Mutual Fund (from above table)	2 Name of Significant Holding of the Mutual Fund	3 Amount of Mutual Fund's Book/Adjusted Carrying Value Attributable to the Holding	4 Date of Valuation

GENERAL INTERROGATORIES

31. Provide the following information for all short-term and long-term bonds and all preferred stocks. Do not substitute amortized value or statement value for fair value.

	1 Statement (Admitted) Value	2 Fair Value	3 Excess of Statement over Fair Value (-), or Fair Value over Statement (+)
31.1 Bonds	1,909,650,365	1,879,899,676	(29,750,689)
31.2 Preferred stocks	0		0
31.3 Totals	1,909,650,365	1,879,899,676	(29,750,689)

31.4 Describe the sources or methods utilized in determining the fair values:
Fair values were obtained from third-party pricing sources. If a security was not priced by a third-party pricing source, internal analytical systems or broker quotes were utilized.

32.1 Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D? Yes [X] No [ ]

32.2 If the answer to 32.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronic copy) for all brokers or custodians used as a pricing source? Yes [X] No [ ]

32.3 If the answer to 32.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure of fair value for Schedule D:

33.1 Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed? Yes [X] No [ ]
33.2 If no, list exceptions:

34. By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security:
a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available.
b. Issuer or obligor is current on all contracted interest and principal payments.
c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal.
Has the reporting entity self-designated 5GI securities? Yes [ ] No [X]

35. By self-designating PLGI securities, the reporting entity is certifying the following elements of each self-designated PLGI security:
a. The security was purchased prior to January 1, 2018.
b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security.
c. The NAIC Designation was derived from the credit rating assigned by an NAIC CRP in its legal capacity as a NRSRO which is shown on a current private letter rating held by the insurer and available for examination by state insurance regulators.
d. The reporting entity is not permitted to share this credit rating of the PL security with the SVO.
Has the reporting entity self-designated PLGI securities? Yes [ ] No [X]

36. By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-designated FE fund:
a. The shares were purchased prior to January 1, 2019.
b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security.
c. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO prior to January 1, 2019.
d. The fund only or predominantly holds bonds in its portfolio.
e. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO.
f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed.
Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria? Yes [ ] No [X]

37. By rolling/renewing short-term or cash equivalent investments with continued reporting on Schedule DA, Part 1 or Schedule E Part 2 (identified through a code (%) in those investment schedules), the reporting entity is certifying to the following:
a. The investment is a liquid asset that can be terminated by the reporting entity on the current maturity date.
b. If the investment is with a nonrelated party or nonaffiliate, then it reflects an arms-length transaction with renewal completed at the discretion of all involved parties.
c. If the investment is with a related party or affiliate, then the reporting entity has completed robust re-underwriting of the transaction for which documentation is available for regulator review.
d. Short-term and cash equivalent investments that have been renewed/rolled from the prior period that do not meet the criteria in 37.a - 37.c are reported as long-term investments.
Has the reporting entity rolled/renewed short-term or cash equivalent investments in accordance with these criteria? Yes [ ] No [X] N/A [ ]

GENERAL INTERROGATORIES

38.1 Does the reporting entity directly hold cryptocurrencies? Yes [ ] No [X]

38.2 If the response to 38.1 is yes, on what schedule are they reported?

39.1 Does the reporting entity directly or indirectly accept cryptocurrencies as payments for premiums on policies? Yes [ ] No [X]

39.2 If the response to 39.1 is yes, are the cryptocurrencies held directly or are they immediately converted to U.S. dollars?

39.21 Held directly Yes [ ] No [ ]

39.22 Immediately converted to U.S. dollars Yes [ ] No [ ]

39.3 If the response to 38.1 or 39.1 is yes, list all cryptocurrencies accepted for payments of premiums or that are held directly.

1 Name of Cryptocurrency	2 Immediately Converted to USD, Directly Held, or Both	3 Accepted for Payment of Premiums

OTHER

40.1 Amount of payments to trade associations, service organizations and statistical or rating bureaus, if any? $ 2,109,043

40.2 List the name of the organization and the amount paid if any such payment represented 25% or more of the total payments to trade associations, service organizations and statistical or rating bureaus during the period covered by this statement.

1 Name	2 Amount Paid
Blue Cross Blue Shield Association	2,109,043

41.1 Amount of payments for legal expenses, if any? $ 14,166,266

41.2 List the name of the firm and the amount paid if any such payment represented 25% or more of the total payments for legal expenses during the period covered by this statement.

1 Name	2 Amount Paid
Omelveny and Myers	3,863,146

42.1 Amount of payments for expenditures in connection with matters before legislative bodies, officers or departments of government, if any? $ 199,000

42.2 List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment expenditures in connection with matters before legislative bodies, officers, or departments of government during the period covered by this statement.

1 Name	2 Amount Paid
Government Advocates	84,000
Ice Miller	60,000
Ockerman Consulting	55,000
Lobbying expenses disclosed reflect amounts reported in the Lobbyist Disclosure Reports filed with the Secretary of State as well as the cost of external contractors who provided lobbying services to the Company. The amount may include expenses that may have been paid by an affiliate on behalf of the Company and, as a result, may not be included in the Underwriting Gain reported on page 4 of the 2023 Annual Statement.	

GENERAL INTERROGATORIES

PART 2 - HEALTH INTERROGATORIES

1.1 Does the reporting entity have any direct Medicare Supplement Insurance in force? Yes [X] No [ ]

1.2 If yes, indicate premium earned on U.S. business only. $ 171,893,788

1.3 What portion of Item (1.2) is not reported on the Medicare Supplement Insurance Experience Exhibit? $

1.31 Reason for excluding

1.4 Indicate amount of earned premium attributable to Canadian and/or Other Alien not included in Item (1.2) above $

1.5 Indicate total incurred claims on all Medicare Supplement Insurance. $ 134,573,714

1.6 Individual policies:

Most current three years:

1.61 Total premium earned $ 39,936,319
1.62 Total incurred claims $ 35,053,973
1.63 Number of covered lives 21,208

All years prior to most current three years:

1.64 Total premium earned $ 105,098,041
1.65 Total incurred claims $ 77,800,313
1.66 Number of covered lives 41,388

1.7 Group policies:

Most current three years:

1.71 Total premium earned $ 0
1.72 Total incurred claims $ 0
1.73 Number of covered lives 0

All years prior to most current three years:

1.74 Total premium earned $ 26,859,430
1.75 Total incurred claims $ 21,719,428
1.76 Number of covered lives 7,594

2. Health Test:

		1 Current Year	2 Prior Year
2.1	Premium Numerator	9,890,936,370	9,236,280,911
2.2	Premium Denominator	9,890,936,370	9,236,280,911
2.3	Premium Ratio (2.1/2.2)	1.000	1.000
2.4	Reserve Numerator	1,184,343,269	1,129,450,523
2.5	Reserve Denominator	1,184,343,269	1,129,450,523
2.6	Reserve Ratio (2.4/2.5)	1.000	1.000

3.1 Has the reporting entity received any endowment or gift from contracting hospitals, physicians, dentists, or others that is agreed will be returned when, as and if the earnings of the reporting entity permits? Yes [ ] No [X]

3.2 If yes, give particulars:

4.1 Have copies of all agreements stating the period and nature of hospitals', physicians', and dentists' care offered to subscribers and dependents been filed with the appropriate regulatory agency? Yes [X] No [ ]

4.2 If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do these agreements include additional benefits offered? Yes [ ] No [ ]

5.1 Does the reporting entity have stop-loss reinsurance? Yes [X] No [ ]

5.2 If no, explain:
The Company has a $1,000,000 maximum risk per Individual for its Medicaid business.

5.3 Maximum retained risk (see instructions)

5.31 Comprehensive Medical $
5.32 Medical Only $
5.33 Medicare Supplement $
5.34 Dental & Vision $
5.35 Other Limited Benefit Plan $
5.36 Other $

6. Describe arrangement which the reporting entity may have to protect subscribers and their dependents against the risk of insolvency including hold harmless provisions, conversion privileges with other carriers, agreements with providers to continue rendering services, and any other agreements:
If the Company becomes insolvent, Elevance Health, Inc. has agreed to the full extent of its assets, to assume all contractual and financial obligations of the Company. The Company's provider contracts include insolvency provisions, continuity of care provisions, and hold harmless language. Benefit certificates include continuation language allowing subscribers and dependents to continue under certain circumstances.

7.1 Does the reporting entity set up its claim liability for provider services on a service date basis? Yes [X] No [ ]

7.2 If no, give details

8. Provide the following information regarding participating providers:

8.1 Number of providers at start of reporting year 90,472
8.2 Number of providers at end of reporting year 109,033

9.1 Does the reporting entity have business subject to premium rate guarantees? Yes [X] No [ ]

9.2 If yes, direct premium earned:

9.21 Business with rate guarantees between 15-36 months $ 113,356,539
9.22 Business with rate guarantees over 36 months $ 3,703,263

GENERAL INTERROGATORIES

10.1 Does the reporting entity have Incentive Pool, Withhold or Bonus Arrangements in its provider contracts? ..... Yes [X] No [ ]

10.2 If yes:
- 10.21 Maximum amount payable bonuses..... $ 144,239,822
- 10.22 Amount actually paid for year bonuses..... $ 181,803,730
- 10.23 Maximum amount payable withholds..... $ .....
- 10.24 Amount actually paid for year withholds..... $ .....

11.1 Is the reporting entity organized as:
- 11.12 A Medical Group/Staff Model, ... Yes [ ] No [X]
- 11.13 An Individual Practice Association (IPA), or, Yes [ ] No [X]
- 11.14 A Mixed Model (combination of above)? .... Yes [ ] No [X]

11.2 Is the reporting entity subject to Statutory Minimum Capital and Surplus Requirements? ..... Yes [X] No [ ]
11.3 If yes, show the name of the state requiring such minimum capital and surplus. ..... Ohio
11.4 If yes, show the amount required. ..... $ 2,500,000
11.5 Is this amount included as part of a contingency reserve in stockholder's equity? ..... Yes [ ] No [X]
11.6 If the amount is calculated, show the calculation
.....

12. List service areas in which reporting entity is licensed to operate:

1 Name of Service Area
State of Ohio .....
State of Indiana .....
.....

13.1 Do you act as a custodian for health savings accounts? ..... Yes [ ] No [X]

13.2 If yes, please provide the amount of custodial funds held as of the reporting date. ..... $ .....

13.3 Do you act as an administrator for health savings accounts? ..... Yes [ ] No [X]

13.4 If yes, please provide the balance of funds administered as of the reporting date. ..... $ .....

14.1 Are any of the captive affiliates reported on Schedule S, Part 3, authorized reinsurers? ..... Yes [ ] No [ ] N/A [X]
14.2 If the answer to 14.1 is yes, please provide the following:

1	2	3	4	Assets Supporting Reserve Credit		
Company Name	NAIC Company Code	Domiciliary Jurisdiction	Reserve Credit	5 Letters of Credit	6 Trust Agreements	7 Other
.....	.....	.....	.....	.....	.....	.....

15. Provide the following for individual ordinary life insurance* policies (U.S. business only) for the current year (prior to reinsurance assumed or ceded):
- 15.1 Direct Premium Written ..... $ .....
- 15.2 Total Incurred Claims ..... $ .....
- 15.3 Number of Covered Lives ....

*Ordinary Life Insurance Includes
Term(whether full underwriting, limited underwriting, jet issue, "short form app")
Whole Life (whether full underwriting, limited underwriting, jet issue, "short form app")
Variable Life (with or without secondary gurarantee)
Universal Life (with or without secondary gurarantee)
Variable Universal Life (with or without secondary gurarantee)

16. Is the reporting entity licensed or chartered, registered, qualified, eligible or writing business in at least two states? ..... Yes [X] No [ ]

16.1 If no, does the reporting entity assume reinsurance business that covers risks residing in at least one state other than the state of domicile of the reporting entity? ..... Yes [ ] No [ ]

FIVE-YEAR HISTORICAL DATA

		1 2023	2 2022	3 2021	4 2020	5 2019
	Balance Sheet (Pages 2 and 3)					
1.	Total admitted assets (Page 2, Line 28)	3,561,355,040	3,100,983,104	2,354,905,400	2,054,011,521	1,926,325,358
2.	Total liabilities (Page 3, Line 24)	1,943,838,646	1,760,359,595	1,349,982,698	1,203,107,333	1,152,587,268
3.	Statutory minimum capital and surplus requirement	2,500,000	2,500,000	2,500,000	2,500,000	2,500,000
4.	Total capital and surplus (Page 3, Line 33)	1,617,516,394	1,340,623,509	1,004,922,702	850,904,188	773,738,090
	Income Statement (Page 4)					
5.	Total revenues (Line 8)	9,851,801,872	9,663,101,593	7,379,553,203	6,568,884,001	5,951,517,993
6.	Total medical and hospital expenses (Line 18)	8,273,515,121	8,385,109,656	6,372,968,211	5,507,058,132	5,028,201,662
7.	Claims adjustment expenses (Line 20)	285,538,794	308,987,451	224,128,777	215,946,654	188,532,867
8.	Total administrative expenses (Line 21)	721,445,883	718,844,908	438,124,490	621,144,326	349,897,239
9.	Net underwriting gain (loss) (Line 24)	572,473,676	251,993,435	346,322,537	226,608,730	386,545,926
10.	Net investment gain (loss) (Line 27)	89,692,801	37,417,274	39,507,155	34,148,387	40,755,251
11.	Total other income (Lines 28 plus 29)	31,972,489	27,185,353	14,401,211	11,313,464	16,397,540
12.	Net income or (loss) (Line 32)	517,285,621	271,239,930	319,740,524	175,040,427	352,244,072
	Cash Flow (Page 6)					
13.	Net cash from operations (Line 11)	541,689,635	554,538,371	105,578,514	431,357,414	434,773,942
	Risk-Based Capital Analysis					
14.	Total adjusted capital	1,617,516,394	1,340,623,509	1,004,922,702	850,904,188	773,738,090
15.	Authorized control level risk-based capital	318,663,254	343,973,192	267,712,803	232,544,489	211,147,238
	Enrollment (Exhibit 1)					
16.	Total members at end of period (Column 5, Line 7)	2,236,645	2,640,223	2,319,841	2,200,781	2,065,570
17.	Total members months (Column 6, Line 7)	27,483,025	31,631,604	27,569,562	26,301,882	24,747,790
	Operating Percentage (Page 4) (Item divided by Page 4, sum of Lines 2, 3 and 5) x 100.0					
18.	Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)	100.0	100.0	100.0	100.0	100.0
19.	Total hospital and medical plus other non-health (Lines 18 plus Line 19)	84.0	86.8	86.4	83.8	84.5
20.	Cost containment expenses	1.6	1.9	1.9	1.9	2.0
21.	Other claims adjustment expenses	1.3	1.3	1.1	1.4	1.1
22.	Total underwriting deductions (Line 23)	94.2	97.4	95.3	96.6	93.5
23.	Total underwriting gain (loss) (Line 24)	5.8	2.6	4.7	3.4	6.5
	Unpaid Claims Analysis (U&I Exhibit, Part 2B)					
24.	Total claims incurred for prior years (Line 17, Col. 5)	674,249,100	681,777,688	589,722,232	495,805,992	443,794,988
25.	Estimated liability of unpaid claims-[prior year (Line 17, Col. 6)]	918,053,304	751,189,738	718,598,435	524,770,166	462,317,829
	Investments In Parent, Subsidiaries and Affiliates					
26.	Affiliated bonds (Sch. D Summary, Line 12, Col. 1)				0	
27.	Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1)			0	0	0
28.	Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)			0	0	0
29.	Affiliated short-term investments (subtotal included in Schedule DA Verification, Col. 5, Line 10)	0	0	0	0	0
30.	Affiliated mortgage loans on real estate			10,016,993		
31.	All other affiliated					
32.	Total of above Lines 26 to 31	0	0	10,016,993	0	0
33.	Total investment in parent included in Lines 26 to 31 above.					

NOTE: If a party to a merger, have the two most recent years of this exhibit been restated due to a merger in compliance with the disclosure requirements of SSAP No. 3, Accounting Changes and Correction of Errors? Yes [ ] No [ ]

If no, please explain:

SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS

Allocated by States and Territories

	States, etc.		1	Direct Business Only								
			Active Status (a)	2 Accident and Health Premiums	3 Medicare Title XVIII	4 Medicaid Title XIX	5 CHIP Title XXI	6 Federal Employees Health Benefits Program Premiums	7 Life and Annuity Premiums & Other Considerations	8 Property/ Casualty Premiums	9 Total Columns 2 Through 8	10 Deposit-Type Contracts
1.	Alabama	AL	N								0	
2.	Alaska	AK	N								0	
3.	Arizona	AZ	N								0	
4.	Arkansas	AR	N								0	
5.	California	CA	N								0	
6.	Colorado	CO	N								0	
7.	Connecticut	CT	N								0	
8.	Delaware	DE	N								0	
9.	District of Columbia	DC	N								0	
10.	Florida	FL	N								0	
11.	Georgia	GA	N								0	
12.	Hawaii	HI	N								0	
13.	Idaho	ID	N								0	
14.	Illinois	IL	N								0	
15.	Indiana	IN	L	5,247,440	133,065,629						138,313,069	
16.	Iowa	IA	N								0	
17.	Kansas	KS	N								0	
18.	Kentucky	KY	N								0	
19.	Louisiana	LA	N								0	
20.	Maine	ME	N								0	
21.	Maryland	MD	N								0	
22.	Massachusetts	MA	N								0	
23.	Michigan	MI	N								0	
24.	Minnesota	MN	N								0	
25.	Mississippi	MS	N								0	
26.	Missouri	MO	N								0	
27.	Montana	MT	N								0	
28.	Nebraska	NE	N								0	
29.	Nevada	NV	N								0	
30.	New Hampshire	NH	N								0	
31.	New Jersey	NJ	N								0	
32.	New Mexico	NM	N								0	
33.	New York	NY	N								0	
34.	North Carolina	NC	N								0	
35.	North Dakota	ND	N								0	
36.	Ohio	OH	L	2,876,337,264	4,036,751,084	1,220,449,032		1,498,490,621			9,632,028,001	
37.	Oklahoma	OK	N								0	
38.	Oregon	OR	N								0	
39.	Pennsylvania	PA	N								0	
40.	Rhode Island	RI	N								0	
41.	South Carolina	SC	N								0	
42.	South Dakota	SD	N								0	
43.	Tennessee	TN	N								0	
44.	Texas	TX	N								0	
45.	Utah	UT	N								0	
46.	Vermont	VT	N								0	
47.	Virginia	VA	N								0	
48.	Washington	WA	N								0	
49.	West Virginia	WV	N								0	
50.	Wisconsin	WI	N								0	
51.	Wyoming	WY	N								0	
52.	American Samoa	AS	N								0	
53.	Guam	GU	N								0	
54.	Puerto Rico	PR	N								0	
55.	U.S. Virgin Islands	VI	N								0	
56.	Northern Mariana Islands	MP	N								0	
57.	Canada	CAN	N								0	
58.	Aggregate Other Aliens	OT	XXX	0	0	0	0	0	0	0	0	0
59.	Subtotal		XXX	2,881,584,704	4,169,816,713	1,220,449,032	0	1,498,490,621	0	0	9,770,341,070	0
60.	Reporting Entity Contributions for Employee Benefit Plans		XXX								0	
61.	Totals (Direct Business)		XXX	2,881,584,704	4,169,816,713	1,220,449,032	0	1,498,490,621	0	0	9,770,341,070	0
	DETAILS OF WRITE-INS											
58001.			XXX									
58002.			XXX									
58003.			XXX									
58998.	Summary of remaining write-ins for Line 58 from overflow page		XXX	0	0	0	0	0	0	0	0	0
58999.	Totals (Lines 58001 through 58003 plus 58998)(Line 58 above)		XXX	0	0	0	0	0	0	0	0	0

(a) Active Status Counts:

1. L - Licensed or Chartered - Licensed insurance carrier or domiciled RRG 2
2. R - Registered - Non-domiciled RRGs 0
3. E - Eligible - Reporting entities eligible or approved to write surplus lines in the state. 0
4. Q - Qualified - Qualified or accredited reinsurer 0
5. N - None of the above - Not allowed to write business in the state 55

(b) Explanation of basis of allocation by states, premiums by state, etc.
Not applicable

SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP
PART 1 – ORGANIZATIONAL CHART

BCBSA Licensee
Regulated Insurance Company
Regulated BCBSA Licensee

ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED



[1] HealthKeepers, Inc. is owned 92.51% by Anthem Southeast, Inc. and 7.49% by UNICARE National Services, Inc.

SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP
PART 1 – ORGANIZATIONAL CHART

ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED



[2] Government Healthcare Solutions LLC. is a joint venture 49% owned by National Government Services, Inc. and 51% owned by MKS2 LLC (non-affiliate)

SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP
PART 1 – ORGANIZATIONAL CHART

ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED



[3] ATH Holding Company, LLC holds a 98% interest in Highland Investor Holdings, LLC, and Wellpoint Corporation holds the remaining 2% interest.

SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP
PART 1 – ORGANIZATIONAL CHART

ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED



SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP
PART 1 – ORGANIZATIONAL CHART

ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED



SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP
PART 1 – ORGANIZATIONAL CHART

ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED

BCBSA Licensee
Regulated Insurance Company
Regulated BCBSA Licensee



[4] HealthKeepers, Inc. is owned 92.51% by Anthem Southeast, Inc. and 7.49% by UNICARE National Services, Inc.

SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP
PART 1 – ORGANIZATIONAL CHART

ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED





SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP
PART 1 – ORGANIZATIONAL CHART

ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED

BCBSA Licensee
Regulated Insurance Company
Regulated BCBSA Licensee



5 Wellpoint Corporation holds a 2% interest in Highland Investor Holdings, LLC, and ATH Holding Company, LLC holds the remaining 98% interest.

6 TriaDD NY, LLC dba MyCompass is 25% owned by Alliance Care Management, LLC and the remaining 75% interest is owned by unaffiliated investors.

SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP
PART 1 – ORGANIZATIONAL CHART

ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED



SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP
PART 1 – ORGANIZATIONAL CHART

BCBSA Licensee
Regulated Insurance Company
Regulated BCBSA Licensee

ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED



[7] Community Care Health Plan of Louisiana, Inc. is a joint venture 75% owned by Anthem Partnership Holding Company, LLC and 25% owned by Louisiana Health Service & Indemnity Company d/b/a Blue Cross and Blue Shield of Louisiana (non-affiliate)

[8] CCHA, LLC is a joint venture 50% owned by Anthem Partnership Holding Company, LLC and 50% owned by Colorado Community Health Alliance, LLC (non-affiliate)

[9] AMH Health, LLC is a joint venture 50% owned by MaineHealth (non-affiliate) and 50% owned by Anthem Partnership Holding Company, LLC

[10] Momentum Health Partners, LLC is a joint venture 50% owned by Anthem Partnership Holding Company, LLC and 50% owned by Blue Cross and Blue Shield of North Carolina (non-affiliate)

[11] GR Health Solutions, LLC is a joint venture 50% owned by Anthem Partnership Holding Company, LLC and 50% owned by Independence Blue Cross, LLC (non-affiliate)

[12] Community Care Health Plan of Nebraska, Inc. is a joint venture 95% owned by Anthem Partnership Holding Company, LLC and 5% owned by Blue Cross and Blue Shield of Nebraska, Inc. (non-affiliate).

[13] APC PASSE, LLC (regulated entity) is a joint venture 49% owned by Anthem Partnership Holding Company, LLC and 51% owned by Arkansas Provider Coalition, LLC (non-affiliate).

[14] Community Care Health Plan of Kansas, Inc. is a joint venture 90% owned by Anthem Partnership Holding Company, LLC, 5% owned by Blue Cross and Blue Shield of Kansas (non-affiliate) and 5% owned by Blue Cross and Blue Shield of Kansas City (non-affiliate).

SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP
PART 1 – ORGANIZATIONAL CHART



[15] Other investors are Asociacion De Medicos Del Oeste, Inc. (13%) and Doctores Asociados Del Noroeste, Inc. (10%). Ownership interest in Consorcio MultiSalud del Oeste, Inc. is based on Eligible Beneficiaries per Primary Medical Group. Ownership shall be revised annually by the end of each year; provided that at least 10% shall remain with each PMG.

[16] Other 50% owned by ACO del Norte, LLC (non-affiliate)

[17] Best Transportation of PR LLC is a joint venture 51% owned by MMM Transportation, LLC and 49% owned by Best Transportation of PR LLC

OVERFLOW PAGE FOR WRITE-INS

Additional Write-ins for Assets Line 25

		Current Year			Prior Year
		1	2	3	4
		Assets	Nonadmitted Assets	Net Admitted Assets (Cols. 1 - 2)	Net Admitted Assets
2504.	Bluecard receivables	33,105		33,105	366,457
2505.	Intangibles	53,119,074	53,119,074	0	0
2506.	Prepaid expenses	15,123,785	15,123,785	0	0
2597.	Summary of remaining write-ins for Line 25 from overflow page	68,275,964	68,242,859	33,104	366,457

Additional Write-ins for Liabilities Line 23

		Current Year			Prior Year
		1	2	3	4
		Covered	Uncovered	Total	Total
2304.	Contingent liability	0		0	49,287,875
2397.	Summary of remaining write-ins for Line 23 from overflow page	0	0	0	49,287,875